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Age-related muscle loss is characterised by reduction in the number of 
myofibres and motor neurons and an additional weakening of the remaining 
fibres, causing reduction in muscle mass and function. Studies associate 
premature muscle wasting with influences during early stages of development, 
including maternal malnutrition. The aim of this study was to examine whether 
protein-deficient females produce offspring with a reduced number of muscle 
fibres and altered neuromuscular homeostasis and whether this can be rescued 
by optimisation of the nutrition in early postnatal stages of development. Female 
Thy1-YFP16 mice, expressing yellow fluorescent protein (YFP) only in neuronal 
cells, were fed either a normal (20%) or a low-protein (5%) diet. Newborn pups 
were then cross-fostered to different lactating dams (maintained on either a 
normal or a low-protein diet), within 24 h after birth and maintained on those 
diets at post-weaning stages until 3 months of age.  
Mice born from dams on 20% diet but introduced to a 5% diet (NLL) 
postnatally show significant reduction in muscle function (strength). Muscle fibre 
size and number was not affected by dietary reduction of protein, but protein 
restriction postnatally resulted in reduced muscle function. Mice on a low 
protein diet postnatally displayed structural abnormalities at neuromuscular 
junction. To examine how the changes in both muscle force and NMJ 
morphology may be controlled, specific microRNA expression levels were 
investigated in muscle and nerve from offspring. Two candidate microRNAs, miR-
128 and miR-133a were selected for further investigation due to their reduced 
expression levels in mice on a low protein diet postnatally and their involvement 
in skeletal muscle and motoneuron cells. Bioinformatic analysis for miR-128 and 
miR-133a indicated several predicted target genes involved in key metabolic 
pathways in skeletal muscle and neuron cell function and maintenance.  
Gain- and loss-of-function of miR-128 was performed in vitro, using C2C12 as 
a model of skeletal muscle cells and NSC-34 cells as a model of α-motoneuron 
cells.  Both inhibition and overexpression of miR-128 in C2C12 cells resulted in 
reduced proliferation and increased cell death, and increased mitochondrial 
toxicity, while in NSC-34 cells only cell death was increased but proliferation 
remained unaffected. Overexpression of miR-128 resulted in no phenotypic 
changes in C2C12 myotubes but reduced the length of axonal outgrowth in NSC-
34 cells. MiR-133a overexpression increased proliferation and reduced cell 
death. Inhibition of miR-133a had the most profound effect on C2C12 myotube 
phenotype and axonal length of NSC-34 cells. Quantitative PCR analysis of miR-
128 predicted target genes of interest revealed changes in gene expression of 
Nrf-1, Pdgfrα, Cox-I, Cox-IV, Grb-2 and Park-2 genes following transfections with 
miR-128 in C2C12 and NSC-34 cells. Western blot analysis, however, showed that 
changes in these predicted target genes on a protein level in both C2C12 and 
NSC-34 cells were not significant. Analysis of Nrf-1 and Cox-IV in TA muscle of 
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mice from the NLL group showed no differences in the expression levels of these 
transcripts. However, Nrf-1 and Grb-2 were significantly upregulated in the 
sciatic nerve of mice from the NLL group.  
To summarise, our data show that maternal protein restriction plays a crucial 
role in neuromuscular development of the offspring.  This could be regulated 
through microRNA-128 and -133a. In vitro, miR-133a and miR-128 affected 
muscle and nerve cell phenotype. These gene expression changes were similar to 
those observed in vivo. These data indicate the potential role of microRNAs as a 
novel mechanism of neuromuscular development and potentially maintenance, 
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SDS  Sodium Dodecyl Sulfate  
SEM  Standard Error of the Mean  
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Ageing is characterised by frailty due to increased muscle wasting and 
reduced muscle function (Faulkner et al. 2007). Age-related decline in muscle 
mass and function, known as sarcopenia, occurs progressively between the ages 
of 50-80 years in humans, and it is accompanied by a loss of muscle fibre and 
motor unit number and additional weakening of the remaining ones (Lexell et al. 
1988; Marzetti et al. 2009). A number of studies have focused on influences that 
occur at early stages of development and their effect on skeletal muscle 
development and function. Such influences can be genetic/biochemical or 
environmental/dietary.  
 
1.1 Skeletal muscle physiology and function 
Skeletal muscle comprises approximately 40% of the total body mass and up 
to date there are 640 named skeletal muscles in the adult human body (Marieb 
and Hoehn, 2010). Skeletal muscles are attached to the bones directly or 
indirectly (via tendons) and control human body movement (Martini, 2006). The 
main functions of skeletal muscles are the generation of body movement, the 
maintenance of body position and posture, the support of soft tissues, the 
safeguarding of entrances and exits in the body, the maintenance of body 
temperature, regulation of metabolism and the storage of nutrients (Martini, 
2006).  
 
1.1.1 Skeletal muscle structure and organisation 
Skeletal muscle consists of 3 types of connective tissue, the epimysium 
surrounding the entire muscle and separating from surrounding tissues; the 
perimysium, which divides the muscle into compartments called fascicles; the 
endomysium, a delicate layer of connective tissue that surrounds the individual 
muscle cells, called muscle fibres and hosts a network of capillaries, satellite cells 
and nerve fibres (Figure 1.1.1) (Martini, 2006).  
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Skeletal muscle fibres are multinucleated, post-mitotic cylindrical cells and a 
characteristic striated morphology (reviewed in Frontera and Ochala, 2015). 
Striations have a dark zone (A band) and a lighter zone (I band). Striations are 
formed when the A bands of each myofibril within a single fibre is aligned with 
the A bands of neighbouring myofibrils (Martini, 2006).  Each muscle fibre 
comprises of hundreds of myofibrils, which are mainly composed of myosin and 
actin filaments. Myosin filaments (or thick filaments) and actin filaments (or thin 
filaments) are organised into bundles within the myofibrils, called myofilaments 
(reviewed in Frontera and Ochala, 2015).  Myofilaments are subsequently 
organised into repeating functional units known as sarcomeres, which are 
approximately 2 μm in length. Interactions between the thin and thick filaments 
in each sarcomere are responsible for skeletal muscle contractions (Martini, 
2006). Between the sarcolemma and the basal lamina of the skeletal muscle fibre 
a population of muscle stem cells, known as satellite cells in a quiescent state in 
mature myofibres (Mauro, 1961). Following muscle injury, satellite cells become 
activated and re-enter the cell cycle and give rise to a myogenic progeny of 
muscle-progenitor cells known as myoblasts, which later differentiate into 
mature muscle fibres (Olguín and Pisconti, 2012). A small number of satellite 
cells do not undergo differentiation but remains in a stem cell state, in order to 
maintain the pool of satellite cells on myofibres (Olguín and Pisconti, 2012). 
Activation and proliferation of satellite cells depends on the expression of muscle 
regulatory transcription factors (MRFs), including MyoD and Myf-5, which are 
not expressed when satellite cells are in their quiescent state, while terminal 
differentiation into myofibres is achieved by expression of myogenin (Olguín and 





Figure 1.1.1 Schematic representation of the skeletal muscle structure and 
organisation  
 
1.1.1.1 Skeletal muscle fibre composition 
Skeletal muscle function is closely associated with the fibre type composition 
within the muscle. Skeletal muscle fibres in mammalian adult skeletal muscle are 
separated into 3 categories depending on the myosin ATPase activity and myosin 
heavy chain composition: type I fibres (or MyHC I), type IIa fibres (or MyHC IIa), 
type IIb fibre (or MyHC IIb) and type IIx fibre (or MyHC IIx) (Schiaffino et al. 
1989). MyHC IIb is found only in small mammals, but this isoform is not seen in 
human skeletal muscle (reviewed in Choi, 2014). Classification of the different 
fibre isoforms depends also on the speed of shortening following contraction, 
the contractile characteristics and force production following stimulation from 
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the motoneuron, degree of fatigability and metabolic pathways being prevalent 
(oxitative or glycolytic) (reviewed in Frontera and Ochala, 2015).  
Type I fibres or slow-twitch fibres have a smaller diameter than the type II 
fibres, with the speed of contraction and force generation being much slower 
than type II fibres (hence slow-twitch) but they are able to maintain contraction 
much longer, making them fatigue-resistant (Martini, 2006). Type I fibres have a 
high network of capillaries and high concentration of myoglobin and 
mitochondria, providing them a high supply of oxygen which is utilised for 
aerobic metabolism and increased ATP production (hence they are also known as 
oxidative fibres) (Martini, 2006).  
Type II fibres or fast-twitch fibres have a larger diameter than the type I fibres 
and they respond very quickly to neuronal stimulation in order to contract 
(hence called fast-twitch). They have relatively small number of mitochondria 
therefore, the amount of ATP production is limited (Martini, 2006). Because type 
II fibres generate very powerful contractions very quickly and due to the 
mitochondria and the ATP produced are limited, type II fibres are susceptible to 
fatigue. These fibres use glycogen for energy source for force production hence 
they are known as glycolytic fibres (Martini, 2006). In rodents, type II fibres are 
separated into type IIa, type IIb and type IIx/d. In humans, type IIa and type IIx, 
but not type IIb isoform, are expressed in skeletal muscle (Smerdu et al. 1994). 
Interestingly, type IIa fibres, present features of both type I and type IIb fibres, as 
they use both oxygen and glycogen for their metabolism and force generation, 
and they seem less susceptible to fatigue than type IIb fibres (Burke et al. 1971; 
Peter et al. 1972). Type IIx/d was discovered later by Schiaffino et al. and they 
resembled similar contractile properties with type IIa and type IIb fibres but their 
resistance to fatigue was intermediate of that seen in type IIa and type IIb 
(Schiaffino et al. 1989; Larsson et al. 1991). Force generation by different fibre 
types follows the pattern: type I < type IIa < type IIx < type IIb, with type IIb fibres 
being the strongest (Martini, 2006). 
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In rodents, muscles are classified into slow- or fast-twitch muscles according 
to their fibre type composition. Soleus (SOL) has a high percentage of type I 
fibres and it is easily noticeable from its red colour. Extensor digitorum longus 
(EDL) anterior tibialis (TA) muscle are composed almost exclusively of type II 
fibres (Figure 1.1.1.1) (reviewed in Schiaffino and Reggiani, 2010; Augusto et al. 
2014).  
 
Figure 1.1.1.1 Fibre type distribution in TA and SOL muscles of adult mice 
following immunofluorescent staining for myosin heavy chain (MyHC) isoforms 
(from Sakellariou et al. 2016).  
 
1.1.1.1.1 Skeletal muscle fibre composition during development 
Fibre type composition in skeletal muscles during development is fluid and 
varies between different muscles. In developing skeletal muscles two more 
isoforms of MyHC are evident, the neonatal (NN) and the embryonic (EMB) 
isoforms, which are predominant during early days of development (Pette and 
Staron, 2000). Moreover, in all muscles a small amount of type I fibre has been 
recorded in all muscles (Agbulut et al. 2003). In EDL muscles fibre type isoforms 
start shifting mainly at postnatal day 7 (P7), with type II isoforms (IIa, IIb and 
IIx/d) slowly replacing the embryonic and neonatal isoforms. By P49, EDL muscle 
is composed almost exclusively of type II fibres (Agbulut et al. 2003). For SOL, 
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gastrocnemius (GTN) and plantaris muscles, fibre type shift is mainly observed at 
P14. Like in EDL, GTN and plantaris muscles is only composed of type II isoforms 
at P49, while SOL muscle is composed of type I fibres and type IIa and IIx fibres 
(Agbulut et al. 2003).  
 
1.1.1.2 Skeletal muscle physiology: The neuromuscular junction (NMJ) 
Muscle contraction depends on the communication between the skeletal 
muscle fibre and the nervous system, which occurs at the neuromuscular 
junction site (NMJ). The neuromuscular junction is the synaptic connection 
between the axon of a motoneuron and a skeletal muscle fibre (Levitan and 
Kaczmarek, 2015). The neuromuscular junction comprises of three main 
components: the pre-synaptic motor nerve terminal, the synaptic space, known 
as synaptic cleft and post-synaptic muscle membrane or motor end plate 
(Verschuuren et al. 2016). In humans and rodents, a neuromuscular junction is 
formed when an α-motoneuron from the lumbar region of the spinal cord 
extends its axon through the peripheral nerve, innervating a muscle fibre. All the 
axons branching from a single α-motoneuron and the skeletal muscle fibres they 
innervate comprise a single motor unit (Fox, 2001). The organisation of a motor 
unit and the morphology of the neuromuscular junction in rodents are shown in 




Figure 1.1.1.2 Innervation of the skeletal muscle and the organisation of a motor 
unit. Schematic (top) from Fox (2001). Images of neuromuscular junction from 
Vasilaki et al. (2016). Neuromuscular junction morphology on individual skeletal 
muscle fibres, presynaptic motor nerve terminal (green), motor end plate (red) 
and skeletal muscle fibres (contrast) observed using a confocal microscope.   
 
1.1.1.2.1 Development of NMJ 
NMJ development is a multistep process that in rodents it starts during 
embryonic development until the NMJ structure matures fully during late post-
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natal/early adulthood stage of development. In rodents, NMJ formation starts 
with the formation of aneural AChR clusters across the length of the muscle fibre 
prior to the arrival of the nerve terminal of the motoneuron, at day E11-12 
(reviewed in Li et al. 2012). At day E13-14, motoneuron axons innervate the 
muscle fibres, inducing the formation of new AChR clusters, leading to dispersion 
of the non-innervated sites (reviewed in Li et al. 2012). This redistribution of 
AChR clusters does not require synaptic or contractile activity (Anderson and 
Cohen, 1997). Newly AChR clusters formed from day E16 are firstly seen as 
plaques with an oval shape that are innervated by more than one axon (multiple 
innervation) (Marques et al. 2000). From day E16 until late postnatal stages 
(P21), the AChR plaques become perforated and gradually from branches, 
adopting a more complex “pretzel”-like morphology, while they are innervated 
only by one axon (reviewed in Li et al. 2012). The maturation of the morphology 
for each NMJ varies temporally, as during early postnatal period there is a 
variation in the shape of NMJs, with some still having the appearance of the 
embryonic plaque shape while others have visible signs of perforation (Marquez 
et al. 2000). Maturation of the synaptic area was also accompanied by an 
increase in its overall size, which was visible during the second postnatal week 
(Balice-Gordon and Lichtman, 1993). AChR-rich areas enlarged along with 
expansion of space between those areas, but no increase in AChR-rich areas was 
noted. This observation suggests the increase in the overall synaptic territory 
from the compact plaque-shape sites seen during embryonic development, 
where AChR clusters were more distributed more densely (Balice-Gordon and 
Lichtman, 1993).  
AChRs also undergo changes during development. AChR is a transmembrane 
nicotinic receptor that acts as an ion channel, mediating neuromuscular signal 
transmission (Missias et al. 1996). AChR are comprised of five homologous 
subunits, giving the receptor a barrel-like shape (Lindstrom, 1997). In 
mammalian skeletal muscle during development, AChR pentamer consist of four 
different type of subunits with the following stoichiometry: α2βγδ (Missias et al. 
1996). There are two sites for ACh binding located between α1-γ and α1-δ 
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subunits (Figure 1.1.1.2.1) (Lindstrom, 1997). Following postnatal development, 
foetal γ subunit substituted by ε subunit, resulting in the following AChR 
stoichiometry: α2βεδ (Missias et al. 1996). Although subunits α β δ are present in 
AChR throughout mammalian development, in rodents, subunit γ is present only 
during early stages of development and during denervation while subunit ε is 
evident late in development and only at the synaptic AChRs (Lindstrom, 1997). In 
humans, subunit γ expression is downregulated but not completely abolished, 
from 31 weeks of gestation and it is maintained at low levels through adulthood 
(reviewed in Webster, 2014).  
 
 
Figure 1.1.1.2.1 The organisation of muscle acetylcholine receptor (AChR). 
Subunit γ is replaced by subunit ε following postnatal development 
(redrawn/adapted from Lindstrom, 1997).  
 
1.1.1.2.2 The neuromuscular junction (NMJ): α-motoneurons 
Motoneuron cells on the spinal cord are organised into longitudinal columns 
across the rostrocaudal axis (Landmesser, 1978). Specifically, α-motoneurons are 
located on the ventral horn of the spinal cord, and they belong to the class of 
lower motoneuron in the central nervous system (CNS) (reviewed in Stifani, 
2014). α-motoneurons have a large cell body and a characteristic neuromuscular 
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ending (pretzel shape) (reviewed in Stifani, 2014). These motoneurons serve a 
key role in muscle force generation, as they are excited monosynaptically, and 
therefore responding quicker to stimuli (Eccles et al. 1960). α-motoneurons are 
divided into three categories, based on the type of muscle fibre they innervate: i) 
Slow-twitch, fatigue-resistant (SFR), ii) Fast-twitch, fatigue-resistant (FFR) and iii) 
fast-twitch, fatigable (FF) (Burke et al. 1973). SFR α-motoneurons innervate slow-
twitch (type I) muscle fibres, they have a significantly lower conduction velocity 
compared to FF and FFR α-motoneurons and they process the smallest cell body 
and the lowest degree of complexity in relation to FF and FFR α-motoneurons 
(reviewed in Kanning et al. 2010). FFR α-motoneurons innervate fast-twitch, 
fatigue-resistant (type IIa) muscle fibres and their characteristics are between 
the FF and SFR α-motoneurons, in terms of body size, complexity and conduction 
velocity (reviewed in Stifani, 2014). Finally, FF α-motoneurons innervate fast-
twitch-fatigable (type IIb/x) muscle fibres and have the highest conduction 
velocity and degree of complexity, as well as largest cell body (reviewed in 
Kanning et al. 2010).  
 
1.1.1.2.3 The neuromuscular junction (NMJ): the synaptic site  
Skeletal muscle contraction can only occur following successful neuronal 
signal transmission from the α-motoneuron to the skeletal muscle fibre at the 
neuromuscular junction (Martini, 2006). In rodents, the neuromuscular junction 
has a characteristic “pretzel”-like shape, with multiple branching points (Figure 
1.1.1.2.3). However, the morphology of the neuromuscular junction can vary 
between vertebrate species (Fox, 2009). A recent study from Jones et al. (2017) 
provided extensive evidence on the morphological differences of the NMJ 
between mice and humans across their lifespan. Variations in NMJ morphology 
can also be evident between different muscle groups and different species of the 
same animal group (i.e. Drosophila melanogaster) (Jones et al. 2017; Campbell 





Figure 1.1.1.2.3 The neuromuscular junction (NMJ) on the EDL muscle of an adult 
mouse (3 months old). The pre-synaptic nerve terminal and post-synaptic motor 
end plate overlap perfectly for efficient signal transmission, giving the NMJ this 
“pretzel”-like shape (further details provided in Chapter 3, Section 3.3.4).  
 
Despite the morphological variations, NMJs have three distinct components: i) 
the pre-synaptic nerve terminal, ii) the synaptic space and iii) the motor end 
plate (Verschuuren et al. 2016).  
The presynaptic nerve terminal comprises of the unmyelinated axonal cone of 
an α-motoneuron, whose myelinated axon is extended through the peripheral 
nerve (Fox, 2009). The unmyelinated axonal cone of the motoneuron is divided 
into branches, which reside in close proximity with the skeletal muscle fibre 
membrane (Fox, 2009). The pre-synaptic nerve terminal is separated from the 
motor end plate by synaptic cleft, a 12-20 nm space that accommodates the 
neurotransmitters for a short period after their release from the nerve terminal 
(Savtchenko and Rusakov, 2007). The postsynaptic membrane is folded into 
junctional folds that can be up to 1 μm in depth (reviewed in Sanes and 
Lichtman, 1999). AChR clusters are located at the shoulders of the junctional fold 
crests, at a density of 10,000/μm2 or higher, and this concentration of AChR falls 
1000-fold in extrasynaptic sites (Salpeter et al. 1988). At the deepest end of the 
junctional folds are the sodium channels and the neuronal cell-adhesion 
molecule (N-CAM) (reviewed in Sanes and Lichtman, 1999). Formation of AChR 
clusters depends heavily on two key molecules, agrin and muscle-specific kinase 
(MuSK). Agrin secreted by motoneuron cells triggers the activation of MuSK, via 
Pre-synaptic 
nerve terminal 




binding to its receptor, low-density lipoprotein (LDL) receptor–related protein 4 
or Lrp4 (reviewed in Li et al. 2017). Activation of the agrin-Lrp4-MuSK complex 
causes AChR cluster formation via recruitment of rapsyn and activation of 
downstream signalling pathways (Verschuuren et al. 2016).  
 
1.1.2 Skeletal muscle contraction 
1.1.2.1 Pre-synaptic signal transmission for muscle contraction 
When the pre-synaptic plasma membrane depolarises following an action 
potential, voltage-gated calcium channels (VGCCs) open up and Ca2+ flows into 
the nerve terminal (Verschuuren et al. 2016). There, Ca2+ binds to synaptotagmin 
located on the synaptic vesicles and triggers the release of the neurotransmitters 
they carry, including acetylcholine (ACh), via exocytosis (Südhof and Rizo, 2011). 
When the exocytosis is complete, the synaptic vesicles are recycled and refilled 
with neurotransmitters, ready to be released. Exosome recycling is regulated via 
multiple pathways (Südhof and Rizo, 2011).  
Upon release from exosomes, ACh (and other neurotransmitters) diffuse 
across the synaptic cleft and are then bound to the ACh receptors (AChR), which 
are tightly clustered on the post-synaptic folds of the motor end plate of the 
muscle fibre (Verschuuren et al. 2016). Following binding, AChR ion channel 
opens up causing local depolarisation, known as the end plate potential. When 
the end plate potential reaches a certain threshold, the voltage-gated sodium 
channels open up sending this action potential across the muscle fibre triggering 
its contraction (Verschuuren et al. 2016). 
 
1.1.2.2 Skeletal muscle fibre activation and contraction 
The theory of skeletal muscle force generation was first described by Huxley 
and Niedergerke, 1954. According to this theory, also known as the sliding 
filament theory, the sarcomere length shortens disproportionally when the 
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muscle contracts, with the I band and H zone of the sarcomere being subjected 
to shortening of their length. However, the length of the A band of the 
sarcomere does not change, but what changes is the degree of overlap between 
the thick (myosin) and thin (actin) filament. Hence, sarcomere contraction does 
not depend on changes in A band length but on the level of sliding between the 
thin and thick filaments, an observation that gave the name to this theory 
(Huxley and Niedergerke, 1954). 
Force generation depends on a number of factors including muscle size and 
architecture, innervation, the space between myofilaments and the number of 
formed myosin-actin cross bridges (reviewed in Frontera and Ochala, 2015). 
Muscle force is normalised to muscle size is called specific force and it is used as 
an indicator of muscle quality. During ageing and disease, as well as during 
denervation, muscle force appears to decline (reviewed in Frontera and Ochala, 
2015).  
Muscle force generation involves the two major proteins, myosin and actin. 
Myosin is the major components of the thick filaments combined with titin, 
which is responsible for the maintenance of the alignment between thick and 
thin filaments (Martini, 2006). Thin filaments are mainly composed of actin along 
with tropomyosin and troponin. Actin in thin filaments is in the form of F actin, 
which consists of molecules of G actin and has a twisted conformation (Martini, 
2006). G actin molecules contain active sites for binding of myosin, which under 
resting conditions is inhibited by the tropomyosin-troponin complex (Martini, 
2006). Upon muscle contraction, Ca2+ is released and binds to troponin 
receptors, triggering a conformational change of the troponin-tropomyosin 
complex and releasing the actin receptors, allowing binding with myosin 
molecules. This interaction between myosin and actin filaments during muscle 
contraction is known as cross-bridges (Martini, 2006). When ATP is available, it 
binds to the active site of the myosin head and it is hydrolysed by the local 
ATPases into ADP+Pi. The Pi molecule forces myosin to pass the actin filament 
following the generation of a power stroke, which results in force generation 
(reviewed in Frontera and Ochala, 2015). The rate of ATP consumption by 
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ATPases in the myosin heads determines the speed of contraction (Bárány 1967). 
When ATP is no longer available, the troponin-tropomyosin complex interaction 
with actin filaments is restored and the muscle stops contracting (Figure 1.2.2.2).  
Consumption of ATP depends on various factors including the number of 
myosin heads and the number of cross-bridges formed between myosin and 
actin filaments. The rate at which ATP is consumed reflects the myosin heavy 
chain isoform expression (reviewed in Frontera and Ochala, 2015). Muscle 
contraction occurs only under the control of the nervous system, when the 
action potential arriving at the neuromuscular junction (NMJ) of each skeletal 
muscle fibre causes release of Ca2+ (Ashley and Ridgwey, 1968).  
 
Figure 1.1.2.2 Schematic representation of the sarcomere structure and 




1.2 Regulation of neuromuscular physiology and function in development and 
ageing or disease 
1.2.1 Lifestyle and dietary influences on neuromuscular physiology 
Epidemiological studies suggest that environmental influences such as 
nutrition during perinatal life may result in detrimental and long-lasting effects. 
Restriction of maternal food intake (50% of daily food intake) during gestation 
and lactation period resulted in 54% reduction in the body weight of the 
offspring in rats (Beermann, 1983). Later studies revealed similar effect of 
maternal nutrition in the birth weight and postnatal muscle growth of the 
mammalian offspring. A study by Bee (2004) demonstrates how fibre type 
distribution in skeletal muscle is influenced by different maternal feeding 
regimen in pigs, whereas muscle fibre area is directly influenced by birth weight. 
Maternal undernutrition in beef has been linked to growth and productivity of 
the offspring, which develop metabolic syndromes later in life (Funston et al. 
2010). In sheep, maternal undernutrition contributes to the rise of metabolic 
diseases later in life, such as glucose intolerance and insulin insensitivity (Costello 
et al. 2008, 2013).  On a cellular level, maternal suboptimal nutrition pre- and 
postnatally reduce myogenic frequency and function in muscle stem cells, 
leading to impairment in repair mechanisms and reduction in skeletal muscle 
mass (Woo et al. 2011). Furthermore, substantial maternal undernutrition during 
gestation and insufficient maternal nutrient supply can impair myogenesis due to 
impairmed growth hormone-insulin-like growth factor (GH-IGF) axis, 
subsequently affecting the growth of mammalian skeletal muscle fibres (Rehfeldt 
et al. 2011). 
A high-saturated fat diet during early developmental stages has been linked to 
development of type II diabetes, obesity and other metabolic disorders later in 
life mammals (Yang et al. 2012). Early exposure to a high-saturated-fat diet in 
rats inhibits the development of skeletal muscle by repression of the expression 
of myogenic genes via Wnt/β-catenin signalling, leading to aberrant muscle 
development (Yang et al. 2012).  
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In terms of protein, maternal high-protein diet has been linked with the 
regulation of offspring's transcriptome, with long-lasting effect. A study by Oster 
et al. (2012) in pigs showed short- and long-term effects of a high-protein diet on 
transcriptional regulation of genes involved in cell cycle regulation, energy and 
nucleic acid metabolism and growth factor signalling pathways in the offspring. 
Their findings show that maternal protein supply regulates programming of the 
offspring's genome; while piglets under a high-protein diet during early postnatal 
stages showed signs of growth retardation obvious at birth and permanently 
altered development and responsiveness to the common environment of the 
transcriptome (Oster et al. 2012).  
Maternal protein-deficient diet can lead to the development of metabolic 
diseases during adulthood. Results from a study from da Silva Aragão et al. 
(2014) show that maternal malnutrition can alter metabolic flexibility long-term 
in skeletal muscle of the offspring of rats born from normal or protein-restricted 
dams, throughout pregnancy and lactation. Their data further suggest that 
metabolic inflexibility can lead to the development of metabolic disorders 
associated with malnutrition in early life (da Silva Aragão et al. 2014). Another 
study from Toscano et al. highlighted the effects of a protein-deficient diet 
during gestation on the biomechanical properties of skeletal muscle of offspring. 
Rats born from a dam fed a low-protein diet demonstrated muscle wasting and 
diminution of maximum twitch and tetanic tension on the EDL and SOL muscle. 
Additionally, muscle fibre type proportions were altered in EDL and SOL muscle 
of 25- and 90-days old pups (Toscano et al. 2008). These data demonstrated the 
effect of low-protein intake in the structure and function of skeletal muscle, 
which could significantly compromise posture and locomotion of the offspring 
(Toscano et al. 2008). 
Exposure to a low-protein diet pre-natally has been shown to have 
detrimental effects in the development of cognition and memory. Rats exposed 
to a protein-deficient diet at neonatal stages demonstrated reduced expression 
of brain-derived growth factor (BDNF) mRNA, a key neurotrophin necessary for 
neurogenesis, synaptic plasticity and cell survival (Marwarha et al. 2017). A study 
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from Gallagher et al. revealed reduction in mitochondrial complex IV activity of 
rats subjected to a low-protein diet during gestation (Gallagher et al. 2005). Low-
protein diet during gestation and at early postnatal stages has been associated 
with reduction neuronal stem cell number in the brain of mice, with concomitant 
uncontrollable upregulation of stem cell differentiation, resulting in memory 
deficits (Gould et al. 2018). A study from Chen et al. (2009) showed that low-
protein diet pre-natally followed by normal-protein diet postnatally resulted in 
shortened lifespan of the offspring. Interestingly, mice born from a mother on a 
normal diet pre-natally but subjected to a protein-deficient diet postnatally 
demonstrated slow growth but had an extended lifespan (Chen et al. 2009). 
Furthermore, protein-deficient diet at early stages of development had an 
impact on key metabolic pathways regulating lifespan, such as IGF-1 signalling 
(Chen et al. 2009). Additionally, a study by Sharma et al. 2015 provides evidence 
of the regulation of small RNA biogenesis by low-protein diet and their influence 
in embryonic gene expression.  
Although several studies have focused on the effect of a low-protein diet on 
muscle mass and function, there is no study up-to-date focusing on the effects of 
a protein-deficient diet immediately after birth, during lactation and later on in 
life, in both the muscle fibres and motoneurons.  
 
1.2.1.1 Skeletal muscle fibre regulation during exercise 
Exercise training can influence fibre type transition in skeletal muscle, as a 
mechanism of adaptation to the energy requirements during different types of 
exercise. Resistance training caused an increase in type IIa fibres with a parallel 
decrease in type IIb fibres in skeletal muscle (Staron et al. 1990; Heather et al. 
1991). High-intensity endurance exercise increased type I and type IIa fibres and 
decreased type IIb fibres in plantaris and EDL muscle of rats (Green et al. 1984). 
Similar results were also recorded in previous studies in human skeletal muscle 
following endurance training (Baumann et al. 1987). This transition in fibre types 
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in skeletal muscle following different exercise regimes highlights the adaptability 
of skeletal muscle in conditions of different metabolic and energy demands.  
 
1.2.1.2 Dietary influences regulating skeletal muscle fibre composition 
Nutrient availability has a key role in fibre type determination in skeletal 
muscle. Diets high in fat and sugar content caused the greatest shift of slow-to-
fast fibre types in SOL while resveratrol treatment had the opposite effect in 
plantaris muscle (Hyatt et al. 2016). This great effect of high fat/high sugar diet 
on SOL is supported by previous studies showing the increased sensitivity of 
oxidative muscles to insulin resistance (Koerker et al. 1990). Interestingly, a long-
term high-fat diet increases type IIx fibres in EDL muscle but the same is not 
observed with short-term high-fat diet (Eshima et al. 2017).  
Caloric restriction has been shown to attenuate the effects of ageing on fibre 
type composition in slow and fast muscles (Faitg et al. 2019). A reduction of 40% 
on caloric intake in adult rats was shown to preserve fibre type composition 
(Joseph et al. 2013). A short-term 20% caloric restriction in rats had no positive 
effect in age-related atrophy of type IIb fibres (Mckiernan et al. 2004).  
Supplementation or restriction of protein has been associated with changes in 
mammalian skeletal muscle morphology. Moderate protein restriction 
upregulates the expression of MyHC I and IIa in skeletal muscles of mammals but 
such change is not observed with a low-protein diet or in MyHC IIb and IIx/d 
expression levels (Li et al. 2016a). High-protein diet has been associated with 
fast-to-slow fibre transformation in rats, due to increased oxidative properties of 






1.2.2 Genetic/biochemical influences of neuromuscular physiology and 
function 
Genetic factors that can affect neuromuscular development and ageing 
include genetic diseases such as spinal muscular atrophy (SMA). SMA is an 
autosomal recessive disease that is associated with loss of motoneurons, leading 
to skeletal muscle denervation and subsequent muscle weakness (Pearn, 1978). 
A study from Martínez-Hernández et al. (2014) showed differences in the 
percentage of fast and slow myosin in foetal skeletal muscle samples of SMA 
patients compared to the control samples. Moreover, their findings showed an 
increase in satellite cell number in postnatal atrophic fibres of SMA patients, 
indicating abnormal myogenesis (Martínez-Hernández et al. 2014). 
Biochemical factors include but are not limited to hormonal signalling such as 
growth and thyroid hormone signalling. Hormonal signalling has a key role in 
proper neuromuscular development. Hormonal deficiencies during pre-natal 
stages of development can result in abnormalities of foetal tissues, including 
skeletal muscles (Fowden et al. 1998, 2006). Glucocorticoids are also central 
mediators of skeletal muscle tissue programming and development during pre-
natal stages of development, due to their responsiveness to environmental cues 
that affect skeletal muscle cell differentiation in utero, with consequences later 
in life (reviewed in Fowden and Forhead, 2009). Furthermore, experiments 
undertaken in pigs showed that the expression patterns of growth hormone 
receptor (GHR) during foetal development along with the percentage of GHR in 
skeletal muscle during gestation suggest the involvement of the growth hormone 
(GH) in foetal muscle growth (Schnoebelen-Combes et al. 1996). Thyroid 
hormone has the potential to regulate muscle fibre type specification in skeletal 
muscle during early postnatal development (Russell et al. 1988). Imbalances in 
thyroid hormone levels result in muscle weakness and a myopathic phenotype 





1.2.2.1 Pathophysiological conditions regulating skeletal muscle fibre switch 
Fibre type isoforms in skeletal muscles can shift to different types or form 
hybrid isoforms under certain physiological conditions. Examples of such 
conditions include ageing, pathophysiological conditions and exercise. Fibre type 
transition tends to follow a fast-to-slow or slow-to-fast transition, which is 
reversible and sequential: MyHC I ↔ MyHC IIa ↔ MyHC IIx/d ↔ MyHC IIb 
(Pette and Staron, 2000). During this transition, hybrid fibres with a combination 
of MyHC isoforms may form, due to slow protein turnover of MyHC (reviewed in 
Schiaffino and Reggiani, 2011). 
Fibre type transitions have been widely observed in certain pathophysiological 
conditions. A well-studied example includes conditions characterised by 
imbalances in thyroid hormone. Thyroid hormone regulates the transition of 
muscle fibre isoforms from neonatal to adult fast MyHC independently of 
innervation (Russell et al. 1988). This transition is delayed during hypothyroidism 
but accelerated during hyperthyroidism (d’Albis et al. 1990). In adult skeletal 
muscle, thyroid hormone overexpression during hyperthyroidism induces a slow-
to-fast type transition in the direction of MyHC I ↔ MyHC IIa ↔ MyHC IIx/d ↔ 
MyHC IIb. The opposite direction is observed under hypothyroidism conditions 
were absence of thyroid hormone drives a fast-to-slow fibre type transition 
(reviewed in Schiaffino and Reggiani, 2011). Recent studies have shown that 
thyroid hormone regulation of fibre type isoforms is achieved via control of 
muscle-specific microRNA expression (Zhang et al. 2014).  
Neurological conditions can also influence fibre type shifting in skeletal 
muscles. One such example is Huntington’s disease, which seems to induce a 
reduction in type IIb isoform with a concomitant increase in type IIx in EDL 
muscle of mice. Transition of type IIa to type I fibres was also observed in the 
SOL muscle of those mice, highlighting the effect of the neurodegenerative 
disease in both fast and slow muscles (Hering et al. 2016). Fibre type switching 
has also been recorded during ALS disease with muscle fibre transitioning from 
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fast to slow. Moreover, hybrid fibres have been observed in muscles of ALS 
(Baloh et al. 2007).  
 
1.2.3 Neuromuscular morphology and function during ageing  
1.2.3.1 Skeletal muscle fibre switch during ageing 
Fibre type changes occur in skeletal muscles during ageing. In fast muscles, 
such as EDL and TA, a transition of type IIb fibres to type IIx is observed (Larsson 
et al. 1993). In slow muscles such as SOL, type IIa fibres switch to type I during 
ageing (Larsson et al. 1995). Muscle fibre atrophy in fast muscles during ageing is 
observed in all type II fibre types, while type IIb fibres appeared to be more 
preferentially lost during ageing (Lexell et al. 1988; Sakellariou et al. 2016). This 
susceptibility of type IIb fibres with ageing might be due to neuronal changes 
resulting in specific denervation of those fibres (Suzuki et al. 2009). Loss of type 
IIb fibres with ageing results in reduction of type II fibre proportion in aged 
muscles (reviewed in Schiaffino and Riggani, 2011). However, the arrangement of 
the different fibre types changes during ageing in humans and rodents, with 
different fibre types tending to group together, as a potential result of 
denervation-reinnervation process (Kanda and Hashizume, 1989; Lexell and 
Downham, 1991).  
 
1.2.3.2 Morphological and functional regulation of NMJs during ageing and 
disease 
NMJs can exhibit morphological and structural alterations during ageing or 
disease. Several changes at the NMJ were characterised by Valdez et al. (2010) in 
ageing mice. These changes include partial or complete denervation of the post-
synaptic site, multiple innervation, fragmentation of the AChR areas, axonal 
swelling, innervation beyond the receptor area and thin axons at the pre-
synaptic site (Valdez et al. 2010). Moreover, NMJ synaptic area enlargement and 
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increased complexity and fragmentation have been recorded in old mice (Rudolf 
et al. 2014).  
Fragmentation of the synaptic site has been observed in ageing mice and in 
adult animal models of muscle disorders, including the mdx mice, which develop 
the characteristics of muscular dystrophy (Pratt et al. 2015). Similar findings on 
NMJ fragmentation on ageing and mdx mice were also reported from other 
groups (Lyons and Slater, 1991; Rudolf et al. 2014). Fragmentation was also 
evident at NMJs of mice following tourniquet-induced injury (Tu et al. 2017). 
Fragmentation of NMJs may also occur following damage in the soma of the 
neuron, injury of the peripheral nerve and during ageing (Kuromi and Kidokoro, 
1984; Apel et al. 2009; Valdez et al. 2010). This morphological change in NMJ 
could be due to muscle fibre degeneration and regeneration; however, the exact 
impact of fragmentation on neuromuscular transmission is not clear yet (Pratt et 
al. 2015).  
NMJ denervation (partial or complete) has been widely studied both in ageing 
animals and during musculoskeletal defects. Similar to fragmentation, 
denervation of the synaptic site may occur as a result of muscle fibre 
degeneration-regeneration cycle (Pratt et al. 2015). However, denervation may 
result in muscle fibre atrophy and motoneuron cell death in ageing mice and 
mice with amyotrophic lateral sclerosis (ALS). In these conditions, the affected 
motoneuron cells do not have the capacity to quickly regenerate their axons and 
re-innervate the muscle fibre (Valdez et al. 2014). Similar results are seen in 
SOD1-/- mice, which have been widely used as a model or accelerated muscle 
ageing (Fisher et al. 2011). Interestingly, a study from Chai et al. (2011) provides 
evidence that NMJ denervation may be independent of motoneuron defects in 
geriatric mice.  
Under certain conditions, NMJ morphology might adopt a plaque-shaped 
conformation, similar to that seen during early stages of NMJ maturation. Such 
conditions include spinal muscular atrophy (SMA). In a study by Kong et al. 
(2009), mice with SMA exhibited delayed maturation of NMJs, which presented 
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the characteristic plaque formation, in comparison with the control mice. SMA 
mice also showed abnormal neurotransmission due to impairments in synaptic 
vesicle release and therefore release of neurotransmitters (Kong et al. 2009).  
Apart from morphological abnormalities, NMJ function and motor unit 
potential may also be impaired during ageing and disease, including SMA, ALS 
and Duchene muscular dystrophy (DMD) and myasthenia Gravis (MG). Although 
these conditions may have different underlying mechanisms, they might share 
some common factors. In humans, lowest motor unit potential is recorded in 
older men with sarcopenia, compared to healthy young men (Piasecki et al. 
2018). Smaller size of motor unit potential has also been associated with 
increased possibility of frailty in humans, independently of age or body mass 
index (Swiecicka et al. 2019). Impaired NMJ function is usually attributed to 
mutations of genes expressing key proteins for AChR clustering. Agrin proteolysis 
has been shown to destabilise NMJs resulting in a sarcopenia-like phenotype in 
mice (Bütikofer et al. 2011). Inhibition of MuSK, agrin and Lrp4 signalling from 
has also been observed in patients with MG, who presented increased level of 
antibodies against these proteins in their plasma (reviewed in Li et al. 2017). 
Interestingly, overexpression of these proteins can prove beneficial in mice 
expressing these diseases (reviewed in Li et al. 2017). Improvement of NMJ 
function and morphology in mice has been evident following exercise and caloric 
restriction (Rudolf et al. 2014; Valdez et al. 2010).  
 
1.3 Key signalling pathways controlling cell function and survival in skeletal 
muscle and neurons 
Skeletal muscle and neuronal function and survival are regulated by key 
signalling pathways, whose dysregulation may be accounted for cell dysfunction 
during ageing or disease. Such pathways include: i) IGF-1/AKT/PI3K/mTOR 
pathway, ii) FoxO signalling, iii) autophagy/mitophagy pathway and iv) 
neurotrophin pathway.   
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IGF-1/AKT/PI3K/mTOR pathway has the capacity to control protein synthesis 
and reduce protein degradation in skeletal muscle. Inhibition of this pathway has 
been associated with muscle wasting, as IGF-1 declines with age but counteracts 
the characteristics of sarcopenia when reactivated (reviewed in Larsson et al. 
2018). Recent studies focus on IGF-1’s role in ameliorating progression of 
neurodegenerative diseases such as ALS, when injected into the muscle of mice 
(Dodge et al. 2008). Another important player regulating protein synthesis and 
protein breakdown is the mammalian target of rapamycin (mTOR), which is 
activated by Akt long with other downstream factors (Schiaffino et al. 2013). 
mTOR binds with other proteins to form two distinct complexes, mTORC1 and 
mTORC2 (Schiaffino et al. 2013). mTORC1 has been identified as a key regulator 
of the autophagy process via phosphorylation of the mammalian autophagy-
initiating kinase Ulk1 in a nutrient-dependent manner (Hosokawa et al. 2009; 
Kim et al. 2011). mTORC1 also controls protein synthesis via phosphorylation of 
key substrates including S6-kinase (S6K) (reviewed in Yang and Guan, 2007). In 
addition to protein synthesis and degradation, mTOR has been shown to control 
mitochondrial respiration and gene expression through YY1-PGC1α complex, via 
direct interaction of transcription factor Yin Yang 1 (YY1) with mTORC1 complex 
in mice (Cunningham et al. 2007). Whole-body knockout of mTOR in mice is 
lethal while muscle-specific knockout of mTOR results in severe myopathy and 
metabolic abnormalities, including impaired mitochondrial respiration, resulting 
in premature death at postnatal stages (Risson et al. 2009).  
FoxO acts downstream of the AKT/PI3K signalling and as a family of 
transcription factors it controls expression of genes involved in cell proliferation, 
survival, differentiation, oxidative stress (Paik et al. 2009). FoxO family comprises 
of four members: FoxO1, FoxO3, FoxO4 and FoxO6 and in muscle they regulate 
muscle atrophy and fibre type specification (reviewed in Xu et al. 2016). FoxO3 in 
particular, is involved in activation of muscle atrophy genes, including atrogin-1, 
and in the regulation of autophagy process (reviewed in Schiaffino and Reggiani, 
2011). FoxO signalling is also involved in the regulation of neurogenesis and 
neuronal stem cell proliferation and renewal (Paik et al. 2009).  
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Mitophagy is a quality control system for mitochondrial maintenance and 
function. Dysfunctioning mitochondria are targeted by autophagosomes and 
delivered to the lysosomes for degradation (reviewed in Yoo and Jung, 2018). 
Autophagy-related protein LC3 and mitophagy-related proteins PINK1 and Parkin 
are critical for selected removal of damaged mitochondria (reviewed in Larsson 
et al. 2018). Dysfunction of autophagy/mitophagy process has been associated 
with ageing phenotype in skeletal muscle due to inability of the cells to discard 
damaged mitochondria. Mice with muscle-specific deficiency in autophagy 
present all normal characteristics of sarcopenia including increased muscle 
wasting, NMJ fragmentation and muscle fibre denervation, leading eventually to 
premature death (reviewed in Larsson et al. 2018).  
Neurotrophin signalling has been widely studied on its role in regulating 
neuronal survival and function, but an increasing number of studies highlight the 
role of neurotrophins in skeletal muscle development and function (reviewed in 
Sakuma and Yamaguchi, 2011). The most studied neurotrophins in skeletal 
muscle include the brain-derived growth factor (BDNF), glial-derived growth 
factor (GDNF), nerve growth factor (NGF) and neurotrophins-3 and -4/5 (NT-3, 
NT-4/5). The expression of BDNF in skeletal muscle of rodents varies between 
different cell types and at different developmental stages (Mousavi and Jasmine, 
2006). BDNF expression levels are highly dependent on physiological and 
pathological conditions, such as exercise in healthy humans and patients with 
multiple sclerosis (Gold et al. 2003). BDNF, along with NT-4, has been shown to 
inhibit agrin-induced AChR clustering on myotubes in vitro (Wells et al. 1999). 
Recent studies have shown a decrease in BDNF levels in the brains of neonatal 
rat offspring following maternal low-protein diet (Marwarha et al. 2017). GDNF 
expression levels have been detected in both motoneuron cells and skeletal 
muscle of humans and rodents (Suzuki et al. 1998; Nguyen et al. 1998). 
Overexpression of GDNF has been associated with hyperinnervation of skeletal 
muscle fibres of mice during neonatal stages of development (Nguyen et al. 
1998). GDNF has also been shown to cause enhanced neurotransmitter release 
from motoneuron to skeletal muscle fibres through NMJs in neonatal mice, 
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highlighting its structural and functional role in maintaining NMJ plasticity in 
neonatal mice (Ribchester et al. 1998). The role of NT-4/5 is diverse and depends 
on the organism species and the stage of postnatal growth; however, studies 
have associated NT-4/5 expression with fibre type conversion, motoneuron 
survival, NMJ formation and neurotransmitter release via binding to tyrosine 
kinase receptors TrkB and p75NTR (also known as NGFR) (reviewed in Sakuma and 
Yamaguchi, 2011). Interestingly, NT-3 has not been associated with regulation of 
skeletal muscle morphology in chickens (Wells et al. 1999). However, NT-3 has 
been associated with improved skeletal muscle reinnervation, following 
peripheral nerve injury in rats (Simon et al. 2001). NGF has been associated with 
improved skeletal muscle regeneration of mdx mice (Lavasani et al. 2006). 
Phenotypic knockout of NFG in mice leads to skeletal muscle atrophy and a 
dystrophic phenotype in adult mice (Ruberti et al. 2000). Additionally, increased 
levels of NGF were recorded in muscle biopsies of patients with ALS, but such 
increase was not observed in skeletal muscle of old rats (reviewed in Sakuma and 
Yamaguchi, 2011).  
 
1.3.1 Mitochondrial bioenergetics   
Mitochondria are the “powerhouses” of the cells, providing the necessary 
energy for the cell’s metabolic activities to occur. Mitochondria regulate cell 
processes including apoptosis, signal transduction, energy production and 
metabolism (Li et al. 2013). Energy production is mainly achieved by oxidative 
phosphorylation (OXPHOS), which is the primary function of the mitochondria (Li 
et al. 2013). The term “oxidative phosphorylation” refers to the process by which 
mitochondria utilise electrons released following oxidation of substrates, which 
are transported through enzymes in the mitochondrial inner membrane to drive 






Figure 1.3.1 Mitochondrial oxidative phosphorylation (OXPHOS) electron 
transport system (ETS) (adapted/redrawn from Matroeni et al. 2017).  
 
Electrons are transported through the inner mitochondrial membrane via four 
enzyme complexes (complex I, II, III and IV), three of which pump H+ to the 
intermembrane space (complexes I, III and IV). This system is known as the 
electron transport system (ETS) or electron transport chain (ETC) (reviewed in 
Gnaiger, 2009). Substrates from nutrient metabolism, such as malate and 
pyruvate, enter the tricarboxylic acid (TCA) cycle, where NADH is produced and 
subsequently reduced to NAD+ by Complex I, which pumps H+ generated from 
this reaction into the intermembrane space of the mitochondria (reviewed in 
Chaba et al. 2014). Complex II or succinate dehydrogenase (SDH) is the only 
enzyme that participates in both the TCA cycle and in ETS. Within the TCA cycle, 
complex II converts succinate to fumarate with subsequent release of electrons. 
These electrons are used by complex II within the ETS to reduce FADH2 to FAD, 
with further release of electrons into the ETS. Complex II is not a proton pump, 
and it is the second entry point (after complex I) to the ETS (Rutter et al. 2010). 
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Complex III converts ubiquinone to ubiquinol via oxidation, pumping generated 
H+ into the mitochondrial intermembrane space, while the electrons enter the 
cytochrome C carrier (reviewed in Chaba et al. 2014). Finally, complex IV, the 
largest enzyme of the ETS, known as cytochrome C oxidase (COX) received 
electrons from cytochrome C and uses them for the conversion of O2 to H2O, 
using H+ present in mitochondrial cytosol (reviewed in Chaba et al. 2014). The 
OXPHOS system contains the enzymes of the ETS plus Complex V or ATPase 
synthase, which uses the H+ dispensed in the intermembrane space to convert 
ADP to ATP (reviewed in Jonckheere et al. 2012).  
The enzymes of the electron transport chain are often seen in the form of 
large complexes, known as supercomplexes. Three main supercomplexes have 
been observed between complex I, III and IV: i) Complexes I + III + IV (known as 
the respirasome), complexes I + III and complexes III + IV (Lapuente-Brun et al. 
2013). The respirasome (Complex I + III + IV) is most abundant in mammals; 
however complex IV is found mostly a monomer and not part of a supercomplex, 
while complex II is the only enzyme that does not form supercomplexes 
(reviewed in Chaba et al. 2014).  
Each enzyme of the respiratory chain is comprised of different subunits, which 
are encoded by both nuclear and mitochondrial genes. Specifically, complex IV is 
comprised of 13 subunits, 3 of which are encoded by genes in the mitochondrial 
DNA (mt DNA) (subunits I, II, II) and the rest 10, including subunit IV, is encoded 
by genes located in the nuclear DNA (Dhar et al. 2008). The expression of those 
genes is regulated by two transcription factors, nuclear respiratory factor 1 (NRF-
1) and nuclear respiratory factor 2 (NRF-2) in both rats, mice and humans (Dhar 
et al. 2008).  
 
1.3.1.1 Mitochondrial dysfunction during ageing and disease   
Mitochondrial dysfunction can have a detrimental effect on cell function and 
survival. During ageing, mitochondrial function and mitochondrial enzyme 
activity decline. This is also accompanied by an accumulation of mutations in 
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mtDNA (Short et al. 2005). Accumulation of mitochondrial mutation has been 
linked to increase in reactive oxygen species (ROS) production, leading to 
reduction in OXPHOS (reviewed in Wallace, 1999). Mitochondrial mutation 
number in neurons is elevated in patients with neurodegenerative disorders, 
including Alzheimer’s and Huntington’s disease and these mutations are 
accompanies by an increase in oxidative damage (reviewed in Wallace, 1999). 
Mitochondrial dysfunction and decline in ATP production have been associated 
with reduction in mtDNA copy number with age (Short et al. 2005).  
Mutation or inhibition of genes encoding mitochondrial proteins has also 
been responsible for mitochondrial dysfunction during ageing and disease. 
Deficiency of MnSOD, a mitochondrial protein with antioxidant properties, 
causes substantial reduction in complexes II and III activity in skeletal muscle of 
mice, inhibiting the ETS (reviewed in Wallace, 1999). Age-related decline in 
complexes I, III and IV during ageing in skeletal muscle and brain of mice is 
believed to be associated with mutations in the mtDNA gene transcripts 
encoding subunits of these complexes (Feuers, 1998). These results are 
supported further by the absence of age-related decline in complex II activity, 
whose subunits are all encoded by genes in nuclear DNA (reviewed in van 
Remmen and Richardson, 2000). Specifically, decline in complex IV activity with 
ageing has been observed in the brain, the synaptic mitochondria and skeletal 
muscle (reviewed in van Remmen and Richardson, 2000). Complex IV is believed 
to be a key player in cell metabolic control, signalling and survival due to its 
position as the terminal enzyme in the ETS (reviewed in Arnold 2012). Complex 
IV defects may be attributed to inhibition of genes encoding its subunits, due to 
silencing of the transcription factors, such as NRF-1, controlling their expression 
(Dhar et al. 2008). Increased mitochondrial stress and damage beyond protein 
level can trigger several pathways including mitochondrial degradation via 
mitochondrial autophagy (mitophagy) (reviewed in Yoo and Jung, 2018).  
Regulation of molecular mechanisms can be tissue-specific, but it may also occur 
simultaneously and in multiple tissues. Factors that have the capacity to control 
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multiple signalling pathways concomitantly in different tissues include small, 
non-coding RNA molecules, such as microRNAs.  
 
1.4 Control of gene expression by microRNAs 
1.4.1 MicroRNA biogenesis, processing and port-transcriptional control of 
gene expression 
MicroRNAs (miRNAs) are small, single-stranded non-coding RNA molecules of 
approximately 20-22 nucleotides in length, that have the ability to control gene 
expression mainly by direct binding to the 3’-untranslated region (UTR) region of 
their mRNA transcript (Ambros, 2001; Lagos-Quintana et al. 2002). The first 
miRNAs, lin-4 and let-7, were discovered in Caenorhabditis elegans (C. elegans), 
where mutants of these two miRNAs caused temporal deregulation of lavae 
development (Lee et al. 1993, Reinhart et al. 2000). Lin-4 and let-7 did not 
encode for any proteins and produced very small transcripts in length from 
precursor RNA molecules with a distinguished hairpin structure (Ambros, 2001). 
A later study on let-7 revealed the conservation of this miRNA, both in length and 
sequence between species (Pasquinelli et al. 2000).  
MicroRNA genes are distributed across the genome and are found either as 
clusters (polycistronic) or as independent units on intergenic regions, intronic 
sequences of transcriptional units or exonic sequences of non-coding genes 
(Figure 1.4.1; reviewed in Fazi and Nervi, 2008). Polycistronic miRNA genes 
generate pri-miRNA transcript processed by endonuclease RNase III Drosha, 
forming a complex with DiGeorge Syndrome Critical Region 8 (DGCR8) protein 
(Drosha/DGCR8 complex), producing multiple pre-miRNAs with a characteristic 
70-90 nt hairpin-shaped stem-loop structure (Lee et al. 2003). Pri-miRNA 
transcripts generated by independent units (intergenic, intronic/exonic) are also 
processed by Drosha/DGCR8, generating a 70-90 hairpin-shaped pre-miRNA 
transcript, which is then exported from the nucleus (Fazi and Nervi, 2008). 
Certain intronic miRNAs are processed in a Drosha-independent manner, 
escaping the canonical pathway of pre-miRNA biogenesis and producing pre-
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miRNA transcripts known as miRtrons (reviewed in Westholm and Lai, 2011). 
miRtrons are shorter in length than the canonical pri-miRNAs and are generated 
by intron splicing and debranching by lariat debranching enzyme (Ldbr), before 
they enter the canonical pathway of pre-mRNA processing (Ruby et al. 2007).  
Pre-miRNAs are actively exported from the nucleus into the cytosol by 
exporting-5 (Yi et al. 2003). There, pre-miRNA is recognised by enzyme Dicer and 
its partner TAR (HIV) RNA binding protein (TRBP) (Dicer/TRBP complex) and 
cleaved near the terminal loop, producing a miRNA/miRNA* duplex with 2 nt 
overhand at both 3’-ends (Bernstein et al. 2001; Hutvagner et al. 2001; reviewed 
in Starega-Roslan et al. 2011). miRNA/miRNA* duplex is loaded onto the 
Argonaute (Ago) protein of the miRNA-induced silencing complex (RISC) 
complex, where the least thermodynamically stable strand at the 5’ end is 
retained by the RISK complex (“guide” strand) while the other strand 
(“passenger” strand) is usually degraded, although in some cases it is functional 
(Schwarz et al. 2003). The “guide” strand bound to the RISC complex (mature 
miRNA) binds to the 3’UTR region of the target mRNA transcripts via a 
complementary sequence known as the “seed” region (2-7 nucleotides in length 
at the 5’ end of the miRNA) and represses their expression or inhibits their 





Figure 1.4.1 The canonical pathway of microRNA biogenesis and processing 
(redrawn from Fazi and Nervi, 2008).   
 
Post-transcriptional gene repression (or in some cases activation) by miRNAs 
occurs mainly by deadenylation and subsequent degradation or translational 
repression of the target mRNA as seen in Figure 1.4.2 (reviewed in Filipowicz et 
al. 2008). mRNA degradation occurs by rapid removal of the poly-(A) tail causing 
destabilisation of the mRNA transcript and decapping, which then leads to mRNA 
decay occurring in the P-bodies (Wu et al. 2006; Eulalio et al. 2007). Degradation 
of target mRNA is also seen of miRNA-AGO2 to the mRNA target site, where 
AGO2 acts as an endonuclease, cleaving the mRNA at the centre (Meister et al. 
2004).  Translational repression of the target mRNA can occur via three different 
mechanisms: repression of translation initiation or repression of post-initiation 
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steps (reviewed in Filipowicz et al. 2008). Translational repression at the 
initiation step is observed when miRNA binds to the m7G cap in the 3’UTR, 
preventing the binding of transcription factors such as elF4E (Humphreys et al. 
2005; Pillai et al. 2005). Translational repression at the initiation step can also 
take place by eLF6 recruitment to the RISC complex, which binds to the 60S 
ribosomal subunit, preventing it from joining the 40S subunit and therefore 
stalling the translation process (Chendrimada et al. 2007). Post-initiation 
translational repression occurs when the ribosomes “drop off” prematurely, 
terminating the translation process prematurely and leaving the nascent 
polypeptide incomplete (Petersen et al. 2005).  
Under certain conditions and in specific tissues or cell types, miRNAs have the 
potential to induce upregulation of post-transcriptional regulation. A study from 
Vasudevan et al. (2007) provides evidence on how a well study microRNA, let-7, 
can induce increased translation of its mRNA targets during cell cycle arrest but 
repress the translation of those mRNA targets during cell proliferation. Based on 
this evidence, they propose a novel role of microRNA function which oscillates 
between repression and activation of the targeted mRNAs during difference 




Figure 1.4.2 Mechanisms of miRNA-mediated post-transcriptional gene 
repression (redrawn from Filipowicz et al. 2008).  
 
 
1.4.2 MicroRNA-128: regulation of key mechanisms in skeletal muscle and 
neurons  
MicroRNA-128 (miR-128) is an intronic miRNA encoded by miR-128-1 and 
miR-128-2 genes located on the introns of R3HDM1 gene (chromosome 2q21.3) 
and RCS gene (chromosome 3p22.3) respectively (Bruno et al. 2011). These 
genes are conserved among human, mouse and rat genome (Megraw et al. 
2010). Following processing, both miR-128-1 and miR-128-2 yield a mature 
microRNA identical in the sequence, called miR-128 (reviewed in Li et al. 2013).  
miR-128 is a brain-enriched microRNA that plays a key role in neuronal 
development and maintenance (reviewed in Ching and Ahmad-Annuar, 2015). 
miR-128 has also been studied extensively in relation to cancer and 
tumorigenesis. Increased levels of miR-128 were found in patients with acute 
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leukaemia and have been considered as a biomarker for prognosis and diagnosis 
of this type of cancer (Zhu et al. 2011). Despite its abundance in the brain and in 
various types of cancer, miR-128 was also found to be highly expressed in 
skeletal muscle tissue (Motohashi et al. 2013).  
 
1.4.2.1 Role of miR-128 in skeletal muscle 
Increased levels of miR-128 expression were recorded in brain and TA muscle 
in adult mice (Motohashi et al. 2013). miR-128 has also been shown to regulate 
the proliferation and differentiation of muscle side population (SP) cells, a 
distinct population of muscle stem cells with multipotent characteristics, which 
do not express the muscle satellite cell marker, Pax7 (Motohashi et al. 2012). In 
their study in 2013, Motohashi et al. demonstrated the regulation of insulin 
signalling pathway by miR-128, through direct targeting of Insr (insulin receptor), 
Isr-1 (insulin receptor substrate-1) and Pi3kr1 (phosphatidylinositol 3-kinases 
regulatory 1) mRNA, inhibiting their expression. Inhibition of miR-128 in vitro, 
resulted in hypertrophy of the cultured myotubes and increase of IRS-1 and AKT 
proteins, while administration of antisense miR-128 in vivo resulted in increased 
skeletal muscle mass in 4 weeks old mice (Motohasi et al. 2013). Results from 
this study show that miR-128 is capable of promoting skeletal muscle 
hypertrophy in vivo and in vitro, following inhibition of its expression levels. 
Further studies have shown miR-128 directly targeting myostatin (Mstn) gene 
transcript in C2C12 cells, while stalling their proliferation and promote their 
differentiation into myotubes (Shi et al. 2015). In vivo experiments showed 
increased expression of miR-128 accompanied by a significant decrease in MSTN 
protein levels in the skeletal muscle of 8-weeks old mice (Shi et al. 2015). 
Another study has shown correlation of miR-128 with ATP levels during myoblast 
differentiation. Specifically, increased levels of miR-128 were in agreement with 
increased ATP levels at Day 4-8 post-differentiation of C2C12 cells (Siengdee et 
al. 2015). Furthermore, miR-128 increased levels in C2C12 myotubes were 
accompanied by up-regulation of the expression levels of genes involved in 
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mitochondrial energy metabolism, including Cox6a2 (Seingdee et al. 2015). 
Cox6a2 gene encodes one of the subunits of Complex IV of the mitochondrial 
respiratory chain and inhibition of this gene has been shown to decrease 
mitochondrial activity and promote muscle-fibre type switching, protecting mice 
against high-fat diet-induced obesity (Quintens et al. 2013). miR-128 has also 
been implicated in skeletal muscle stress response by directly targeting the v-Maf 
avian musculoaponeurotic fibrosarcoma oncogene homolog G (MAFG) gene 
transcript and therefore controlling biochemical pathways associated with 
oxidative stress (Caggiano et al. 2017). In line with previous studies, Dai et al. 
(2016) demonstrate the ability of miR-128 to regulate bovine satellite cell 
proliferation and differentiation in skeletal muscle via direct targeting and 
inhibition of Sp1 transcript. Similar results were obtained from studies in 
cardiomyocytes, where inhibition of miR-128 resulted in increased proliferation 
of postnatal cardiomyocytes cells; the opposite results were seen with tissue-
specific overexpression of miR-128 in neo-natal mice (Huang et al. 2018).  
 
1.4.2.2 Role of miR-128 in neuronal cells 
The abundance of miR-128 expression in the brain and central nervous system 
(CNS) has made it an ideal candidate for investigation of the mechanisms it 
regulates. miR-128 has the capacity to determine neuronal progenitor cell fate in 
vivo and in vitro by directly targeting Pcm1, which controls proliferation and 
neurogenesis of NPC cells in the developing cortex of mice (Zhang et al. 2016). 
Overexpression of miR-128 in vitro and in utero enhanced neuronal 
differentiation of NPC cells but inhibited their proliferation, by supressing the 
translation of Pcm1 mRNA (Zhang et al. 2016). Spatial as well as temporal 
regulation of miR-128 expression is important for the regulation of neuronal 
development in the cortex of mouse embryo (Franzoni et al. 2015). In their 
study, Franzoni et al. (2015) have demonstrated how inhibition of miR-128 
caused excessive migration of neuronal cells in the upper layer of the cortex. 
Two more studies have demonstrated the role of miR-128 in neuronal excitability 
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in mice. The first study from Tan et al. (2013) highlighted the modulation of 
motor behaviour by miR-128 through regulation of neuronal signalling pathways 
and neuron excitability. Specifically, they demonstrated the effect of miR-128 
inhibition on neuronal motor hyperactivity in adult neurons, resulting in seizure 
and a Parkinson’s-like phenotype in mice (Tan et al. 2013). An inverse 
relationship was observed between neurons overexpressing miR-128 and motor 
activity, which appeared decreased and was accompanied by a reduction in ERK2 
activation (Tan et al. 2013). Similar data were shown in a later study from 
McSweeney et al. (2016), where inhibition of miR-128 in neuronal cells in vitro 
caused increased neuronal hyperactivity.  
Apart from direct targeting of specific mRNAs, miR-128 has been shown to 
control gene expression in developing neurons by controlling nonsense-
mediated decay (NMD) process. NMD mediates degradation of mRNA transcripts 
and inhibition of this process has been associated with impaired 
neurotransmitter signalling and synaptic vesicle cycling at the neuromuscular site 
(Long et al. 2010). miR-128 disrupts NMD by direct targeting of one of its genes, 
Upf1, causing disruption in NMD pathways and subsequent upregulation of the 
mRNA transcripts regulated by NMD for degradation (Bruno et al. 2011).  
Several studies have focused on the association of miR-128 with 
neuropsychiatric disorders, due to its ability to regulate neuronal cell behaviour 
and fate. Of particular interest is the interaction of miR-128 with Arpp21, as miR-
128 gene is located within an intron of the longest isoform of Arpp21 gene, 
which it also targets (Megraw et al. 2010). Deregulation of Arpp21 expression 
has been associated with several neurological syndromes, including but not 







1.4.2.3 Role of miR-128 in cell senescence, metabolism and cancer 
Aside from its role in skeletal muscle and CNS, miR-128 has been shown to be 
involved in regulating cell senescence, cholesterol metabolism and various forms 
of cancer biology. miR-128 promotes cell senescence by direct targeting of Bmi-
1, which results in inhibition of cancer cell growth by increased intracellular ROS 
levels (Venkataraman et al. 2010). Several studies have reported miR-128 as a 
tumour suppressive microRNA, as downregulation of its expression levels is seen 
in various types of cancer, such as glioblastoma, medulloblastoma and acute 
myeloid leukaemia (reviewed in Feliciano et al. 2010).  A study from 
Papagianakopoulos et al. (2012) highlighted miR-128 tumour suppressive 
properties by targeting and repression of Egfr and Pdgfrα genes, involved in the 
receptor tyrosine kinase (RTK) signalling. Cell apoptosis in embryonic kidney stem 
cells was induced by repression of Bcl-2-associated X protein (Bax) gene through 
direct targeting by miR-128 (Adlakha and Saini, 2011). BAX, a member of the Bcl-
2 family, is translocated under stress conditions from the cytosol to the outer 
membrane of the mitochondria, creating pores and impairing mitochondria 
respiration, leading the cells to apoptosis (Adlakha and Saini, 2011). Findings 
from the study by Lian et al. (2018) are also in line with these findings. 
Specifically, Lian et al. have demonstrated the regulation of colorectal cancer cell 
apoptosis during overexpression of miR-128, which supresses the expression of 
its direct target sirtuin-1 (Sirt-1), leading to accumulation of intracellular ROS 
(Lian et al. 2018). Apart from its pro-apoptotic properties, miR-128 has also been 
associated with the regulation of cholesterol homeostasis. Upregulation of miR-
128 was associated with decreased expression of genes involved in cholesterol 
metabolism by repression of genes involved in cholesterol efflux (Aldakha et al. 
2013). Whether miR-128 retains similar properties under the effect of dietary 





1.4.3 MicroRNA-133a: regulation of key mechanisms in skeletal muscle and 
neurons  
MicroRNA-133a belongs to a family of microRNAs expressed specifically in 
muscle tissue and are therefore known as “myomiRs” (reviewed in van Rooij et 
al. 2008). miR-133a gene is clustered with miR-1 gene on chromosome 2 
(seprated by 9.3 kb) and on chromosome 18 (separated by 2.5 kb) in mice (Chen 
et al. 2005). Both miR-1 and miR-133a are expressed as a bicistronic transcript 
specifically in cardiac and skeletal muscle tissue (Chen et al. 2005). miR-133a-1 
and miR-133a-2 (chromosomes 18 and 2 respectively) have an identical 
sequence which only differs in the last 2 nucleotides at the 3’ end of miR-miR-
133b (reviewed in van Rooij et al. 2008). This similarity in miR-133 sequences can 
prove challenging in functional studies.  
 
1.4.3.1 Role of miR-133a in cardiac and skeletal muscle 
The role of microRNA-133a (miR-133a) in muscle development and function 
has been extensively studied, since its tissue-specific expression was reported by 
Lagos-Quintana et al. (2002). miR-133a has been identified as a key regulator of 
skeletal muscle and cardiac muscle cell proliferation and differentiation in vitro 
and in vivo. In their study, Chen et al. (2005) identified miR-133a as an inducer of 
myoblast proliferation in C2C12 cells. Temporal regulation and level of miR-133a 
expression was also proven essential, as increased miR-133a levels in 
malformations of cardiac tissue during development (Chen et al. 2005). 
Furthermore, Chen et al. (2005) identified serum response factor (Srf) gene, a 
key player in proliferation and differentiation of skeletal muscle, as a direct 
target of miR-133a. Expression levels of miR-133a are higher during 
differentiation of C2C12 myotubes but levels are not detectable in C2C12 
myoblasts, implying that its expression is induced during differentiation in vitro 
(Rao et al. 2006). Furthermore, findings from Rao et al. (2006) demonstrated the 
regulation of miR-133a expression by MyoD and myogenin in C2C12 myotubes, 
which is in line with findings from previous findings from Chen et al. (2006). 
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Inhibition of miR-133a in C2C12 myotubes appeared affect myotube elongation 
and morphology rather than differentiation process, as seen with other myomiRs 
(Kim et al. 2006). Expression of miR-133a in C2C12 myotubes was suppressed 
with addition of FGF which is a key component of ERK/MAPK pathway 
(Sweeetman et al. 2008). During early development, miR-133a expression is also 
regulated by MEF-2 enhancer on a transcriptional and post-transcriptional level 
in skeletal and cardiac muscle of mice (Liu et al. 2007). Regulation of myogenesis 
in vitro also occurs through repression of uncoupling protein -2 (UPC-2) gene, 
which is a direct target of miR-133a (Chen et al. 2009b). Repression of Upc-2 
expression in C2C12 cells resulted in attenuated proliferation and enhanced 
myoblast differentiation, highlighting further the key role of miR-133a in the 
regulation of myogenesis (Chen et al. 2009b).  
Three studies focused on the effect of gain- and loss-of function of miR-133a 
in skeletal muscle fate and disease. A study from Huang et al. (2011) revealed 
direct targeting of Igf1r transcript by miR-133a. Gain- and loss-of-function 
experiments showed suppression of Igf1r expression in C2C12 myotubes 
following overexpression of miR-133a; however supplementation of IGF-1 (ligand 
of IGF-1R) in C2C12 cells resulted in upregulation of miR-133a expression (Huang 
et al. 2011). The findings from this study indicate regulation of miR-133a 
expression via IGF-1 mediated feedback loop in modulation of myogenesis, 
suggesting that miR-133a could be a promising therapeutic target for skeletal 
muscle diseases (Huang et al. 2011). A second study from Deng et al. (2011) 
investigated the effect of miR-133a overexpression in mdx mice, a model of 
Duchene muscular dystrophy. miR-133a expression levels were significantly 
increased in the skeletal muscle of those mice; however, transgenic mice 
overexpressing miR-133a in skeletal muscle demonstrated normal muscle 
development and function (Deng et al. 2011). Interestingly, a third study from Liu 
et al. (2011) demonstrated the effect of miR-133a deletion in vivo, adult-onset 
centronuclear myopathy in fast-twitch muscle fibres, impaired mitochondrial 
function and fibre type switching in mouse skeletal muscle. miR-133a was also 
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implicated in the regulation of fibre type conversion through modulation of 
thyroid hormone action in skeletal muscle (Zhang et al. 2013).  
Further studies have focused on the role of miR-133a in the regulation of 
myogenesis via modulation of different pathways. In their study, Zhang et al. 
(2012) indicated Sp-1 transcript as a direct target of miR-133a, inducing mitotic 
arrest in C2C12 myoblasts and inhibiting proliferation. Moreover, miR-133a was 
identified as a repressor of ERK1/2 signalling pathway activity, by directly 
targeting two components of this signalling pathway, Fgfr1 and Ppp2ac 
transcripts (Feng et al. 2013). Repression of ERK1/2 signalling resulted in 
repressed cell proliferation and promotion of cell differentiation (Feng et al. 
2013). Inhibition of miR-133a in chick embryos led to an increase in the 
expression levels of the target genes BAF60a and BAF60b transcripts, impairing 
the timing of myogenic differentiation (Goljanek-Whysall et al. 2014). Foxl2 
transcript was also identified as a direct target of miR-133a, regulating skeletal 
muscle differentiation in vitro through a different mechanism than the ones 
previously described (Luo et al. 2015). A recent study from Mok et al. (2018), also 
implicated Hedgehog pathway modulation via miR-133a in the regulation of 
myogenesis at embryonic stages.  
 
1.4.3.2 Role of miR-133a in neuron cells 
Despite its specific expression in skeletal and cardiac muscle, recent studies 
have associated changes in miR-133a expression following neuronal alterations 
and injury. Expression levels of known target genes of miR-133a were 
significantly altered in rats 7 days following traumatic spinal cord injury (SCI), 
suggesting a possible relationship between miR-133a and injury responses at the 
spinal cord (Yunta et al. 2012). These findings are in line with previous evidence 
from Nakanishi et al. (2009) showing an upregulation of miR-133a expression 
levels just 24 hours after spinal cord injury in mice. Interestingly, during early 
embryonic development, miR-133a appears to have an inhibitory role in stem 
cell differentiation to neuron cells, by suppression of neuronal genes involved in 
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neuronal cell fate specification in vitro (Ivey et al. 2008; Izarra et al. 2017).  
Recent study by Hoye et al. (2017) has shown the potential role of miR-133a in 
motoneuron cells, with a number of its target genes showing increased 
expression levels in those cells during postnatal growth. In the context of 
neuromuscular junctions, expression of miR-133a does not seem to be 
significantly altered after 10 days of denervation in TA muscle of ALS mouse 
model (Williams et al. 2009).  
In recent years, microRNAs have been of particular interest due to their potential 
of controlling multiple signalling pathways in many different tissues 
simultaneously, making them a high-throughput mechanism of gene expression. 
This is of particular importance in the field of skeletal muscle development and 
ageing where multiple events occur simultaneously.  
 
1.5 Hypothesis 
Pre- and/or early postnatal protein restriction adversely affects the 
homeostasis of muscle fibres and/or neuromuscular junctions and this is, at least 
partially, regulated by modified microRNA-target interactions in muscles and 
nerves of the offspring. Therefore, manipulation of microRNA expression may 
serve as a tool for restoration of neuromuscular morphology and function during 
dietary protein restriction.  
 
1.6 Aims 
The aims of this study were to:  
i) Determine the effects of protein-deficient diet during pre- and postnatal 
stages of development in skeletal muscle and neuromuscular junctions of 
12-week old mice (Chapter 3) 
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ii) Identify changes in expression levels of microRNAs, selected based on their 
function, in skeletal muscle and peripheral nerve of 12-week old mice on a 
protein-deficient diet pre- or postnatally (Chapter 4) 
iii)  Identify predicted target genes of microRNAs with potential role in 
regulating neuromuscular homeostasis and differentially expressed in 
muscle and/or nerve of 12-week old mice on a protein-deficient diet pre- or 
postnatally using in silico analysis (Chapter 4) 
iv) Investigate the effect of gain- and loss-of-function of miR-128 and miR-133a 
in skeletal muscle cell phenotype in vitro (Chapter 5) 
v) Investigate the effect of gain- and loss-of-function of miR-128 and miR-133a 
in motoneuron cell phenotype in vitro (Chapter 6) 
vi) Investigate the expression levels of miR-128 predicted target genes and their 
































2 Materials and Methods 
2.1 Animals 
In this study female and male C57BL/6 Thy1-YFP16 transgenic mice were used 
(The Jackson Laboratory; Thy-1 YFP-16, Stock# 003709). These mice express 
yellow fluorescent protein (YFP) in the motor neurons and sensory neurons at 
high levels (with no expression in non-neuronal cells and no apparent toxic 
effects) allowing the visualisation of motor neurons and muscle innervation from 
mid-gestational stages without the use of antibody staining (Vasilaki et al. 2016). 
This provides a novel approach in the assessment of structural alterations in 
motor neurons and neuromuscular junctions (NMJs) in muscle using fluorescent 
microscopy.  
All experiments were performed in 12-week old mice, allowing the 
examination of the effect of a protein-deficient diet until the end of postnatal 
period. All mice were housed in the Biomedical Services Unit at the University of 
Liverpool under a control environment and subjected to 12 h light-12 h dark 
cycle.  
Two weeks prior mating, nulliparous female mice where introduced to either 
a control diet (20% Crude Protein W/W ISO’ (P), Code 829206, Special Diet 
Services, Essex, UK) or a low protein diet (5% Crude Protein W/W ISO’ (P), Code 
829202; Special Diet Services, Essex, UK) and maintained in those diets 
throughout the study. Both diets will be isocaloric but differ in the amount of 
casein as previously described (Chen et al. 2009; Appendix, Table A6). After 
acclimation to the chow, breeders were placed together and maintained in those 




Figure 2.1.1 Experimental design (N) 20% diet (L) 5% diet. Group N: Control mice 
produced from dams fed on normal chow. Group L: Mice produced from dams 
maintained on a low protein diet. Group N-N: Mice produced from dams 
maintained on a normal protein diet and fed postnatally by a dam maintained on 
a normal diet. Culled and analysed at weaning (21 days). Group N-L: Mice 
produced from dams maintained on a normal protein diet but fed postnatally by 
a dam maintained on a low diet. Culled and analysed at weaning (21 days). 
Group L-N: Mice produced from dams maintained on a low protein diet but fed 
postnatally by a dam maintained on a normal diet. Culled and analysed at 
weaning (21 days).  Group N-N-N: Control mice produced from dams fed on 
normal protein chow, fed postnatally by a dam maintained on a normal diet until 
weaning and maintained on a normal diet until 3 months of age. Group N-L-L: 
Control mice produced from dams fed on normal protein chow, fed postnatally 
by a dam maintained on a low diet until weaning and maintained on a low diet 
until 3 months of age. Group L-N-N: Mice produced from dams fed on low 
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protein chow, fed postnatally by a dam maintained on a normal diet until 
weaning and maintained on a normal diet until 3 months of age.    
Newborn pups born from either a mother on a normal protein diet (M(N)) or 
a protein-deficient diet (M(L)) were cross-fostered to a different lactating dam 
maintained either on a normal or a low-protein diet, within 24 hours after birth, 
generating the following 3 groups: NN, NL, LN. (Figure 2.1.1). Pups were culled 
either at weaning (21 days) by cervical dislocation or were weaned onto either 
the deficient or the control diet until 12 weeks of age, generating 3 groups: NNN, 
NLL, LNN. Group N-N-N represents the control group with mice produced from 
dams fed on normal protein chow, lactated postnatally by a dam maintained on 
a normal diet until weaning and maintained on a normal diet until 12 weeks of 
age. Group N-L-L represents mice produced from dams fed on normal protein 
chow, fed postnatally by a dam maintained on a low-protein diet until weaning 
and maintained on a low-protein diet until 12 weeks of age. Group L-N-N 
represents mice produced from dams fed on low-protein chow, fed postnatally 
by a dam maintained on a normal diet until weaning and maintained on a normal 
diet until 3 months of age. 
A more detailed explanation for the keys of each group is shown in Figure 2.1.2 




Figure 2.1.2 Schematic illustration of the key name that has been used to distinct 
separate mice in the different experimental groups based on their protein diet 
they were under at different time points and up until 12 weeks of age. 
 
2.2 EDL muscle force measurements 
At 12 weeks of age, mice were collected and anaesthetised via intraperitoneal 
(IP) injections of ketamine hydrochloride (66 mg/kg) and medatomidine 
hydrochloride (0.55 mg/kg).  
Following successful anaesthesia of the mouse, the distal level of the tendon 
of the EDL muscle was exposed and secured to the lever arm of a servomotor 
(Aurora Scientific). The knee of the hindlimb was fixed and bipolar platinum wire 
electrodes were placed across the exposed peroneal nerve. Optimal length (Lo) 
of the EDL muscle was recorded using serial increments of 1 Hz stimulation and 
set at the length that generates the maximal force. To determine the Po, EDL 
muscle was electrically stimulated to contract at Lo with optimal stimulation 
voltage (8–10 V) every 2 min for 300 ms with 0.2 ms pulse width. The frequency 
of stimulation was then increased from 10 to 50 Hz and followed by 50 Hz 
increments to a maximum of 300 Hz. When the maximum force of the EDL 
muscle reached a plateau, despite the increase of the stimulation frequency, Po 
was recorded.  
 
2.3 Tissue collection and preparation 
Reagents: 
• 10% neutral-buffered formalin (NBF) (Cat# HT501128; Sigma Aldrich, 
Dorset, UK) 
• Tissue preservative solution: 
o 0.01 M phosphate buffered saline buffer solution (PBS) (Cat# 
P4417; Sigma Aldrich, Dorset, UK) 
75 
 
o 0.1% w/v NaN₃ (Cat# S2002; Sigma Aldrich, Dorset, UK) 
Protocol: 
Mice were sacrificed by cervical dislocation. Body weight of the mice was 
recorded immediately following culling and muscle from both lower hindlimbs 
and both sciatic nerves were isolated and their weight was recorded. Following 
dissection, tissues were processed accordingly. Samples were then stored at -
80oC or 4oC until used. The fur of the mouse was removed from the rest of the 
body which was then fixed with 10% NBF for 24 h before stored in 0.1% PBS-
NaN₃.  
 
2.4 Neuromuscular junction (NMJ) staining 
Reagents: 
• α-bungarotoxin Alexa Fluor™ 594 Conjugate (Cat# B13423; Molecular 
Probes, Life Technologies Ltd, UK) 
• 0.01 M phosphate buffered saline buffer solution (PBS) (Cat# P4417; 
Sigma Aldrich, Dorset, UK) 
• 0.1% w/v NaN₃ (Cat# S2002; Sigma Aldrich, Dorset, UK) 
• 0.1% v/v Triton X-100 (Cat# X100; Sigma Aldrich, Dorset, UK) 
• 0.04% v/v Tween-20 (Cat# P1379; Sigma Aldrich, Dorset, UK) 
Protocol:  
To visualise acetylcholine receptors (AChRs) in Thy1-YFP16 mice, EDL muscles 
were stained as described previously (Valdez et al. 2010). Fixed EDL muscles 
were immersed into 0.1% PBS-Triton X-100 solution for 30 min, for 
permeabilisation of the tissue. Muscles were then stained 1:500 Alexa 594-
conjugated α-bungarotoxin (α-BTX) for 30 min in the dark at room temperature 
(RT). Finally, the muscles were washed once in 0.04% PBS-Tween-20 solution for 




2.5 Visualisation and analysis of NMJs 
To perform NMJ structural analysis, maximum intensity multichannel images 
were generated from confocal z-stacks using Nikon Ni-E Elements software 
(Nikon, Tokyo, Japan). Merged images from each muscle were then montaged 
into a single image file using ImageJ software (Image Processing and Analysis in 
Java; National Institutes of Health, Bethesda, MD, USA). AChR innervation (motor 
end plate) was defined as co-localisation of the presynaptic terminal (green) with 
fluorescently labelled AChRs (red).  NMJ structural changes were scored and 
divided into 3 main groups: Normal, partially or completely denervated and 
morphologically abnormal NMJs. NMJs classified as normal when presenting a 
“pretzel”-like morphology and full colocalisation between the presynaptic 
terminal (nerve; green) and the AChR clusters (red). Partially denervated NMJs 
were defined as those with the motor end plate not completely apposed by the 
nerve (pre-synaptic end) terminal. Fully denervated NMJs were those with no 
presence of presynaptic terminal in the junction leaving all motor end plate 
unoccupied. Morphologically abnormal NMJs were considered those with full 
colocalisation but were presenting morphological characteristic outside of the 
“pretzel-like” shape of the NMJs. Morphologically abnormal NMJs were divided 
into 3 subgroups: limited branching; limited folds or “branches” of the receptor 
area, fragmentation; irregularly formed NMJ sites with “open” formation, 
discontinuous to the oval “pretzel-like” shape, small size; NMJs with considerably 
smaller size compared to normal neighbouring ones. Examples of such NMJs are 
shown in Figure 2.5. Criteria for structural classifications of NMJs were adjusted 









Figure 2.5 Structure of NMJs in mouse EDL muscle. A) Normal “pretzel-like” NMJ 
structure, branching and co-localisation of motor end plate (AChRs; red) and pre-
synaptic end terminal (nerve; green) being evident, B) Partially denervated NMJ, 
motor end plate not apposed by a pre-synaptic end terminal in the majority of 
the junction, C) Fragmented NMJ, lack of “pretzel-like” shape, structure appears 
“broken” in two separate parts, D) Limited/defective branching, periphery of 
NMJ is present but branching in the centre is very limited, E) Limited 
branching/small size NMJ, pre- and post-synaptic terminals are present but 
structure is not fully formed, F) Small size of NMJ in comparison with a 




2.6 Histology and gelatine embedding  
Reagents: 
• Sucrose solution: 
o 0.01 M phosphate buffered saline buffer solution (PBS) (Cat# 
P4417; Sigma Aldrich, Dorset, UK) 
o 30% w/v sucrose (Cat# S9378; Sigma Aldrich, Dorset, UK) 
• Gelatine solution: 
o 0.01 M phosphate buffered saline buffer solution (PBS) (Cat# 
P4417; Sigma Aldrich, Dorset, UK) 
o 7.5% (w/v) porcine-derived gelatine solution (Cat# G1890; Sigma 
Aldrich, Dorset, UK) 
o 15% (w/v) sucrose (Cat# S9378; Sigma Aldrich, Dorset, UK) 
o 0.1% (w/v) NaN₃ (Cat# S2002; Sigma Aldrich, Dorset, UK) 
• Optimal Cutting Temperature (O.C.T.) compound (Cat# KMA-0100-00A; 
CellPath, Powys, UK) 
• Isopentane (Cat# 15711819; Fisher Scientific, Loughborough, UK) 
• Liquid Nitrogen (LN2) 
Protocol: 
Gelatine embedding is a method commonly used to provide rigidity to fragile 
tissues and preserve their structure during preparation and cryosectioning (Gill 
et al. 2016). It is also used as a method of preservation of samples but also serves 
as a mold for sample positioning prior to sectioning (Fan et al. 2015). Sucrose 
incubation of fixed tissues ensures dehydration of tissues, forcing H2O molecules 
out of the tissue, preventing crystal formation and cryo-damage of the tissue. 
Gelatine embedding provided a stable structure for whole muscle tissue to be 
positioned transversely on the cork before snap-freezing. 
Tissues embedded in gelatin were then vertically aligned on cork disks, were 
covered in O.C.T mounting medium and frozen in isopentane cooled in LN2. 
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Samples remained immersed in ice-cold isopentane for a minimum of 30 sec 
before covered with foil and stored at -80oC until cryosectioning.  
Prior to sectioning, tissues were placed inside the cryostat chamber for 30 min 
to allow acclimatisation of tissue samples to the cryostat temperature. Cryostat 
(Leica 1890) was set to -22oC and sectioning thickness was set at 12 μm. Sections 
were collected on gelatine coated slides and left to air-dry overnight before 
stained the following day.  
 
2.7 Gelatine-coating of glass slides for tissue sections 
Reagents: 
• 1 g porcine-derived gelatine (Cat# G1890; Sigma Aldrich, Dorset, UK) 
• 0.19 g Chromium (III) Potassium Sulfate (KCr(SO₄)₂) (Cat# 1010360250; 
Merck, Dorset, UK) 
• 0.5 g NaN3 (Cat# S2002; Sigma Aldrich, Dorset, UK) 
• dH2O 
Protocol: 
Gelatine powder was dissolved in 200 mL of dH2O at 45oC on a heating 
magnetic stirrer. When fully dissolved, chromium (III) potassium sulfate and 
NaN3 were added. Solution was stirred at 45oC until all the components were 
homogenised in the solution. Gelatine solution was then filtered in a clean glass 
baker using a filter paper and poured into a histo-staining glass pot and covered 
to avoid dust accumulation in the solution. Microscopy slides were immersed 
into the solution for 3-5 sec and were positioned vertically and let to dry 
overnight at RT and covered to protect from dust attaching on them. Slides were 
stored into a slides’ box until used. The remaining gelatine solution was 





2.8 Transverse muscle sections staining  
Reagents: 
• Wheat germ agglutinin (WGA) – fluorescein (5 μg/mL) (Cat# FL-1021-5; 
Vector Laboratories Ltd., Peterborough, UK) 
• 4′,6-diamidino-2-phenylindole (DAPI) – hard set (Cat# H-1500; Vector 
Laboratories Ltd., Peterborough, UK) 
• Ice-cold methanol (MetOH) (Cat# 34860; Sigma Aldrich, Dorset, UK) 
• 0.01 M phosphate buffered saline buffer solution (PBS) (Cat# P4417; 
Sigma Aldrich, Dorset, UK) 
• 0.04% v/v Tween-20 (Cat# P1379; Sigma Aldrich, Dorset, UK) 
Protocol: 
Muscle sections were retrieved from -20oC and left to air-dry at RT for aprox. 
10 min. Sections were fixed with ice-cold MetOH for 10 min at RT before washed 
2x 5 min with PBS-Tween-20 (0.04%). Muscle sections were incubated in 300 μL 
of 1:1000 WGA diluted in 0.01M PBS solution for 10 min in the dark at RT. 
Following staining slides were washed 2x 5 min with PBS-Tween-20 (0.04%) 
before mounted with hard-set DAPI. The slides were left to set overnight in the 
dark at RT before being imaged.  
 
2.9 Confocal microscopy 
Fluorescence images were obtained using a C1 Nikon Eclipse Ti confocal laser 
scanning microscope (Nikon, Tokyo, Japan) equipped with a 405 nm excitation 
diode laser, a 488 nm excitation argon laser, and a 543 nm excitation helium–
neon laser. Slides were kept in the dark at all times. Consecutive images were 
acquired using 20x objective and were stitched into a single high-resolution 





2.10 Image analysis of EDL and TA muscle sections 
Image analysis of EDL and TA transverse muscle sections was performed using 
ImageJ software ((Image Processing and Analysis in Java; National Institutes of 
Health, Bethesda, MD, USA). All analyses were performed semi-automatically, 
using the “Tissue Cell Geometry Stats” macro created by the Institute for 
Research in Biomedicine, University of Barcelona (Barcelona, Spain) 
(http://adm.irbbarcelona.org/image-j-fiji#TOC-Automated-Multicellular-Tissue-
Analysis).  
Individual images acquired from different areas of the muscles were stitched 
together to create a montaged multichannel image of the whole muscle section 
using Adobe Photoshop. Images were imported into ImageJ software, split into 
individual channels and only the channel with the muscle fibre membrane stain 
(green) was used for the analysis. Image was converted to 8-bit file and “Tissue 
Cell Geometry Stats” plugin was selected for the analysis of the muscle fibres. 
Parameters were set as follows: default parameters were selected, “Light 
background” was deselected, “Noise tolerance” was set between 10-23, 
depending on the quality of each section, output type as “Segment particles” and 
“Preview point selection” was maintained. Following merging/segmentation of 
the muscle fibres and calculation of the number and size of the fibres in the 
image, further processing was performed to exclude any selections that were not 
fibres (vessels, gaps etc.). All files generated from the image analyses were saved 
accordingly.  
 
2.11 In silico analysis of predicted gene targets of miR-128 and miR-133a  
Bioinformatic analysis of the predicted target genes of miR-128 and miR-133a 






TargetScanMouse7.1 (http://www.targetscan.org/mmu_71/)   
In order to investigate the predicted target genes for miR-128 and miR-133a, 
TargetScanMouse7.1 database was used. MiR-128 and miR-133a were selected 
from the list of broadly conserved microRNA families and a full list of predicted 
target genes was obtained. For certain gene targets, the name was imported in 
the appropriate section of the home page. A list of all the microRNAs and their 
equivalent target sites (conserved and/or poorly conserved) were obtained. A 
number of predicted target genes of interest was selected for further analysis. 
 
STRING (Version 10.5; https://string-db.org/)  
The full list of predicted target genes of each microRNA as obtained from 
TargetScanMouse7.1 was imported into STRING database (Version 10.5), in order 
to investigate the interactions between the predicted target genes on a protein 
level. Each protein (derived from a gene transcript) was depicted as a node, 
which was connected to neighbouring nodes. Disconnected or individual nodes 
were excluded from the network analysis. Interactions between the nodes were 
assessed based on degree of confidence (low=0.150, medium=0.400, high=0.700, 
highest=0.900). Information obtained was used for illustration of the network 
using CytoScape software.  
 
KEGG (https://www.genome.jp/kegg/)  
Following network analysis on a protein level, selected predicted target genes, 
which demonstrated strong interactions on a protein level (degree of confidence 
set to “highest” (0.900)), were imported into KEGG Pathway database in order to 
investigate the signalling pathways they are involved in and/or share. KEGG 
Reference number (KO number) was imported into KEGG Mapper tool, and 
“Search&Color Pathway” was selected. The KO number was imported in the box 
followed by background (bg) colour and foreground (fg) colour. An example of 
such import is: “K15290 brown,yellow”. When all proteins have been imported, 
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“uncoloured diagrams were selected in order to obtain coloured items only for 
the proteins of interests in the pathways. Pathways of interests were selected 
from the list of all the pathways were one or more of the proteins of the list are 
involved in. Proteins encoded from predicted target genes were coloured in cyan 
(miR-128) or orange (miR-133a), depending on the microRNA by which they were 
targeted. 
 
2.12 RNA isolation from tissue and cell samples  
Reagents: 
• TRIzol reagent (Cat# 15596026; Invitrogen, Paisley, UK) 
• Liquid Nitrogen (LN2) 
• Nuclease-free H2O (Part of Cat# 218073; QIAGEN, Manchester, UK) 
• Iso-amyl alcohol:chloroform 25:1 (Cat# 25666; Sigma Aldrich, Dorset, UK) 
• Isopropanol (Cat# 59304; Sigma Aldrich, Dorset, UK) 
• Ethanol (EtOH) (Cat# 51976; Sigma Aldrich, Dorset, UK) 
Protocol:  
Muscles and nerves were ground in LN2 in pestle and mortar and transferred 
into 1 mL of TRIzol. Prior to RNA isolation, TRIzoL samples were allowed to stand 
at RT for 5 min before addition of 200 μL of chloroform. Samples were shaken 
vigorously for 20-30 sec and let to stand at RT for 5 min. Samples were 
centrifuged at 12,000 x g for 10 min at 4oC and incubated for 5 min at RT. 
Following incubation, approximately 250 μL of aqueous phase containing the 
RNA were collected and transferred into a new Eppendorf tube. To achieve RNA 
precipitation, the aqueous phase collected was mixed with 500 μL of 100% 
isopropanol and mixed by manual inversion of the tubes for 10-15 sec. Samples 
were incubated at RT for 25-30 min and then centrifuged at 21,100 x g for 30 min 
at 4oC. Following centrifugation, the supernatant was discarded and pellet was 
left to dry for 5 min before washed in 250 μL of 70% EtOH. Samples were 
incubated for 30 min at RT before centrifuged at 21,100 x g for 5 min at 4oC. 
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Supernatant was discarded and samples were centrifuged again at 21,100 x g for 
5 min at 4oC for the remaining EtOH residues to be collected at the bottom of the 
tubes and be discarded. Any excess EtOH was left to evaporate at RT for a 
maximum of 5 min. Finally, RNA pellet was resuspended in 10 μL RNase-free H2O 
and placed immediately on ice to avoid degradation. RNA concentration and 
purity were estimated according to the 260/280 and 260/230 ratio recorded 
using Nanodrop2000 (ThermoFisher).  
 
2.13 First strand cDNA synthesis  
Reagents: 
For microRNA cDNA synthesis: 
• miScript HiSpec Buffer (5x) (Part of Cat# 218161; QIAGEN, Manchester, 
UK) 
• miScript Nucleics Mix (10x) (Part of Cat# 218161; QIAGEN, Manchester, 
UK) 
• miScript Reverse Transcriptase mix (Part of Cat# 218161; QIAGEN, 
Manchester, UK) 
• RNase-free H2O (Part of Cat# 218161; QIAGEN, Manchester, UK) 
For mRNA cDNA synthesis:  
• SuperScript™ II Reverse Transcriptase kit (Cat# 18064014; Invitrogen, 
Paisley, UK) 
o 200 U/mL Superscript II reverse transcriptase  
o 5x First-strand Buffer  
o 100 mM Dithiothreitol (DTT) 
• 50 μM Random hexamers (Cat# N8080127; Invitrogen, Paisley, UK) 
• 10 mM Deoxynucleotides (dNTP’s) mix: 
o 100 mM Deoxynucleotide Set (Cat# DNTP100; Sigma Aldrich, 
Dorset, UK) 
o RNase-free water (Part of Cat# 218161; QIAGEN, Manchester, UK) 
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• 40 units/μL RiboLock RNase inhibitor (Cat# EO0381; Invitrogen, Paisley, 
UK) 
• RNase-free water (Part of Cat# 218161; QIAGEN, Manchester, UK) 
Protocol: 
cDNA synthesis for microRNA and mRNA was performed using 100-200 ng 
RNA from tissues or cells using the T100 Thermocycler (BioRAD, Hertfordshire, 
UK). Each cDNA required a different RT reaction mix, using the reagents and 
volumes as shown in the table below:  
 





For microRNAs, one-step cDNA synthesis was performed using RTscript enzyme 
according to the diagram bellow:  
Figure 2.13.1 cDNA synthesis protocol for microRNAs. Each reaction containing 
RNA template, RNAse-free H2O and RT reaction mix was placed in the 
Thermocycler and cDNA synthesis was performed according to the steps shown.  
 
For gene transcripts, two-step cDNA synthesis was performed using Superscript II 
enzyme, according to the following protocol:  
Figure 2.13.2 cDNA synthesis for gene transcripts (mRNA), in a two-step 
protocol. Addition of RT mix occurs between 1st and 2nd step of cDNA synthesis, 




 Following cDNA synthesis, all sample were diluted 1:10 with 180 μL of RNase-
free H2O and stored at -20oC until used for quantitative PCR (qPCR).  
 
2.14 Primer design 
Primers for qPCR on mRNA transcripts were designed using the NCBI primer 
blast tools.  
For target genes from miR-128 and -133a, the following parameters were used 
during primer design:  
 
Table 2.14 Parameters used for primer design. 
 
From the list of candidate primer pairs, those with repeated base a T as an 
ultimate base or with 3 or more G/C bases at 3’ end were disregarded. Primer 
pairs with low self-complementarity, Tm difference less than 1oC were preferred 
and no non-specific binding to other target sequences were preferred.  
 
2.15 Quantitative Polymerase Chain Reaction (qPCR) 
Reagents: 
For microRNA expression analysis: 
• cDNA (microRNA, 10x diluted)  
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• SsoAdvanced Universal SYBRGreen Supermix (Cat# 1725271; BioRAD, 
Hertfordshire, UK) 
• microRNA primers (QIAGEN, Manchester, UK) 
• Universal primers (Part of Cat# 218073; QIAGEN, Manchester, UK) 
For mRNA expression analysis:  
• cDNA (mRNA, 10x diluted)  
• SsoAdvanced Universal SYBRGreen Supermix (Cat# 1725271; BioRAD, 
Hertfordshire, UK) 
• mRNA primers (Sigma Aldrich, Dorset, UK) 
Protocol:  
Primers, cDNA and SsoAdvanced SybrGreen Supermix were added in each well 
of a 96-well plate (BioRAD Hertfordshire, UK), according to the following table:  
 





Each cDNA sample was loaded 3 times to create technical replicates. Each 
plate contained a no-template control (NTC) triplicate, containing all the 
components of a reaction (Table 2.15.1), but lacking the cDNA template. NTCs 
served as a negative control to assess genomic contamination, secondary 
structures of primers or primer dimers. Following loading of reagents and 
template, plates were sealed, centrifuged for 5 sec and placed into the BioRAD 
CFX Connect™ Real-Time PCR Detection System (BioRAD Hertfordshire, UK).  
Expression relative to SNORD-61 or RNU-6 for microRNAs and 18S or β2-
microglobulin for mRNA transcripts was calculated using the delta delta Ct (ddCt) 
method. The qPCR conditions for each run are shown on the table below:  
 
Table 2.15.2 qPCR conditions for microRNAs and mRNAs. 
 
All qPCR runs were assessed using a melt curve to ensure detection of a single 
product and assess formation of primer dimers and/or contamination. Melt 
curves were generated following the end of the 40th cycle of the qPCR run. Melt 
curve conditions for both microRNA and mRNA qPCR runs were: 95oC for 10 sec, 
65-95oC, with 0.5oC increments for 5 sec each and plate read at 95oC for 50 sec.  
 
2.16 Cell culture of muscle and nerve cells 
Reagents: 
For C2C12:  
• Growth Media (GMC2C12): 
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o Dulbecco’s Modified Eagle’s Medium with high glucose (Cat# D5671; 
Sigma Aldrich, Dorset, UK) 
o 10% v/v foetal bovine serum (FBS) (Cat# 10100147; Sigma Aldrich, 
Dorset, UK) 
o 1% v/v GlutaMax (Cat# 35050061; Gibco, Paisley, UK) 
o 1% v/v penicillin–streptomycin (Cat# P4333; Sigma Aldrich, Dorset, 
UK) 
• Differentiation Media (DMC2C12): 
o Dulbecco’s Modified Eagle’s Medium with high glucose (Cat# D5671; 
Sigma Aldrich, Dorset, UK) 
o 2% v/v horse serum (HS) (Cat# 26050-070; Sigma Aldrich, Dorset, UK) 
o 1% v/v GlutaMax (Cat# 35050061; Gibco, Paisley, UK) 
o 1% v/v penicillin–streptomycin (Cat# P4333; Sigma Aldrich, Dorset, 
UK) 
• Growth Media (GMNSC-34): 
o 1:1 mixture of Dulbecco’s Modified Eagle’s Medium/Nutrient Mixture 
F-12 Ham with L-Glutamine (Cat# D8437; Sigma Aldrich, Dorset, UK) 
o 10% v/v foetal bovine serum (FBS) (Cat# 10100147; Sigma Aldrich, 
Dorset, UK) 
o 1% v/v penicillin–streptomycin (Cat# P4333; Sigma Aldrich, Dorset, 
UK) 
• Differentiation Media (DMNSC-34): 
o 1:1 mixture of Dulbecco’s Modified Eagle’s Medium/Nutrient Mixture 
F-12 Ham with L-Glutamine (Cat# D8437; Sigma Aldrich, Dorset, UK) 
o 3% v/v foetal bovine serum (FBS) (Cat# 10100147; Sigma Aldrich, 
Dorset, UK) 
o 1% v/v penicillin–streptomycin (Cat# P4333; Sigma Aldrich, Dorset, 
UK) 
Protocol: 
In vitro experiments were performed using C2C12 myotubes as a model of 
myofibres and NSC-34 cells as a model of motoneuron cells.  
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C2C12 cell line is a subclone cell line of skeletal muscle cells originally derived 
from the C2 cell line isolated from mdx mice (Yaffe and Saxel, 1977). NSC-34 is a 
hybrid cell line created by fusion of neuroblastoma mouse cells and motoneuron-
enriched embryonic mouse spinal cord cells (Egget et al. 2000).  
Prior to plating, cells were centrifuged at 1,500 rpm for 5 min to discard 
freezing media containing DMSO, and cell pellet was resuspended in pre-warmed 
20% FBS growth media (GMC2C12, GMNSC-34) for 24 h to aid attachment of the cells. 
Following 24 h, media was replaced with 10% FBS growth media (GMC2C12, GMNSC-
34) and was renewed every 48 h. All cells were cultured in T75 cell culture flask 
and differentiated in 6- and 12-well flat-bottom plates (Costar), in a humidified 
incubator at 37oC with 5% CO2. 
Differentiation of C2C12 cells was induced when cells reached 90% 
confluency. Confluent cells were cultured in differentiation media (DMC2C12) for 
7-10 days before staining. Fusion of cells and formation of myotubes was visible 
from Day 2 post differentiation.   
For cell differentiation, NSC-34 cells were cultured in differentiating media 
(DMNSC34), as described by Egget et al. 2000. To successfully induce 
differentiation and allow development of axonal projections, cells were 
introduced to differentiation media when they reached a confluency of 60-80%. 
 
2.17 Cell passaging 
Reagents: 
• Dulbecco’s Phosphate Buffered Saline (DPBS) (Cat# D8537; Sigma Aldrich, 
Dorset, UK) 
• TrypLE Express (Cat# 12604013; Gibco, Paisley, UK)  
Protocol: 
For cell dissociation from a T75 flask, media was discarded and cells were 
washed 1-2 times for 10 sec each with 3mL of DPBS followed by incubation with 
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2 mL TrypLE for 20 sec. TrypLE was discarded and flasks were incubated at 37oC 
for 3 min. Following incubation, cells were immediately collected from the flasks 
using growth media and the flask was washed several times to ensure collection 
of maximum number of cells. Cells were transferred to a sterile falcon tube and 
diluted accordingly before being plated into a new flask or plate.   
 
2.18 Preparation of tissue culture plates for cell imaging 
Reagents:  
• Laminin, 1 mg/mL (Cat# 114956-81-9; Sigma Aldrich, Dorset, UK) 
• Dulbecco’s Phosphate Buffered Saline (DPBS) (Cat# D8537; Sigma Aldrich, 
Dorset, UK) 
Protocol:  
Cells to be stained and imaged were plated in 12-well plates coated with 
laminin according to a standard protocol (Soriano-Arroquia et al. 2017). Laminin 
working solution was prepared in 1x DPBS in 5 μg/mL concentration. In each 
well, 500 μL of laminin solution were added and plate was incubated in a 
humidified incubator at 37oC with 5% CO2 for 30-60 min. Following incubation, 
laminin solution was removed from the wells carefully to avoid contact with the 
bottom of the well.  All wells were washed with DPBS and cells were immediately 
seeded onto the plate, to prevent laminin from drying out.   
 
2.19 Seeding of C2C12 and NSC-34 cells 
Reagents:  
• Dulbecco’s Phosphate Buffered Saline (DPBS) (Cat# D8537; Sigma Aldrich, 
Dorset, UK) 
• TrypLE Express (Cat# 12604013; Gibco, Paisley, UK) 
• Growth medium (GMC2C12, GMNSC34) 




Cells were dissociated from the T75 flasks using TryPLE enzyme (Section 2.17). 
Following incubation, TryPLE was inactivated with growth medium and cells were 
centrifuged at 1,500 rpm for 5 min. Following centrifugation, the supernatant 
was discarded and the cell pellet was resuspended in 10 mL growth medium. 
Immediately after resuspension, 10 μL of cell suspension was mixed 1:1 with 
trypan blue stain and 10 μL of the mixture were placed in a Neubaeur 
haemocytometer. When observed under a microscope, dead cells appear blue 
(stained with Trypan Blue) whilst live cells appear unstained. Live cell number 
was recorded from each of the 4 corner squares (Figure 2.19). Following counts, 
cells per volume unit was calculated and an appropriate amount of cell 
suspension was diluted in growth media (GMC2C12, GMNSC34) before being added 
to flat-bottom plates (Costar). For cell imaging, cells were plated in 12-well plates 
pre-coated with laminin (Section 2.18). For C2C12, 1 mL of cell suspension was 
plated in each well of a 12-well plate to achieve confluency before inducing 
differentiation. For NSC-4 cells, 10,000 cells/well (2,632 cells/cm2) were plated to 
achieve optimum confluency for neuronal differentiation.  
 
Figure 2.19 Standard gridline of an Improved Neubaeur haemocytometer. A-D 





2.20 Cell harvesting for RNA and protein isolation 
Reagents: 
• Dulbecco’s Phosphate Buffered Saline (DPBS) (Cat# D8537; Sigma Aldrich, 
Dorset, UK) 
• TrypLE Express (Cat# 12604013; Gibco, Paisley, UK)  
• TRIzol reagent (Cat# 15596026; Invitrogen, Paisley, UK) 
Protocol: 
Cells plated on a 6-well plate were rinsed once with pre-warmed PBS and 
were incubated with 300 μL of TryPLE for 3 min in a humidified incubator at 37oC 
with 5% CO2. TryPLE was inactivated by dilution with 600 μL of PBS and cells from 
each well were collected into a separate pre-chilled Eppendorf tube. The wells 
were washed with additional 600 μL of PBS to collect remaining cells and added 
to the respective tubes, which were immediately placed on ice. Following 
collection of all samples, cells were centrifuged at 21,100 x g for 5 min in a pre-
cooled centrifuge at 4oC. For RNA samples, supernatant was discarded and cell 
pellet was resuspended in 1mL TRIzoL reagent. Protein samples were frozen 
without further processing. All samples were stored at -20oC until used for RNA 
isolation or protein extraction. For each transfection condition, 6 wells were used 
for either RNA or protein expression analysis, whilst each well represents a 
biological replicate (n number).   
 
2.21 Cell transfections with miR-128 and miR-133a 
Reagents:  
For miR-128: 
• Lipofectamine 2000 (Cat# 11668027 ; Invitrogen, Paisley, UK) 




• 5 nmol miScript miR-128-3p inhibitor (Cat# MIN0000140; QIAGEN, 
Manchester, UK) 
• 5 nmol miScript Inhibitor Negative Control (Cat# 1027271; QIAGEN, 
Manchester, UK) 
• Dulbecco’s Modified Eagle’s Medium with high glucose (Cat# D5671; 
Sigma Aldrich, Dorset, UK) 
• Differentiation Media (DMC2C12, DMNSC34) 
For miR-133a:  
• microRNA inhibitor negative control (Scr) (100 μM; Dharmacon, Colorado, 
USA)  
o Sequence:  
– Antisense: 5’-Fl-mA*mC*mUmCmAmCmCmGmAmCmAmGmC 
mGmUmUmGmAmA*mU*mG*mU*mU-Cholesterol-3’  
– Sense: 5'mC(*)mA(*)mGmUmAmCmUmUmUmUmGmUmGmU 
mAmGmUmA(*)mC(*)mA(*)mA-Cholesterol-3' 
• microRNA-133a mimic (miR) (100 μM; Dharmacon, Colorado, USA) 
o Sequence:  
– Antisense: 5’-UUUGGUCCCCUUCAACCAGCUG-3’FITC  
– Sense: 5’-Chol-GCUGGUAAAAUGGAACCAAAU-3’ 
• microRNA-133a inhibitor (AM) (100 μM; Dharmacon, Colorado, USA) 
o Sequence: 5’-Fluorescein-mC*mA*mGmCmUmGmGmUmUmGm 
AmAmGmGmGmGmAmCmC*mA*mA-mA*-3’Chol 
o - phsophorthioate bonds 
o m -  2’-O-methyl bonds 
Protocol:  
Transfections of miR-128 mimic and antagomir were performed using 
Lipofectamine 2000. 24 h following seeding, plates were retrieved from the 
incubator and the media was discarded. For each well of a 6-well plate 1 mL of 
pre-warmed DMEM media was added and for each well of a 12-well plate 500 μL 
of DMEM was added. DMEM media containing no additives was used to avoid 
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interference of additive solutions with the transfection reagents. Cells were 
incubated for 40-50 min with DMEM media in a humidified incubator at 37oC 
with 5% CO2. In the meantime, lipofectamine working solution was prepared for 
each of the negative control (Scr; scrambled), miR mimic (miR) and miR inhibitor 
(AM; antagomiR) (Table 2.21.1). Lipofectamine was added to DMEM media with 
no FBS or Pen/Strep and left to incubate for 5 min. Following incubation, 
lipofectamine solution was added drop-by-drop to each working solution of Scr, 
miR and AM in 1:1 volume, to a final of 500 μL/well for a 12-well plate and a 1 
mL/well for a 6-well plate.  
 
Table 2.21.1 Reagents used for miR-128 mimic and antagomir transfections. 
Same concentrations and volumes were used for both C2C12 and NSC-34 cells.  
 
 
Lipofectamine 2000 was incubated with Scr/miR/AM for 30 min at RT. Next, 
plates were retrieved from the incubator, media was discarded and 1 mL of 
transfections solution was added in each well of a 6-well plate and 500 μL of the 
transfection solution was added in each well of a 12-well plate. For control cells, 
DMEM was added in the same volume as the transfection solutions. Cells were 
incubated with the transfection solution for 5-6 h in a humidified incubator at 
37oC with 5% CO2 before media was replaced with differentiation media 
(DMC2C12, DMNSC34). For C2C12 cells, transfection protocol was repeated on Day 3 
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and Day 5 post-seeding, to enhance efficiency of transfection in myotubes. NSC-
34 cells were transfected 24 h following seeding of the cells.   
For miR-133a, transfection protocol did not require Lipofectamine, as the Scr, 
miR and AM reagents were cholesterol conjugated. For cells to be transfected 
with miR-133a, differentiation media (DMC2C12, DMNSC34) was added to the wells 
24 h following cell seeding for NSC-34 cells and 3 days following seeding for 
C2C12 (signs of myotube formation). Transfection reagents were added directly 
on the wells according to Table 2.21.2:  
 
Table 2.21.2 Reagents used for miR-133a mimic and antagomir transfections. 
Same concentrations and volumes were used for both C2C12 and NSC-34 cells.  
 
 
Cells were collected for RNA and protein isolation 48 h post transfections. For 
imaging, C2C12 cells were stained 7 post transfections while NSC-34 were 
stained 10 days following transfections.  
 
2.22 Immunostaining of C2C12 and NSC-34 cells 
Reagents:  
• Dulbecco’s Phosphate Buffered Saline (DPBS) (Cat# D8537; Sigma Aldrich, 
Dorset, UK) 
• Block 1 solution: 
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o 0.1% v/v Triton-X100 (Cat# X100; Sigma Aldrich, Dorset, UK) 
o 10% horse serum (HS) (Cat# 26050-070; Sigma Aldrich, Dorset, UK) 
o DPBS (Cat# D8537; Sigma Aldrich, Dorset, UK) 
• Block 2 solution:  
o 0.05% v/v Triton-X100 (Cat# X100; Sigma Aldrich, Dorset, UK) 
o 10% horse serum (HS) (Cat# 26050-070; Sigma Aldrich, Dorset, UK) 
o DPBS (Cat# D8537; Sigma Aldrich, Dorset, UK) 
• Methanol (MetOH) (Cat# 34860; Sigma Aldrich, Dorset, UK) 
• DAPI (Cat# MBD0015; Sigma Aldrich, Dorset, UK) 
For C2C12:  
• Anti-MyHC 1ry Ab (Cat# MF20-c 2ea; Developmental Studies Hybridoma 
Bank) 
• Goat Anti-Mouse Alexa Fluor 488 Conjugate, 2ry Ab (Cat# A-10680; 
Invitrogen, Paisley, UK) 
For NSC-34: 
• Anti Beta-III Tubulin, Alexa Fluor 488 Conjugate (Cat# AB15708A4; 
Millipore, Middlesex, UK) 
Protocol:  
Cells were retrieved from the incubator and the media was aspirated. Wells 
were rinsed 1-2 times with DPBS and cells were then fixed with MetOH for 10-15 
min. For C2C12, cold MetOH was used for 10 min while for NSC-34 cells MetOH 
at RT was used for 15 min for cell fixation, to prevent cell detachment during 
fixation. Following fixation, 500 μL of DPBS was added to the wells containing 
MetOH and then the solution was discarded. Mixing of MetOH with DPBS prior 
to removing it from the wells prevents cells from drying out quickly. Cells were 
rinsed 1-2 times with PBS followed by addition of 500 μL of Block 1 solution for 
1-2 h at RT. Following blocking, cells were washed once with PBS for 5 min 
followed by incubation with Block 2 solution containing the primary antibody 
(Ab) (MF-20, 1:1000, β-III Tubulin, 1:400). Cells were covered in foil and allowed 
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to incubate at 4oC overnight. Following incubation with primary Ab, cells were 
retrieved from 4oC and left at RT for approximately 1 h. Staining solution was 
removed from wells and stored at 4oC until future use. Cells were washed 2-3 
times for 5 min with DPBS.  
For C2C12, 500 μL of anti-mouse Alexa Fluor - 488 2ry Ab solution (1:1000 in 
Block 2) was added to each well and left to incubated in the dark at RT for 1-2 h 
on a rocker at low speed.  
Cells were washed 1-2 times with DPBS for 5 min before 500 μL of DAPI stain 
(1:1000 in PBS) was added to each well and left to incubate for 15 min. DAPI 
staining solution was removed from wells and stored at 4oC until future use and 
cells were washed 1 time with DPBS. Finally, 1 mL of DPBS was added to each 
well and plate was sealed with Parafilm to avoid evaporation. Imaging of cells 
took place the following day.  
C2C12 cells were placed on a rocker at low speed during staining while NSC-34 
cells were left on a flat surface as rocking would cause detachment of cells.  
 
2.23 Image analysis of C2C12 and NSC-34 cells 
For C2C12: 
Following immunostaining, cells were imaged under the Nikon Ti Live Cell 
imaging microscope under x20 magnification. Images were analysed using 
ImageJ Software (Image Processing and Analysis in Java; National Institutes of 
Health, Bethesda, MD, USA). The diameter of each myotube was measured from 
three different points across the length of the myotube (each end and the centre 
of myotube). The average value of the three diameter measurements was 
calculated, in order to determine the diameter of each myotube. Nuclei present 
in each of the myotubes were counted manually and were recorded in order to 
determine fusion index. Threshold value expressed as a % was determined using 
the “threshold” function. Threshold value determined the % of “empty area” 
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over the “green area” on each field of view, providing an indication of how much 
area is occupied by MF20+ stained (green) cells (myotubes).  
 
For NSC-34: 
Immunostained NSC-34 cells were imaged using the Nikon Ti Live cell imaging 
microscope under x20 magnification. Z-stack images were acquired and analysed 
using ImageJ Software (Image Processing and Analysis in Java; National Institutes 
of Health, Bethesda, MD, USA). Z-stack images were segmented into single 
channels and the “green” channel (B-III tubulin+) was used for axonal tracing of 
NSC-34 cells. Images were then converted to 8-bit image files and the “simple 
Neurite Tracer” plugin was used from “Plugins” > “Segmentation” drop down 
menu. Axonal length, branching point were recorded. For NSC-34 cells to be 
considered as differentiated, axonal length should be equal or longer than 2x the 
diameter of the cell body of the neuron (Chai et al. 2011).  
 
2.24 Sample preparation for protein extraction 
Reagents:  
• Dulbecco’s Phosphate Buffered Saline (DPBS) (Cat# D8537; Sigma Aldrich, 
Dorset, UK) 
• 1% SDS (Cat# L3771; Sigma Aldrich, Dorset, UK) 
• Protease inhibitors (Cat# A32955; ThermoFisher, Paisley, UK) 
Protocol: 
Cell pellets were obtained from -20oC and left to thaw on ice. Cell pellets were 
centrifuged at 21,100 x g for 5 min in a pre-cooled centrifuge at 4oC and the 
supernatant was discarded. Cell pellet was resuspended in 50 μL of 1% SDS 
containing protease inhibitors Cells were sonicated on ice for 3x 5 sec and 




2.25 Determination of protein concentration by bicinchoninic acid assay (BCA) 
Reagents:  
• Bicinchoninic acid (BCA) solution (Part of Cat# BCA1; Sigma Aldrich, 
Dorset, UK, Dorset UK) 
• Copper sulphate (Part of Cat# BCA1;Sigma Aldrich, Dorset, UK, Dorset UK) 




BCA assay was performed on a 96-well plate. In order to determine protein 
concentration of the cell samples, a standard curve of known protein 
concentration samples was generated. Sample concentrations used for the 
standard curve are shown in Table 2.25:   
 
Table 2.25 Concentration of standard curve samples used for protein 
determination in BCA assay.  
 
 
Each standard was added in a duplicate in a volume of 20 μL per well. The 
average value was calculated from the values of the duplicate and was used to 
plot the standard curve. Protein samples from cells were added on the plate in 
triplicates, in 1:19 dilution, to a final volume of 20 μL per well. Copper sulphate 
solution was diluted 50x with BCA solution and a volume of 200 μL from this 
mixture was added in each well. The plate was incubated at 37oC for 30 min 
followed by the measurement of the absorbance at 570 nm using a 
spectrophotometer (BMG laboratories, Buckinghamshire, UK). Protein 
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concentration for each sample was calculated based on the standard curve 
values.  
 
2.26 Estimation of the protein content of samples using SDS-PAGE and 
western blotting techniques 
2.26.1 Polyacrylamide gel preparation 
Reagents:  
• 30% acrylamide solution (Cat# EC-890; Protogel, National Diagnostics, 
USA) 
• ProtoGel Resolving Buffer (4X) (Cat# EC-892; Protogel, National 
Diagnostics, USA) 
• ProtoGel Stacking Buffer solution (Cat#  EC-893; Protogel, National 
Diagnostics, USA) 
• 10% ammonium persulphate solution (APS) (Cat# A3678; Sigma Aldrich, 
Dorset, UK, Dorset UK) 
• NNN’N-tetramethylethylene-diamine (TEMED) (Cat# T9281; Sigma 
Aldrich, Dorset, UK) 
• dH2O 
• Ethanol (EtOH) (Cat# 51976; Sigma Aldrich, Dorset, UK) 
Protocol: 
The polyacrylamide gel was prepared in two stages. First, 12% of acrylamide 
concentration gel (resolving) was prepared as described in Table 2.26.1 and 
poured between 2 gel plates (8 x 10 cm) with 1.5mm spacers at a volume of 8 
mL. Approximately 300 μL of EtOH was added at the top of the gel to disrupt any 
bubbles formed and create an even top surface on the gel. When the resolving 
gel was set, EtOH was discarded and the top of the gel was washed 3 times with 
dH2O to discard any EtOH residues. Excess H2O was removed using blot papers. 
Stacking gel at 4% acrylamide concentration was prepared according to 
instructions in Table 2.26.1. Stacking gel was added until the top edge of the 
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glass plates and 1.5 mm-thick 12-well comb was secured at the top of the plates, 
to allow sample loading. Gels were stored at 4oC overnight until used the 
following day. 
Table 2.26.1 Volumes of reagents for resolving and stacking gel preparation.  
 
 
2.26.2 SDS-PAGE for protein samples 
Reagents: 
• Pre-stained protein marker (8-260 kDA) (Cat# 928-60000; Chameleon 
Duo, LI-COR Biosciences, Ltd., UK) 
• Protein Loading Buffer Blue (5x) (Cat# EC-886; National Diagnostics, USA) 
• Running buffer (1x): 
o 10x Tris/Glycine/ SDS (w/v) solution (Cat# EC-870; National 
Diagnostics, Hull, UK) 
o dH2O 
Protocol: 
Protein samples were retrieved from -20oC and thawed on ice. Samples were 
diluted with dH20 to yield a 20 μg protein sample. Following dilution, 2 μL of 5x 
protein loading buffer was added to each sample to a final volume of 10 μL. 
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Samples were heated to 95oC for 10 min and centrifuged at 21,000 x g briefly and 
kept on ice until loaded on the gel.   
Polyacrylamide gels were loaded into a tank and filled with running buffer 
diluted 1:10 with dH2O, to produce a 1x running buffer solution. The comps were 
removed from the gels and 3 μL of protein ladder was loaded followed by 10 μL 
of protein samples in each neighbouring well. The lid was placed over the tank 
with the electrodes connected to a gel electrophoresis power supply, and the 
power was set to 20 mA per gel. Gels were allowed to run until the lowest ladder 
(8 kDa) reached the bottom of the gel.  
 
2.26.3 Western blotting 
Reagents: 
• Anode 1 buffer, pH 10.4:  
o 0.3 M Tris (Sigma Aldrich, Dorset, UK)  
o 20% MetOH (Cat# 34860; Sigma Aldrich, Dorset, UK) 
• Anode 2 buffer, pH 10.4:  
o 25 mM Tris (Sigma Aldrich, Dorset, UK)   
o 20% MetOH (Cat# 34860; Sigma Aldrich, Dorset, UK) 
• Cathode buffer, pH 7.6:  
o 40 mM 6-amino n hexanoic acid (Sigma Aldrich, Dorset, UK)  
o 20% MetOH (Cat# 34860; Sigma Aldrich, Dorset, UK) 
• Ponceau S stain (Sigma Aldrich, Dorset, UK) 
Protocol: 
Proteins were transferred from the acrylamide gel to a nitrocellulose 
membrane (Cat# 10600002; GE Healthcare Life Sciences, Buckinghamshire, UK) 
using a semi-dry trans-blot system (Trans-Blot SD Semi-Dry Transfer Cell; BioRAD, 
Hertfordshire, UK). The acrylamide gel was removed from the glass plates, the 
stacking gel was discarded and the resolving gel was placed on the nitrocellulose 
membrane soaked in Anode II buffer, and sandwiched as shown in Figure 2.26.3. 
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The current was set to 100 mA per gel for 1 h to achieve good protein transfer. 
Following transfer, nitrocellulose membrane was stained with Ponceau S stain to 
confirm equal loading and transfer of all proteins.   
 
 
Figure 2.26.3 Schematic showing the semi-dry transfer set-up system for transfer 
of proteins from the SDS-PAGE gel to the membrane.  
 
2.26.4 Processing of nitrocellulose membrane and protein detection 
Reagents: 
• 0.005% v/v PBS-Tween-20 (PBS-T) solution  
• Blocking solution:  
o 5% milk powder 
o 0.005% PBS-T 
• Primary antibody (1ry Ab) solution:  
o 1% milk powder  
o 0.005% PBS-T 
• Secondary antibody (2ry Ab) solution:  
o 3% milk powder  
o 0.005% PBS-T 




Following confirmation of protein transfer and amount by Ponceau S, the 
nitrocellulose membrane was washed with ddH2O followed by PBS, until 
Ponceau S was removed from the membrane. The nitrocellulose membrane was 
then blocked with 10 mL of blocking solution for 1 h at RT. Following blocking, 
the membrane was washed 3x 5 min with PBS-T before incubated with the 
appropriate 1ry Ab solution overnight at 4oC. Following overnight incubation, the 
membrane was left to equilibrate at RT for approximately 15 min and then 
washed 3x 5 min with PBS-T before incubated with the appropriate 2ry Ab 
solution for 1 h at RT. The membrane was then washed 3x 5 min with PBS-T and 
imaged using a LI-COR Odyssey CLx imaging system (LI-COR, Cambridge, UK).   
 





2.26.5 Data analysis of Western blot experiments 
Following imaging of the membrane, the intensity of the bands was recorded 
using ImageJ software (Image Processing and Analysis in Java; National Institutes 
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of Health, Bethesda, MD, USA). The intensity of the bands was normalised to the 
intensity of the Ponceau S bands from the entire sample, which has been 
described as a more reliable method for accurate protein quantification (Aldridge 
et al. 2008; Eaton et al. 2013; Li and Shen, 2013; Taylor and Posch, 2014).  
 
2.27 Proliferation assay 
Reagents: 
• Cell Counting Kit – 8 (CCK-8) solution (Cat# 96992; Sigma Aldrich, Dorset, 
UK) 
• Growth Media (GMC2C12) (Section 2.16) 
• Growth Media (GMNSC34) (Section 2.16) 
• Transfection reagents (Section 2.21) 
Protocol: 
C2C12 and NSC-34 cells were plated as previously described into a 96-well 
plate in 1,000 cells/well (3,125 cells/cm2) confluency. Cells were incubated in 
growth media (GMC2C12, GMNSC34) at 37oC and 5% CO2 for 24 h to allow proper 
attachment. The plates were then retrieved from the incubator and transfected 
with miR-128 (Scr, mimic, AM) or miR-133a (Scr, mimic, AM), according to the 
protocol in Section 2.21. After 6 h of transfection, media was replaced to 3% FBS 
in both C2C12 and NSC-34 cells to ensure survival and prevent over-proliferation 
until the assay was performed. The plates were then retrieved from the 
incubator 48h following transfections and a known number of viable C2C12 or 
NSC-34 cells were plated (Table 2.27) for preparation of a standard curve. Plates 
were incubated for 4-6 h to allow attachment of newly plated cells. Following 
incubation, the plates were retrieved from the incubator and 10 μL of CCK-8 
reagent were added in each well. The plates were left to incubate for 3 h in the 
dark at 37oC and 5% CO2. Following incubation, the plates were retrieved from 
the incubator and the absorbance was measured at 450 nm using a microplate 
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reader. The number of cells following transfections with miR-128 and miR-133a 
was calculated using the standard curve.  
 
Table 2.27 Known number of viable cells plated in each plate for the generation 
of a standard curve.  
  
 
2.28 Cytotoxicity assay 
Reagents: 
• CytoTox 96® Non-Radioactive Cytotoxicity Assay kit (Cat# G1780; 
Promega, Southampton, UK)  
• Passive Lysis 5x Buffer (Cat# E1941; Promega, Southampton, UK) 
• 1 M acetic acid (Cat# A6283; Sigma Aldrich, Dorset, UK) 
• 100 μM H2O2 (Cat# H1009-100mL; Sigma Aldrich, Dorset, UK)  
• Growth Media (GMC2C12) (Section 2.16) 
• Growth Media (GMNSC34) (Section 2.16) 
• Transfection reagents (Section 2.21) 
Protocol: 
NSC-34 and C2C12 cells were plated as previously described into a 96-well 
plate at a 2,000 cells/well (6,250 cells/cm2) confluency and incubated in growth 
media (GMC2C12, GMNSC34) at 37oC and 5% CO2 for 24 h to ensure good 
attachment. Both C2C12 and NSC-34 cells were then retrieved from the 
incubator and transfected with miR-128 (Scr, mimic, AM) or miR-133a (Scr, 
mimic, AM) as previously described (Section 2.21). Additionally, 12 wells with 
cells (C2C12 or NSC-34) in each plate were used for transfections with 
lipofectamine-conjugated Scr (6 wells) and cholesterol-conjugated Scr (6 wells). 
These wells were incubated with 100 μM H2O2 in 3% FBS media (100 μL/well of 
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GMC2C12 or GMNSC34) following 6 h of transfections, to serve as a positive control 
for maximum cell cytotoxicity. The rest of the wells were incubated only in 3% 
FBS media (100 μL/well of GMC2C12 or GMNSC34) following 6 h of transfections. 
Plates were then placed in an incubator for 48 h at 37oC and 5% CO2. Following 
incubation, plates were retrieved from the incubator and 50 μL aliquots from all 
wells were transferred to a new 96-well plate, according to manufacturer’s 
instructions. Each well was then supplemented with 50 μL of CytoTox 96® 
Reagent and plates were then incubated for 30 min at RT in the dark. Following 
incubation, 50 μL of 1 M acetic acid was added in each well to stop the reaction 
and the absorbance was recorded at 490 nm using a microplate reader.  
For Maximum lactate dehydrogenase (LDH) Release Control, 6 wells were 
used per plate for both C2C12 and NSC-34 cells and 20 μL of Passive Lysis 5x 
Buffer were added to these wells 45 min before transfer of aliquots on to fresh 
plates.   
 
2.29 Mitotoxicity assay 
Reagents: 
• Mitochondrial ToxGlo™ Assay (Cat# G8000; Promega, Southampton, UK) 
• 20 μM Carbonyl cyanide 3-chlorophenylhydrazone (CCCP) (Cat# C2759; 
Sigma Aldrich, Dorset, UK): 
o Diluted in 100 mM DMSO to produce a 20 mM stock solution 
• Dimethyl sulfoxide (DMSO) (Cat# D4540; Sigma Aldrich, Dorset, UK) 
• Growth Media (*GMC2C12) (Section 2.16):  
o DMEM (Cat# D5671) replaced by DMEM/low glucose media (Cat# 
31885049; Gibco™, ThermoFisher, Paisley, UK)   
• Growth Media (*GMNSC34) (Section 2.16):  
o DMEM (Cat# D5671) replaced by DMEM/low glucose media (Cat# 
31885049; Gibco™, ThermoFisher, Paisley, UK) 




C2C12 and NSC-34 cells were plated as previously described into a 96-well 
plate (opaque walls/clear flat bottom) at a confluency of 2,000 cells/well (6,250 
cells/cm2) and 3,000 cells/well (9,375 cells/cm2) respectively. Cells were 
incubated in growth media (GMC2C12, GMNSC34) at 37oC and 5% CO2 for 24 h to 
ensure good attachment. Both C2C12 and NSC-34 cells were then retrieved from 
the incubator and transfected with miR-128 (12 wells for each: Scr, mimic, AM) 
as previously described (Section 2.21). Extra wells were left untreated in both 
plates, in order to use as positive and negative control. Following 6 h of 
transfections, media was replaced to 3% FBS growth media (*GMC2C12, *GMNSC34) 
and left to incubate for 48 h according to the protocol. From each transfection 
group (Scr, miR, AM), 6 wells were treated with CCCP in order to induce 
mitophagy. Control wells were also treated with DMSO, to use as vehicle control 
for CCCP. Both plates were then retrieved from the incubator following 
transfections and 20 μL of 5x Cytotoxicity reagent was added to each well. Both 
plates were allowed to incubate at 37oC for 30 min in the dark before 
fluorescence was measured using a fluorescence plate reader equipped with a 
rhodamine 110 filter set. Plates were left to equilibrate for 10 min at RT before 
the addition of 100 μL of ATP Detection Reagent in each well. Luminescence was 
then recorded using a microplate luminometer (Promega). Cytotoxicity and 
mitotoxicity were expressed as fold-change of each well divided by the average 
absorbance value of the Scr wells.  
 
2.30 Statistical Analysis 
All statistical analysis was performed with Graphpad 5 software (San Diego, 
USA). One-way ANOVA followed by a Dunnett’s post-hoc analysis was performed 
for comparison of groups with the control group (NNN for in vivo experiments 
and Scr-transfected cells for in vitro experiments). Chi-squared (χ2) test was 
performed for detection of significant changes in data distributions. Data were 
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represented as mean ± SEM. N number represents animals for in vivo studies and 











Effect of low-protein diet pre- and 
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Age-related sarcopenia is characterised by loss of skeletal muscle mass and 
function (Faulkner et al. 2007). Loss of muscle mass and function is linked to loss 
of skeletal muscle fibres and motor neurons, with an additional weakening of the 
remaining muscle fibres (Marzetti et al. 2009). These physiological changes 
during ageing have been associated with influences that occur early in life. 
Longitudinal studies provide a link between individual birth weight and muscle 
function later in life, providing evidence that early development may affect 
muscle mass and function during ageing (Sayer et al. 2006).  
Maternal nutrition has been strongly associated with pre- and postnatal 
growth in both rodents and humans. Specifically, suboptimal nutrition during 
gestation has been linked to reduction in body weight and impaired muscle 
growth in mice (Beermann, 1983; Rehfeldt et al. 2011). Lower birth weight of the 
offspring has been linked to maternal undernutrition in humans (Victora et al. 
2008). Maternal low-protein nutrition during gestation and lactation can cause 
long-term metabolic changes in the skeletal muscle of the offspring (da Silva 
Aragão et al. 2014). Skeletal muscle wasting, reduction in EDL muscle forces and 
change in muscle fibre type proportion in EDL and SOL muscles has been 
demonstrated in rats born from dams on a protein-deficient diet (Toscano et al. 
2008).   
Preliminary studies from our laboratory indicate that mice born from dams 
maintained on a normal protein diet but fed postnatally by a foster dam 
maintained on a low-protein diet (NL) demonstrated significant reduction in 
body size, body weight, muscle weight and length and muscle fibre size at 21 
days of age days of age when compared with pups from dams maintained on a 
normal protein diet throughout the in utero and postnatal periods (NN) (Figure 
3.1 A-F). Moreover, mice born from dams maintained on a low-protein diet but 
fed postnatally by a dam maintained on a normal diet (LN) demonstrated 
significant reduction only in the EDL muscle length, compared to the control 



















































































































Figure 3.1 The effects of reduced protein intake in utero or postnatally on A) 
body size and B) total body weight (g) of 21-day old mice. *represents significant 
differences compared with NNN (control) group, ***P ≤0.001 (mean ± SEM; 
n=11-12, One-Way ANOVA with Dunnett’s post-hoc analysis). C) Transverse 
section of EDL muscle from 21-day old mice (NN, NL, LN) stained with WGA 
(green) and DAPI (blue) and visualised under a confocal microscope, Scale bar: 
100 μm, Magnification: x20, Section thickness: 12 μm, D) EDL muscle weight 
(mg), E) EDL muscle length (mm), F) EDL fibre size (expressed as Ferret’s 
diameter) of 21-day old mice (NN, NL, LN). *represents significant differences 
compared with NNN (control) group *P ≤0.05, **P ≤0.01, ***P ≤0.001 (mean ± 
SEM; n=4-6, One-Way ANOVA with Dunnett’s post-hoc analysis). Keys for NN, NL 
and LN explained in detail in Chapter 2, Section 2.1.   
 
The aim of this study was to examine whether these changes associated with 
low protein intake during gestation or lactation persist during early adulthood 
and whether these changes affect muscle mass, function and/or motor neuron 




3.2.1 Mice preparation 
Groups of mice were weaned at 21 days old onto either the deficient diet or 
the 20% protein control diet to produce the three following groups: NNN; NLL; 
LNN (Chapter 2, Section 1). Mice were maintained until 12 weeks of age. Prior to 
culling, EDL force measurements were conducted as described in Chapter 2, 
Section 2.2, in order to determine the maximum force generated by the EDL 




3.2.2 Isolation and preparation of EDL muscles from 12-week old mice for 
histological analyses and NMJ imaging 
EDL muscles from the left limb of 12-week old mice were dissected following 
culling and processed as described in Chapter 2, Section 2.3. The EDL muscle 
from the right limb of those mice was dissected, mounted on a silgard-coated 
dish using surgical pins and fixed with 10% NBF for 1 h at RT (Chapter 2, section 
2.3). Following, fixation, EDL muscles were rinsed twice with PBS and stored in 
0.1% PBS-NaN₃ until used for staining and imaging of neuromuscular junctions 
(NMJs) (described in Chapter 2, Sections 2.4, 2.5). For determination of muscle 
fibre size, EDL muscles were sectioned using a cryotome (Leica 1890) at 12 μm 
thickness. EDL sections were mounted on Superfrost Plus slides (Thermofisher) 
and sections allowed to air-dry for a minimum of 1 h at RT prior to staining. EDL 
muscle sections were stained with WGA and DAPI, according to protocol 
described in Chapter 2, Section 2.8. Image acquisition was performed using a 
Nikon Ti Confocal Microscope (Chapter 2, Sections 2.9) and image analysis was 
performed as described in Chapter 2, Section 2.10. For NMJ visualisation and 
scoring, pre-fixed EDL muscles were stained with Alexa Fluor-594 α-
bungarotoxin, according to protocol described in Chapter 2, Section 2.4. Image 
acquisition was performed using a Nikon Eclipse Ni-E Intravital confocal 
microscope (Nikon, Tokyo, Japan) and images were processed and scored as 
described in Chapter, Section 2.5.   
 
3.2.3 First Strand cDNA synthesis and real-time qPCR analysis of marker genes 
in TA muscle of 12-week old mice  
TA muscles from the right limb of 12-week old mice were dissected following 
24 h whole-body fixation and were grounded in a mortar using LN2. When fully 
grounded, TA muscles were immersed in TRIzol and were prepared for RNA 
isolation using phenol-chloroform method, as described in Chapter 2, Section 
2.12. RNA concentration and purity were recorded using NanoDrop2000 
(Thermofisher Scientific). First Strand cDNA synthesis was performed using 
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SuperScript™ IV VILO™ Master Mix (Cat# 11756050, Invitrogen, Paisley, UK) 
according to manufacturers’ protocol. In each cDNA reaction, 100 ng of RNA was 
used (5 ng/μL). cDNA reaction volume was diluted 1:10 to a final volume of 200 
μL and stored at -20oC until used for qPCR. Real-time qPCR was performed 
according to the protocol in Chapter 2 Section 2.15. Gene expression analysis 
was performed according to the delta-delta Ct method (ddCt), using 18S as the 
housekeeping gene. Primer sequences are shown in Table 3.2.3 below: 
 
Table 3.2.3 Primer sequences of the gene transcripts.  
Gene name Primer sequences (5’ – 3’) 
 Forward Reverse 
Atrogin-1 GCAGAGAGTCGGCAAGTC CAGGTCGGTGATCGTGAG 
FoxO-3 AGTGGATGGTGCGCTGTGT CTGTGCAGGGACAGGTTGT 
MuSK GCCTTCAGCGGGACTGAG GAGGCGTGGTGACAGG 
MyHC I TTGTGCCGTAGGAATGTGGG CCTTTCTCGGAGCCACCTTG 
MyHC IIa CTCCAAGGACCCTCTTATTTCCC ACTGCTGAACTCACAGACCC 
MyHC IIb GAGGCAATCAGGAACCTTCGG TGTGTGTCCTTCAGCATTCCC 
MyHC IId/x AAGTTTGGACCCACGGTCG CAGTGAGAGAGCCTGCCTTTA 
18S CGGCTACCACATCCAAGGAAGG CCCGCTCCCAAGATCCAACTAC 
 
 
3.2.4 Statistical Analysis 
Statistical analysis was performed using Graphpad 5 (Graphpad Software, San 
Diego, USA). Statistical comparisons from physiological and histological analyses 
were performed using One-way ANOVA with Dunnett’s post-hoc analysis, using NNN 
as the control group. Data were represented as mean ± SEM. N number represents 






3.3.1 The effect of pre- or postnatal protein-deficient diet on body and 
muscle weight of 12-week old mice  
Total body and muscle weights of 12-week old mice subjected to a protein-
deficient diet (5% protein) either pre- or postnatally is shown in Figure 3.3.1.1. 
Body weight of mice on a protein-deficient diet postnatally (NLL) was 
significantly lower compared with mice on a normal diet (NNN) (Figure 3.3.1.1 
A). Muscle weight of EDL and TA muscle showed no significant changes between 
the three experimental groups (Figure 3.3.1.1 B, C), although the weight of SOL, 
GTN and Quad muscles was significantly reduced in NLL mice (Figure 3.3.1.1 D-
F). No visible difference in the body size was observed upon collection of the 
animals. 
Ratio of skeletal muscle weight in relation to total body weight of NNN, NLL 
and LNN mice is shown in Figure 3.3.1.2. The ratio of EDL, TA, SOL, GTN and 
Quad muscle weight to total body weight showed no significant changes 


















Figure 3.3.1.1 Total body and muscle weight of 12-week old mice. (A) Total body 
weight (g) and (B-F) muscle weight of EDL (B), TA (C), SOL (D), GTN (E) and 
Quadriceps (F) muscles (mg) isolated from 12-week old mice subjected to a 

























































































































differences compared with NNN (control) group, *P ≤0.05, **P ≤0.01, ***P 
≤0.001 (mean ± SEM; n=5-14; One-Way ANOVA with Dunnett’s post-hoc 
analysis).  
  
Figure 3.1.1.2 Muscle-to-body weight ratio of 12-week old mice. Ratios body to 


















































































































































subjected to a protein-deficient diet (5% protein) pre- or postnatally, expressed 
as a %.  NNN was used as the control group for statistical comparisons (mean ± 
SEM; n=5-14; One-Way ANOVA with Dunnett’s post-hoc analysis). 
 
3.3.2 The impact of protein-deficient diet during pre- or postnatal stages of 
development on skeletal muscle force generation in 12-week old mice 
Maximum force of EDL muscle, correlation between muscle force versus EDL 
muscle weight and body weight of 12-week old mice are shown in Figure 3.3.2. 
Maximum force of EDL muscle was significantly lower only in the NLL group, 
compared to the control (NNN), but the specific muscle force showed not 
differences between the groups (Figure 3.3.2 A, B). Correlation analysis for 
maximum force versus total body weight indicated a week correlation between 
the two, with Pearson’s coefficient (R) <0.5 (Figure 3.3.2 B). However, 
correlation analysis for maximum force and EDL muscle weight showed a 
significant but moderate correlation, with Pearson’s coefficient (R) just above 0.5 




























Forces vs Body Weight
























C. Forces vs EDL Muscle Weight






















































Figure 3.3.2 EDL muscle forces in 12-week old mice. A) Maximum force of EDL 
muscle (mN) of 12-week old mice and B) Specific tetanic force of EDL muscle 
(Specific Force (mN/mm2)) of 12-week old mice, *represents significant 
differences compared with NNN (control) group, **P ≤0.01 (mean ± SEM; n=5-
14; One-Way ANOVA with Dunnett’s post-hoc analysis). C) Correlation of 
maximum muscle force (mN) versus total body weight (g) and D) Correlation of 
maximum force (mN) versus EDL muscle weight (mg) of 12-week old mice, R ≥ 
0.25 indicates a week correlation between the two variables, R ≥ 0.50 indicates a 




3.3.3 Histological examination of the EDL muscle in 12-week old mice 
following a 5% protein diet pre- or postnatally 
Histological analyses of EDL muscle are shown in Figure 3.3.3.1. EDL fibre size 
showed no significant differences between the three groups (Figure 3.3.3.1 C).  
EDL fibre number was significantly lower in both NLL and LNN mice compared to 
the control group (Figure 3.3.3.1 B). Distribution curves for EDL fibre size for all 
three groups were plotted, in order to assess whether fibre sizes follow similar 
distribution patterns across all experimental groups. Distribution of the EDL fibre 
sizes was similar between the three groups, with no significant shift been 












Figure 3.3.3.1 Histological examination of the EDL muscle of 12-week old mice. 
A) Transverse sections of EDL muscle from 12-week old mice stained with WGA 
(green) and visualised under a confocal microscope. Scale bar: 200 μm, 
Magnification: x20, Section thickness: 12 μm. B) EDL fibre number and C) EDL 





























































NNN (control) group, *P ≤0.05, **P ≤0.01 (mean ± SEM; n=4-8, One-Way 
ANOVA with Dunnett’s post-hoc analysis). Representative images shown.  
 
Figure 3.3.3.2 Myofibre distribution analysis of EDL muscle, expressed as a 
percentage of total muscle fibres analysed in EDL muscle of 12-week old mice 
(mean ± SEM; n=4-6, Chi-square test).   
 
3.3.4 Assessment of NMJ integrity in 12-week old mice following a low-
protein diet pre- and postnatally  
Images and analysis of NMJ morphology in EDL muscles of 12-week old mice 
following a low-protein diet pre-or postnatally is shown in Figure 3.3.4.1 and 
Figure 3.3.4.2. Analysis of NMJ images revealed the presence of morphological 
abnormalities in NLL and LNN, rather than denervation (partial or complete) of 
the synaptic site (Figure 3.3.4.1). Individual NMJs where subsequently scored 
into normal, morphologically abnormal and denervated in all three groups. 
Significant differences in the number of NMJs with morphological abnormalities 
were recorded in NLL compared to the control group (NNN) (Figure 3.3.4.2 A). 
EDL Fiber Size Distribution


























NMJs with morphological abnormalities in all three groups were then scored and 
subdivided into fragmented, small in size or with limited/defective branching 
(Chapter 2, Section 2.5). The proportion of NMJs with small size, fragmented or 
defective branching was higher in NLL mice compared to the control group 
(NNN) (Figure 3.3.4.2 B-D).  
 
Figure 3.3.4.1 Characterisation of NMJs in EDL muscle of 12-week old mice on a 
normal or a protein-deficient diet pre- or postnatally. The pre-synaptic terminal 
expressing YFP (green) and the post-synaptic end plate stained with α-
bungarotoxin (red) show perfect overlap. A number of NMJs in NLL and LNN mice 
show morphological aberrations (arrow) in comparison with the “pretzel” shape 
seen in the control group. Scale bar: 50 μm, Magnification: x60. Representative 
images shown.  








Figure 3.3.4.2 Classification of NMJs changes in EDL muscle of 12-week old mice 
on a normal or a protein-deficient diet pre- or postnatally. A) NMJs were divided 
into 3 main categories: normal (N), morphologically abnormal (MA) and 
denervated (partial or complete) (D) and expressed as a percentage of the total 
number of NMJs scored per muscle. B-D) Scoring of NMJs with morphological 
abnormalities into 3 sub-categories: fragmented (B), with limited/defective 
branching (C) or with small synaptic area (D) *represents significant differences 
compared with NNN (control) group, *P ≤0.05, **P ≤0.01, ***P ≤0.001 (mean ± 



















































































3.3.5 Gene expression analysis of marker genes for muscle fibre isoforms, 
muscle atrophy and NMJ formation in TA muscle of 12-week old mice 
following a low-protein diet pre- and postnatally 
Expression analysis of genes involved in determination of myosin heavy chain 
isoforms in TA muscle of 12-week old mice are shown in Figure 3.3.5.1. 
Expression levels of MyHC-IIa revealed significant increase in gene expression 
levels in NLL group, compared to the control group (NNN) (Figure 3.3.5.1 B). 
Expression levels of MyHC-I (Figure 3.3.5.1 A), MyHC-IIb (Figure 3.3.5.1 C) and 
MyHC-IId/x (Figure 3.3.5.1 D) showed no significant differences between the 
groups. However, the sample variation and the small N number did not allow a 
definitive conclusion to be drawn.   
Expression levels of Atrogin-1, MuSK and FoxO-3 genes are shown in Figure 
3.3.5.2. Analysis of Atrogin-1 expression levels showed significant increase in 
expression levels both in NLL mice and LNN, compared to the control group 
(NNN) (Figure 3.3.5.2 A). On the contrary, MuSK and FoxO-3 expression levels 














Figure 3.3.5.1 Expression analysis of MyHC isoforms in TA muscle of 12-week old 
mice following a low-protein diet pre- or postnatally. Relative expression levels 
of A) MyHC-I, B) MyHC-IIa, C) MyHC-IIb and D) MyHC-IId/x. *represents 
significant differences compared with NNN (control) group, *P≤0.05 (mean ± 












































































































Figure 3.3.5.2 Expression analysis of A) Atrogin-1, B) MuSK and C) FoxO-3 genes 
in TA muscle of 12-week old mice following a low-protein diet pre- or 
postnatally. *represents significant differences compared with NNN (control) 





The aim of this study was to determine the effect of reduced protein diet pre- 
or postnatally on NMJ structure, muscle mass and function in mice during 














































































lactation were subjected to a normal or a low-protein diet after weaning, until 12 
weeks of age (NNN, NLL, LNN mice; Chapter 2, Section 2.1). Assessment of body 
and muscle physiology and function in mice subjected to a protein-deficient diet 
was performed in order to investigate whether changes seen during gestation or 
lactation stages (21-day old mice) persist until early adulthood (preliminary data, 
Figure 3.1). This assessment would also indicate in which developmental stage 
dietary modifications play a crucial role in skeletal muscle wasting. Data collected 
from 12-week old mice showed a reduction in total body weight and muscle 
strength, accompanied by reduction in the muscle weight of specific skeletal 
muscles of the lower limbs. However, the reduction in maximum force 
generation of the EDL muscle was not accompanied by a reduction in its specific 
force. Therefore, the reduction of the maximum force may be attributed to the 
morphological alterations seen at the NMJs rather than changes in muscle fibre 
number. No structural differences were observed in muscle fibre size, but 
noticeable differences in the morphology of the NMJs and muscle fibre number 
were recorded. Quantitative expression analysis of marker genes involved in 
regulation of muscle mass and function revealed changes in the expression levels 
of those genes in mice on a protein-deficient diet. These changes could indicate 
the potential impact of dietary protein restriction early in life in the regulation of 
molecular mechanisms of muscle composition, muscle morphology and function 
and NMJ maintenance. 
  
3.4.1 The effect of low-protein diet pre- or postnatally on body and muscle 
mass, muscle size and muscle function of 12-week old mice 
Analysis of total body weight and maximum force generation in EDL muscle 
showed significant decline of both only in mice on a low-protein diet at postnatal 
stages of development (NLL) (Figure 3.3.2). Similar reduction was seen in the 
weight of SOL, GTN and Quad muscle in NLL mice but no changes were recorded 
in the weight of EDL and TA muscle of NLL mice, compared to the control group 
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(NNN) (Figure 3.3.1.1). Muscle weight of mice from the LNN group showed no 
differences, compared to the control group (NNN) (Figure 3.3.1.1).  
The reduction in body weight in 12-week old mice on 5% protein diet 
postnatally highlights the systemic effect of dietary interventions and the 
important role of nutrients during development. Changes in body weight 
following restriction of nutrients have been previously reported in both mice 
(Yang et al. 2014; Chen et al. 2009) and humans (reviewed in Soliman et al. 
2014). In terms of protein restriction in humans, several cases of malnutrition 
due to suboptimal protein intake have been recorded in infants even in 
developed countries with wide range of adverse effects (Tierney et al. 2010). 
Several studies have highlighted the link between body weight and muscle 
function, where muscle strength was assessed. Specifically, in humans low body 
weight early in life has been associated with reduced muscle function later in life 
(Sayer et al. 2004). In mice, early life protein restriction has been linked to lower 
body and organ weight and changes in the expression of key proteins associated 
with muscle function and maintenance (Chen et al. 2009). Data from this study 
showed significant reduction in the muscle weight in SOL, GTN and Quad muscle 
(composed of type I and type II muscle fibres) but not in EDL and TA muscles 
(composed predominantly of type II muscle fibres). However, correlation analysis 
of EDL muscle weight compared with the maximum force showed a link between 
lower muscle weight and reduced maximum muscle force (Figure 3.3.2 D). 
Similar results were obtained from correlation analysis between body weight and 
maximum muscle force. Specific muscle force showed no differences between 
the three groups, indicating that maximum muscle force generation in NLL mice 
may be reduced due to morphological alterations seen at the synaptic site rather 
than intrinsic muscle mechanisms. These data indicate that individual muscle 
weights may not show significant differences between the groups, but they could 
be directly associated with lower maximum force generation from the muscle. 
Absence of significant differences in mice in the LNN group suggests that pre-
natal protein restriction does not have a direct impact on skeletal muscle weight 
and force generation during adulthood.  
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3.4.2 The effect of maternal protein restriction on muscle physiology 
Histological analysis of the EDL muscle was necessary in order to assess any 
potential effect of maternal protein restriction in skeletal muscles of the 
offspring. EDL muscle has a high percentage of fast-twitch muscle fibres (MyHC 
type II isoforms) (Augusto et al. 2004), which are preferentially lost during 
ageing. Therefore, this muscle is ideal for measurement of the contractile 
properties of skeletal muscle in mice. Morphological analysis of the EDL muscle 
showed no differences in muscle fibre size. However, significant reduction in EDL 
fibre number was recorded in NLL and LNN mice (Figure 3.3.3.1). This reduction 
in fibre number of NLL mice at 12 weeks of age may be the result of preferential 
loss of smaller muscle fibres at earlier stages of development. It is interesting 
that we did not see a significant reduction in the weight of the EDL muscles in 
this group given this finding. However, it is possible that the muscles of these 
mice have gained bulk via other sources such as fat infiltration, which was not 
examined in this thesis. Furthermore, the small size of the EDL muscle makes it 
technically challenging to detect changes in its weight between the three 
experimental groups.  
Mice from the LNN group also had a significant reduction in myofibres 
number at 12 weeks of age (Figure 3.3.3.1). It is possible that the loss of muscle 
fibre size in mice from the NLL and LNN group would be due to different 
mechanism involved, as suggested by qPCR data. Distribution analyses of the 
fibre size in EDL muscle showed no significant shift in the fibre size distribution 
(Figure 3.3.3.2). Again, the lack of a significant reduction in the weight of the EDL 
muscles may be due to bulk gained via other sources such as fat infiltration. In 
order to determine whether that is indeed the case, further investigation is 
required.  
Previous studies have demonstrated a strong link between muscle force and 
muscle physiology in terms of muscle fibre size and number. Weaker muscles 
have been associated with reduced number of muscle fibre size and/or number, 
one of the main characteristics of sarcopenia (reviewed in Doherty, 2008). 
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Recent studies have demonstrated a reduction in muscle strength during early 
ageing but in the absence of muscle atrophy, suggesting that reduction in the 
muscle force may be a predecessor of physiological changes seen in the muscle 
at later stages (Chan et al. 2010). Although loss of muscle function without 
changes in muscle physiology has not been frequently reported, other factors 
may be equally responsible for a reduction in muscle strength. Examples of such 
factors include changes in MyHC isoforms, affecting the contractile properties of 
the muscle (Barany, 1967), innervation and signal transmission at the synaptic 
site of the muscle (Sheth et al. 2018), changes in the levels of ROS (Palomero et 
al. 2013), mitochondrial content (Short et al. 2005) and changes in key molecular 
mechanisms regulating muscle mass and function (reviewed in Jackman and 
Kandarian, 2004).  Molecular changes of critical molecules for skeletal muscle 
mass and function, the structure and morphology of synaptic sites and 
mitochondrial homeostasis were further investigated in our study. 
 
3.4.3 Physiological changes at the neuromuscular junction site in 12-week old 
mice on a protein-deficient diet 
To elucidate the mechanisms causing a reduction in muscle force generation 
in 12-week old mice on a protein-deficient diet postnatally, assessment of the 
structure of the NMJ was assessed. Firstly, NMJs were categorised into normal, 
morphologically abnormal or denervated (partial or complete) in order to 
examine whether changes in structure and morphology would be as severe as 
those seen in diseases (Lyons and Slater, 1991; Pratt et al. 2015) or during ageing 
(Vasilaki et al. 2016). Scoring of NMJs showed a significantly higher proportion of 
morphologically altered NMJs in the NLL group compared to the control group; 
although perfect overlap between the pre-and post-synaptic site was evident in 
the majority of NMJs (Figure 3.3.4.1). Moreover, partial denervation in a small 
number of NMJs in both NLL and LNN groups was noted but their proportion was 
below 5% of total NMJs scored and presented no significant differences 
compared to the control group (NNN) (Figure 3.3.4.2). This small proportion of 
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partially denervated NMJs was not surprising, considering that evidence of 
complete denervation in the muscle is not common in young/adult mice not 
affected by a severe condition such as muscular dystrophy, in which more 
striking physiological effects are also noted (Lyons and Slater, 1991).  
Since significant differences in the NMJs with morphological abnormalities 
were recorded in the NLL group, subsequent scoring of those NMJs was 
performed. Three subcategories of morphological abnormalities were generated 
based on fragmentation of the synaptic components, limited or defective 
branching and small synaptic surface area. Similar criteria for NMJ scoring have 
been used in previous studies (Valdez et al. 2010) although the NMJ phenotype 
was much more severe than the one seen in our study. Data collected showed a 
significant increase in the proportion of the NMJs in all three subcategories in 
mice from the NLL group, compared to the control (NNN) group (Figure 3.3.4.2).  
Collectively, results from the NMJ scoring indicate alterations in the 
morphology of the NMJ site but very little evidence of partial denervation and no 
visible impairments in the overlap of the pre- and post-synaptic components 
were recorded. Although defects in the NMJs have been previously reported to 
impact skeletal muscle function, such defects are usually quite striking, including 
partial or fully denervated NMJs or lack of overlapping of the junction 
components (reviewed in Tintignac et al. 2015). These aberrations have been 
recorded in mice models with severe muscle defects (Lyons and Slater, 1991; 
Fischer et al. 2011) and during ageing (Vasilaki et al. 2016). Alterations in the 
morphology of the NMJs such as the ones seen in this study may be the results of 
delayed development. Small NMJ size and limited branching in the synaptic site 
similar to that observed in mice from the NLL group has been recorded in several 
studies examining the developmental stages and maturation of NMJs in mice 
(Slater, 1982; reviewed in Shi et al. 2012). Assuming that mice from the NLL 
group exhibit delayed development, this would align with the small proportion of 
partially denervated NMJs and any fragmentation seen which may be the result 
of NMJ remodelling rather than a deficit. Indeed NMJ remodelling in mice during 
postnatal stages of development includes branching elimination, parts of 
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unoccupied AChR clusters and along with structural other structural changes 
(Balice-Gordon and Lichtman, 1993; Marques et al. 2000). It is noteworthy that 
recent studies performing functional tests in muscle fibres occupied by an 
abnormal NMJ (e.g. fragmented) showed that such abnormalities per se do not 
affect the contractile properties of the skeletal muscle fibre (Willadt et al. 2016). 
However, there are studies showing a close association between NMJ 
morphology and muscle function in mice following injury (Tu et al. 2017). Here, 
we advocate that the NMJ structural alterations observed in this study may be 
the result of underlying dysregulation in molecular mechanisms due to maternal 
protein restriction. This would result in a phenotype agreeing with delayed 
development in mice from the NLL group. Unlike the NMJ phenotype observed in 
mice from the NLL group, no significant changes in NMJ structure where seen in 
12-week old mice from the LNN group, compared to the control. This is in line 
with the normal force generation of the EDL muscle of these mice. As such, pre-
natal protein restriction does not result in aberrations of NMJ morphology during 
adulthood. 
 
3.4.4 The impact of protein-deficient diet on molecular mechanisms of 
skeletal muscle morphology, muscle atrophy and NMJ formation in TA 
muscle of 12-week old mice 
In order to examine the hypothesis that protein restriction could have an 
effect on molecular mechanisms in the muscle during development, quantitative 
analysis of gene expression was performed for genes associated with muscle and 
NMJ physiology and function. Isolated RNA from TA muscle of 12-week old mice 
was used for cDNA synthesis and qPCR for the following genes: MyHC type I, IIa, 
IIb and IId/x isoforms, Atrogin-1, FoxO-3 and MuSK. 
Relative expression analysis of MyHC type IIa isoform in TA muscle revealed a 
significant upregulation in gene expression levels in the NLL group compared to 
the control group. Expression levels of MyHC type I, type IId/x and type b showed 
no significant differences between the groups. Increased intragroup variability in 
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gene expression levels along with a low n number for each group were important 
restrictions for accurate estimation of the gene expression levels of these gene 
transcripts (Figure 3.3.5.1).  
Several studies have established the TA muscle as a MyHC type IIb-rich muscle 
similar to the EDL in adult mice (Augusto et al. 2004) with MyHC type IId/x being 
the second most abundant isoform, followed by type IIa. During development, 
the composition of a skeletal muscle changes, with some MyHC isoforms being 
replaced. Specifically, the EDL muscle is predominantly composed by MyHC type 
IIb fibres at the age of 21 days, when MyHC type IIa is still present. By 90 days of 
age, the EDL muscle is devoid of the type IIa isoform and is composed almost 
exclusively of type IIb fibres and in smaller proportion type IId/x (Agbulut et al. 
2003). Very similar composition has also been observed in TA muscle, with MyHC 
type IIb being more abundant in adult mice (Augusto et al, 2004). Changes in 
muscle fibre composition in terms of MyHC isoforms can have an impact on the 
contractile properties of the muscle. Knockout mice for MyHC IIb or IId/x show 
distinct differences in muscle force generation (Acakpo-Satchivi et al. 1997). 
Other studies have shown that adult mice lacking of MyHC IId expression 
demonstrated an increase in the expression of MyHC IIa isoform, potentially 
acting as a compensatory mechanism (Santorius et al. 1998). Although MyHC IIa 
and IId/x fibres generate less force than type IIb fibres, upregulation of MyHC 
type IIa expression in mice from the NLL group might be a compensatory 
mechanism or an indicator of developmental defect in the TA muscles of those 
mice. However, it is possible that this level of overexpression may not be 
sufficient to recover muscle force in these mice. In order to examine whether this 
is indeed the case and whether these data are consistent in both EDL and TA 
muscles, immunofluorescent staining in transverse sections of those muscles 
would be necessary. Quantification of myofibres of different MyHC isoforms 
would provide an indication of potential shifts between different isoforms or the 
presence of hybrid myofibres in these muscles.   
In addition to the expression patterns of MyHC isoform genes, differences in 
the expression levels of genes involved in muscle atrophy and synapse formation 
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were also investigated (Figure 3.3.5.2). Relative gene expression of Atrogin-1 in 
TA muscle showed a significant increase in the expression levels in mice from 
both the NLL and LNN group. Atrogin-1 is a muscle-specific gene highly expressed 
during skeletal muscle atrophy (Gomez et al. 2010) but lower expression levels 
have been reported in aged mice with sarcopenia (Edström et al. 2006). 
Upregulation of this gene in mice of the NLL and LNN groups does agree with the 
reduction in muscle fibre number in the EDL muscle of these mice, but it may 
also be an early indicator of the tendency of those muscle fibres to undergo 
atrophy, a phenotype that could be studied later on in adult life. In terms of 
synaptic formation, expression levels of MuSK gene showed no significant 
differences between the groups. During postnatal development in mice, MuSK 
activation plays a fundamental role in NMJ maintenance and maturation in vivo 
(DeChiara et al. 1996; Hesser et al, 2006). Taken into account the structural 
changes seen in NMJ morphology in this study, it is possible that molecular 
changes in MuSK gene my have not yet been evident. In order to assess the 
molecular changes underlying the morphological alterations seen in NMJs, it 
would be important to examine the expression levels of additional genes, 
including AChR-α, AChR-ε and AChR-γ subunit genes. Upregulation in gene 
expression of the AChR-γ gene may indicate possible damage at the NMJ site, 
including denervation (Valdez et al. 2014). AChR-γ subunit is gradually 
substituted by AChR-ε subunit during NMJ maturation at early stages of 
development (Missias et al. 1996). Therefore, analysis of the expression level of 
the two AChR isoforms would be a useful tool to access whether delayed 
development or NMJ denervation/remodelling occurs in mice of the NLL group.  
All things considered, reduction of EDL muscle force seen only in NLL mice 
might be the combined result of myofibres loss and defective NMJs. Myofibre 
loss in LNN mice but normal NMJ structure might be insufficient for reduction in 
EDL muscle force. Examination of MyHC isoforms and AChR subunits would 
provide a more collective explanation on the effect of the protein-deficient diet 








MicroRNA expression and in silico 







MicroRNAs are important regulators of gene expression, controlling the 
expression of multiple transcripts in more than one tissue. Data from our lab 
show that several microRNAs have been associated with the regulation of 
skeletal muscle and nerve homeostasis, including miR-181, miR-199 and miR-
378. MiR-181 has been identified as a key microRNA for the establishment of 
skeletal muscle phenotype during muscle development, with expression levels 
being upregulated in the muscle during differentiation (Naguibneva et al. 2006). 
MiR-181a, a member of miR-181 family, has been shown to regulate Sirt-1 
expression on a protein level in skeletal muscle cells regulating myotube size 
(Soriano-Arroquia et al. 2016). MiR-181d, another member of miR-181 family, 
has been identified as negative regulator of axonal outgrowth and elongation 
(Wang et al. 2015). Studies have shown that miR-378 expression is positively 
regulated by MyoD during muscle cell differentiation (Gagan et al. 2011). Mice 
lacking of miR-378 expression show resistance to obesity induced by a high-fat 
diet and enhanced mitochondria metabolism (Carrer et al. 2012). MiR-199a 
expression has been induced in several model organisms of muscular dystrophy, 
including mdx mice (Alexander et al. 2013). Moreover, miR-199a was identified 
as a regulator of myogenesis via negative regulation of several factors of the 
WNT signalling pathway (Alexander et al. 2013). Ablation of miR-199a gene has 
been linked to reduced mTOR activity and induction of neurodevelopmental 
pathophysiology (Tsujimura et al. 2015), while miR-199b has been associated 
with attenuation of acute spinal cord injury (Zhou et al. 2016).  
Expression of microRNAs may often be tissue specific with some microRNAs 
being more abundantly expressed in certain tissues and under certain conditions. 
Examples of such microRNAs are miR-128 and miR-133a, which are highly 
expressed in skeletal muscle.  
MicroRNA-128 is expressed at high levels in the central nervous system, 
specifically the brain, and in skeletal muscles (Lee et al. 2008). Increased levels of 
miR-128 have also been reported during development (Franzoni et al. 2015). 
Studies have shown that miR-128 is an important regulator of neurogenesis and 
140 
 
neuronal differentiation (Zhang et al. 2016; reviewed in Li et al. 2013). Expression 
levels of miR-128 increase gradually in mice during postnatal development and 
peak during adulthood (Tan et al. 2013). The role of miR-128 appears to be more 
versatile, as it is has also been described as a tumour suppressor. A study from 
Papagiannakopoulos et al. has demonstrated the tumour suppressive role of 
miR-128 by direct targeting of EGFR and PDGFRa, both interacting with RTKs 
(Papagiannakopoulos et al. 2012). Another study has identified Irs1, Insr, and 
Pi3k1r, components of Insulin signalling/Akt pathway as direct target genes of 
miR-128 (Motohashi et al. 2013). These findings are in agreement with studies 
showing pathways in cancer, neurotrophin signalling, MAPK and insulin signalling 
pathway as highly enriched pathways with miR-128 target genes (Motohashi et 
al. 2013; Ching and Ahmed-Annuar, 2015).  
Unlike miR-128, microRNA-133 belongs to a conserved family of microRNAs 
known as “myomiRs” and it is specifically and highly expressed in skeletal and 
cardiac muscle (Chen et al. 2006). Expression of miR-133 is closely regulated by 
myogenic factors MyoD and SRF, which subsequently regulates skeletal muscle 
cell proliferation and differentiation (Chen et al. 2006; Rao et al. 2006). 
Regulation of myoblast proliferation and differentiation by miR-133 has been 
observed via ERK1/2 signalling pathway (Feng et al. 2013). Moreover, a study 
from Deng et al. revealed an upregulation in the expression of miR-133a, a 
member of miR-133 family, in skeletal muscle of mdx mice at one month of age 
(Deng et al. 2011). This study also reported that both skeletal and cardiac muscle 
development in mdx mice overexpressing miR-133a was not compromised (Deng 
et al. 2011). Although, miR-133 and specifically miR-133a has been studied 
extensively on muscle in vitro and in vivo, there is not much evidence of its 
involvement in motoneuron cell survival and function. Hoye et al. have identified 
enrichment of miR-133a in motoneurons of mice, similar to that of miR-218, 
known as “motomiR” (Hoye et al. 2017). Moreover, their data supports that miR-
133a may play a functional role in the regulation of postnatal motoneuron fate 
(Hoye et al. 2017).  
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The aim of this chapter was to assess the expression levels of candidate 
microRNAs in skeletal muscle and peripheral nerve of 12-week old mice that 
have been subjected to either a normal or a protein-deficient diet pre- or 
postnatally for functional studies. Data collected from this chapter was used for 
microRNA gain- or loss-of-function experiments and identification of potential 
target genes in muscle and nerve in vitro (Chapters 5-7). 
 
 
4.2 Materials and methods 
4.2.1 cDNA synthesis and qPCR for microRNAs 
Protocols for cDNA synthesis and qPCR for microRNAs have been described in 
detail in Chapter 2. Briefly, for first strand cDNA synthesis, 100 ng of RNA isolated 
from TA and SN tissues was used. RNA template, RNase-free H2O and cDNA 
reaction mix containing RT enzyme were added to a final volume of 20 μL, as 
shown in Chapter 2, Section 2.13 (Table 2.13). cDNA synthesis protocol for 
microRNAs is described in Chapter 2, Section 2.13 (Figure 2.13.1). Following 
cDNA synthesis, reaction volume was diluted 1:10 to a final volume of 200 μL and 
was either used immediately for qPCR or stored at -20oC until future use. For 
qPCR on microRNAs, each cDNA sample was run in triplicate, with a final reaction 
volume of 11.4 μL. Reagents for each qPCR reaction sample are shown in Chapter 
2, Section 2.15 (Table 2.15.1). Protocol for qPCR run on microRNAs is described 
in Chapter 2, Section 2.15 (Table 2.15.2). Quantification of microRNA expression 
was performed using the delta delta Ct (ddCt) method (Livak and Scmittgen, 
2001). Relative expression of microRNAs was normalised to SNORD-61 or RNU-6 






Table 4.2.1 Primer IDs used in qPCR for each microRNA tested in TA and SN of 










4.2.2 Identification of miR-128 and miR-133a predicted target genes and 
investigation of their role in metabolic processes  
Predicted target genes of miR-128 and miR-133a were investigated using 
TargetScanMouse 7.1 (http://www.targetscan.org/mmu_71/). Both miR-128 and 
miR-133a are within the conserved families of microRNAs among different 
organisms, with identical mature sequences. The list of predicted target genes 
was obtained for each microRNA, and a number of predicted target genes of 
interest associated with skeletal muscle physiology and NMJ formation, 
morphology and function was selected. The selected predicted target genes 
were imported into STRING database (Version 10.5; https://string-db.org/). Each 
gene was illustrated as a node connected with one or more neighbouring nodes. 
Disconnected nodes were excluded from the network. Interactions between the 
nodes were assessed based on degree of confidence (low=0.150, medium=0.400, 
high=0.700, highest=0.900). Network was illustrated using CytoScape Software, 
based on the information obtained from STRING Database. To evaluate the role 
of each gene in specific biochemical processes, Kyoto Encyclopaedia of Genes 
and Genomes (KEGG) Pathway database was used 
(https://www.genome.jp/kegg/). KEGG Reference number (KO number) for each 
protein encoded by each predicted target gene of interest was obtained and 
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imported into KEGG Mapper. Signalling pathways containing all or a number of 
those target genes were shown. Following selection of signalling pathway of 
interest, proteins encoded from predicted target genes were coloured in cyan 
(miR-128) or orange (miR-133a), depending on the microRNA by which they were 
targeted.  
 
4.2.3 Statistical analysis 
Statistical analysis of qPCR results was performed using Graphpad 5 
(Graphpad Software, San Diego, USA). Data analysis was performed using One-
Way ANOVA with Dunnett’s post-hoc analysis, using NNN as the control group. 




4.3.1 Expression levels of candidate microRNAs in TA muscle and sciatic nerve 
of 12-week old mice on a low-protein diet in pre-or postnatal stages of 
development 
Analysis of the expression levels of candidate microRNAs is shown in Figures 
4.3.1. and 4.3.2. Expression of miR-199a, -199b, -181a, -181d and -378 appeared 
upregulated in the TA muscle of NLL mice compared to the rest of the groups, 
but the P value was 0.2242, 0.1234, 0.0667, 0.0831 and 0.0658 respectively  
(Figure 4.3.1). Analysis of the expression levels of miR-128 in TA muscle revealed 
a significant reduction of miR-128 levels in both NLL and LNN mice (Figure 4.3.2 
A). Interestingly, miR-133a levels were significantly lower only in the TA muscle 
of NLL mice, with the LNN mice recording a P value of 0.051 (Figure 4.3.2 B). 
Despite the significant differences recorded in the TA muscle, miR-128 and -133a 
levels in the SN showed no differences between the three experimental groups 
(Figure 4.3.2 C, D). Based on this data, miR-128 and miR-133a were selected for 




Figure 4.3.1 Expression levels of candidate microRNAs in TA muscle of 12-week 
old mice subjected to a normal or a low-protein diet pre- or postnatally. 
Quantitative PCR analysis of microRNA A) miR-199b, B) miR-199a, C) miR-181a, 


























































































































as control group for statistical comparison, (mean ± SEM; n=3-7, One-Way 
ANOVA with Dunett’s post-hoc analysis).  
 
 
Figure 4.3.2 Expression levels of microRNAs miR-128 and miR-133a in (A, B) TA 
and (C, D) SN of 12-week old mice subjected to a normal or a low-protein diet 
pre- or postnatally. Expression relative to SNORD-61 is shown. *represent 
significant differences compared with the NNN (control) group, (mean ± SEM; 





































































































4.3.2 Identification of predicted target genes of miR-128 and miR-133a using 
TargetScanMouse 7.1 database 
The predicted target genes of miR-128 and miR-133a were investigated using 
TargetScanMouse 7.1 database. From the pool of the predicted target genes 
(>1000) for miR-128 recorded from TargetScan, only a 19 of those genes were 
selected to be further investigated (Table 4.1.2.1). Similarly, 16 selected 
predicted target genes for miR-133a are shown in Table 4.1.2.2, as selected from 
a pool of target genes (>600) recorded using TargetScan. These genes are 
involved in key pathways regulating NMJ integrity and signalling as well as 
muscle mass and function. Seed sequence of the miR-128 in the 3’UTR of the 
predicted target gene was the following: 5’–CACUGUGA–3’. Seed sequence for 
miR-133a in the 3’UTR of the predicted target gene was the following: 5’–
GGACCAAA–3’. Each candidate predicted target genes had at least one 
conserved seed region on the 3’UTR, with some target genes having seed 
regions, which were poorly conserved across the species. A number of predicted 
target genes (shown in red) may be targeted by both miR-128 and miR-133a on 





Table 4.3.2.1 List of the selected miR-128 predicted target genes as recorded using TargetScanMouse 7.1. Ensembl ID and seed region in 3’UTR 
are shown. Genes marked in red may also be targeted by miR-133a.  
miR-128 predicted target genes (TargetScan)         
      Seed region (in the 3'-UTR) 
Name Gene Ensembl ID Conserved Poorly conserved  
nerve growth factor receptor (TNFR superfamily, member 16) Ngfr ENSMUST00000000122.6 272-279 N/A  
nerve growth factor receptor (TNFRSF16) associated protein 1 Ngfrap1 ENSMUST00000178632.2 28-34 N/A  
growth factor receptor bound protein 2 Grb2 ENSMUST00000106497.2 1695-1701 N/A  
platelet derived growth factor receptor, alpha polypeptide Pdgfra ENSMUST00000000476.9 2852-2858 2398-2404 
son of sevenless homolog 1 (Drosophila) Sos1 ENSMUST00000068714.5 3529-3535 446-452, 1727-1433, 1477-1483 
growth factor receptor bound protein 2-associated protein 1 Gab1 ENSMUST00000034150.8 1198-1204 N/A  
insulin receptor Insr ENSMUST00000091291.4 207-213 3851-2858 
insulin receptor substrate 1 Irs1 ENSMUST00000069799.2 230-237 N/A  
F-box protein 32 (atrogin-1) Fbxo32 ENSMUST00000022986.6 4341-4347 N/A  
forkhead box O1 Foxo1 ENSMUST00000053764.5 415-421 N/A  
forkhead box O4 Foxo4 ENSMUST00000062000.4 228-234 N/A  
sirtuin 1 Sirt1 ENSMUST00000120239.2 744-750 N/A  
neural cell adhesion molecule 1 Ncam1 ENSMUST00000114476.2 1028-1035 586-592, 612-627, 2169-2175 
neurocan Ncan ENSMUST00000002412.8 3181-3187 865-871 
synaptosomal-associated protein 25 Snap25 ENSMUST00000028727.5 407-713, 1159-1165 N/A  
synaptotagmin I Syt1 ENSMUST00000105276.2 1460-1467, 1692-1698 N/A  
nuclear respiratory factor 1 Nrf1 ENSMUST00000115212.2 N/A 1232-1239, 1603-1609 
nuclear factor, erythroid derived 2, like 2 (Nrf-2) Nfe2l2 ENSMUST00000102672.4 60-66 N/A  
parkin RBR E3 ubiquitin protein ligase Park2 ENSMUST00000191124.1 N/A 715-722 
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Table 4.3.2.2 List of the selected miR-133a predicted target genes as recorded using TargetScanMouse 7.1. Ensembl ID and seed region in 
3’UTR are shown. Genes marked in red may also be targeted by miR-128. 
miR-133a predicted target genes (TargetScan)         
      Seed region (in the 3'-UTR) 
Name Gene Ensembl ID Conserved Poorly conserved  
clathrin, light polypeptide (Lca)  Clta ENSMUST00000107846.4 94-101 N/A 
synaptotagmin I  Syt1 ENSMUST00000105276.2 1606-1612, 2246-2252 N/A 
vesicle-associated membrane protein 2  Vamp2 ENSMUST00000117780.1 1378-1384 N/A 
regulating synaptic membrane exocytosis 1  Rims1 ENSMUST00000115273.3 1777-1784 N/A 
unc-13 homolog A (C. elegans)  Unc13a ENSMUST00000030170.9 2204-2211 N/A 
adaptor-related protein complex 2, mu 1 subunit  Ap2m1 ENSMUST00000007216.8 254-260 N/A 
complexin 2  Cplx2 ENSMUST00000026985.8 4109-4115 N/A 
Braf transforming gene  Braf ENSMUST00000002487.9 5803-5810 N/A 
insulin receptor  Insr ENSMUST00000091291.4 1063-1069 N/A 
fibroblast growth factor 1  Fgf1 ENSMUST00000117566.2 353-360 N/A 
paired box 7  Pax7 ENSMUST00000030508.8 2128-2134, 3326-3332 1970-1976 
GRP1 -associated scaffold protein  Grasp ENSMUST00000000543.4 275-282 N/A 
myosin IXb  Myo9b ENSMUST00000168839.2 569-576 235-241 
myosin, heavy polypeptide 1, skeletal muscle, adult (MHC II d/x) Myh1 ENSMUST00000124516.2 22-28 N/A 
translocase of outer mitochondrial membrane 20 Tomm20 ENSMUSG00000093904 N/A 3889-3896 
nuclear respiratory factor 1 Nrf1 ENSMUST00000115212.2 457-463 N/A 
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4.3.3 Protein interactions of predicted target genes of miR-128 and miR-133a 
using STRING Database 
 
The interactions between the predicted target genes of miR-128 and miR-
133a were examined on a protein level, in order to determine whether they are 
involved in biological processes associated with skeletal muscle and NMJ 
formation and function. Interactions were investigated using STRING database 
(Version 10.5) and were illustrated using CytoScape software. Interactions of 
predicted target genes of miR-128 shown in Figure 4.3.3.1 are depicted 
according to the level of confidence, with the weakest interactions marked with 
green lines and the strongest with red. Same pattern of interaction is also shown 
for miR-133a predicted target genes (Figure 4.3.3.2). Examination of the 
interactions between the predicted target genes of both microRNAs indicated 
strongest relationship between a cluster of target genes, which could potentially 
be involved in the same metabolic process. For miR-128, the predicted target 
genes with strongest interactions are: Syt1, Grb2, Gab1, Sos1, Ngfr, Ngfrap1, 
Pdgfra, Isr1, Insr, Foxo1, Foxo4, Sirt1 and Atrogin1 (Figure 4.3.3.1). For miR-133a, 
strongest interactions were observed between the following target genes: Clta, 
Ap2m1, Vamp, Syt1, Cplx2, Rims1 and Unc13a (Figure 4.3.3.2).  
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Figure 4.3.3.1 Interactions of predicted target genes of miR-128 using CytoScape 
software. Green lines indicate the weakest interactions (confidence level <150) 
and red lines indicate the strongest interactions (confidence level ≥ 0.900). 
Interactions were drawn based on the combined scored of interactions recorded 
on STRING database. 
 
Figure 4.3.3.2 Interactions of predicted target genes of miR-133a using 
CytoScape software. Green lines indicate the weakest interactions (confidence 
level <150) and red lines indicate the strongest interactions (confidence level ≥ 
0.900). Interactions were drawn based on the combined scored of interactions 






4.3.4 Investigation of predicted target gene involvement in signalling 
pathways using KEGG PATHWAY Database 
 
Involvement of predicted target genes of miR-128 and miR-133a in key 
signalling pathways was investigated using KEGG PATHWAY Database. Target 
genes from both microRNAs appear to be involved in 4 signalling pathways: 
synaptic vesicles cycle, neurotrophin, FOXO and longevity signalling pathway 
(Figure 4.3.4 A-D). Predicted target genes of miR-128 are shown in cyan colour 
and those of miR-133a are shown in orange. Additional predicted target genes to 
those described in Section 4.3.3 are also involved in each of those signalling 
pathways. One such example is the Cacna1a gene, encoding VGCC protein in the 
synaptic vesicle cycle, which is a predicted target gene of miR-128 (Figure 4.3.4 
A). Exclusion of multiple predicted target genes from the analysis performed 
previously was decided, taking into consideration factors including, but not 
limited, to strength of interactions with other predicted target genes, relevance 
to skeletal muscle and/or NMJ physiology and function and novelty of the 
predicted target (not previously published as a direct target of the miR). 
It is noteworthy that miR-133a target genes are mostly involved in the 
synaptic vesicle cycle, while a group of miR-128 predicted target genes (Grb2, 
Gab1, Sos1, Insr, Irs1) appear in more than one signalling pathway (Figure 4.3.4 
B-D). Furthermore, FoxO signalling and longevity regulating pathway are also 


































Figure 4.3.4 Involvement of predicted target genes of miR-128 and miR-133a in signalling pathways. A) Synaptic vesicle cycle, B) Neurotrophin 
signalling pathway, C) FoxO signalling pathway and D) Longevity regulating pathway. Predicted target genes shown on a protein level are 
highlighted as cyan (miR-128) or orange (miR-133a) depending on the microRNA by which they are targeted. Signalling pathways adapted from 







The aim of this Chapter was to examine the expression levels of candidate 
microRNAs in skeletal muscle and peripheral nerve of 12-week old mice 
subjected to a normal or a low-protein diet at pre- or postnatal stages of 
development, for functional studies. Identification of candidate microRNAs with 
altered expression patterns in muscle and/or nerve may be responsible for 
changes of signalling molecules on an mRNA level. As such, genes targeted by 
microRNAs with dysregulated expression pattern, are predicted to have a 
downstream implication on the regulation of signalling pathways they are 
involved.  Quantitative qPCR analysis from RNA isolated from muscle and nerve 
of 12 weeks old mice showed differences in the expression of miR-128 and miR-
133a. Investigation of predicted target genes for both microRNAs indicated 
interaction between a group of genes involved in key signalling pathways, which 
control muscle:nerve cross-talk, muscle physiology and function and lifespan.  
  
4.4.1 Expression of candidate microRNAs in muscle and nerve of 12-week old 
mice on a normal or protein-deficient diet pre- or postnatally 
Quantitative PCR analysis of candidate microRNAs in TA muscle revealed no 
changes in the expression level of miR-199a, -199b, -181a, -181d and -378 in NLL 
mice. In contrary, expression analysis of miR-128 showed significant 
downregulation in the expression levels in TA muscle of both NLL and LNN mice, 
but no changes in miR-128 expression were observed in SN. Similarly, miR-133a 
was significantly downregulated in TA muscle of NLL mice, but not LNN mice 
where P value = 0.051. As seen with miR-128, expression of miR-133a in SN was 
not significantly different between the three experimental groups.  
Data obtain from qPCR analysis suggest that a protein deficient diet at pre- or 
postnatal stages of development may have the potential to alter molecular 
mechanisms, such as microRNA expression. Specifically, altered microRNA 
expression appears to be tissue-specific, as both miR-128 and miR-133a show 
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significant differences in the expression levels in TA muscle but not in SN, which 
could indicate muscle-specific changes important for NMJ alterations or other 
mechanisms. 
It is not surprising that miR-133a expression is affected in muscle but not in 
peripheral nerve, as miR-133 family is widely known as “myomiRs” due to high 
expression levels in skeletal muscle (reviewed in Horak et al. 2016). Involvement 
of miR-133 isoforms has been widely investigated in muscle in vivo (Chen et al. 
2006; Deng et al. 2011; Zhang et al. 2014) and in vitro (Zhang et al. 2012; Feng et 
al. 2013). Studies have also examined the role of this microRNA in NMJ integrity 
during ageing (Valdez et al. 2014). Although there is some evidence of miR-133b 
involvement in functional recovery and regeneration of axons following 
peripheral nerve or spinal cord injury (Wu et al. 2011; Yu et al. 2011), the role of 
miR-133a in peripheral nerve has not been extensively investigated.  Moreover, 
recent studies have shown increased expression of miR-133a in mouse spinal 
cord (Bak et al. 2008).  
In contrast with miR-133a, miR-128 is mostly abundant in the CNS in mice (He 
at al. 2012). Higher expression of miR-128 has been recorded during 
development (Franzoni et al. 2015) and in cancer (reviewed in Li et al. 2013; Yu 
et al. 2017). Although a brain-enriched microRNA, miR-128 expression levels in 
skeletal muscle are the highest following those observed in CNS (Motohashi et al. 
2013; Lek Tan et al. 2013). Recent studies carried out in vitro have highlighted 
the role of miR-128 in key signalling processes regulating skeletal muscle 
physiology in primary mouse myoblasts (Motohashi et al. 2013) and C2C12 
myoblasts (Shi et al. 2015). In combination with our qPCR data from TA muscle of 
NLL and LNN mice showing downregulation of miR-128 expression levels, miR-






4.4.2 Investigation of miR-128 and miR-133a predicted target genes and their 
interactions using TargetScanMouse 7.1 and STRING database 
Detailed information on miR-128 and miR-133a was obtained from miRBase. 
Mature microRNAs were identified as mmu-miR-128-3p and mmu-miR-133-3p 
accordingly. These two mature miRs were used in TargetScanMouse database to 
identify the list of predicted target genes. In total, 1097 predicted target genes 
carrying conserved sites for miR-128 binding were identified while 616 predicted 
target genes carrying conserved sited for miR-133 were identified. For miR-128, 
19 predicted target genes were selected, of which 2 genes (Nrf1, Park2) were 
carrying only poorly conserved sites for miR-128 binding (Table 4.1.2.1). The rest 
17 genes were carrying either only a conserved site or both conserved and 
poorly conserved sites. Similarly, for miR-133, 16 predicted target genes were of 
interest and only 1 of those (Tomm20) was carrying only a poorly conserved site 
for miR-133 binding (Table 4.1.2.2), while the rest were carrying a conserved 
only or both conserved and a poorly conserved site. Interestingly, miR-128 and 
miR-133 share 13 of the predicted target genes of interest, with each miR 
targeting either conserved or poorly conserved sites on the same gene transcript 
(Appendix, Table A1 and A2).   
For miR-128, from the 19 predicted target genes only 17 are shown in the 
network as 2 genes (Ncam1 and Ncan) showed no interactions with the rest of 
the gene transcripts. Strongest interactions were recorded between the 
following transcripts: Syt1, Grb2, Gab1, Sos1, Ngfr, Ngfrap1, Pdgfra, Isr1, Insr, 
Foxo1, Foxo4, Sirt1 and Atrogin1. Gene transcripts Irs1 and Insr have been 
established as direct targets of miR-128, resulting in alterations in Irs1/Akt insulin 
signalling during myogenesis (Motohashi et al. 2013). Gene transcript Grb2 has 
been implicated in NMJ homeostasis (Gingras et al. 2016) while Sos1 and Pdgfra 
mutations have been associated with severe embryonic phenotype and skeletal 
defects (Wang et al. 1996; Fantaouzzo and Soriano, 2014). Previous studies have 
shown that Ngfr (also known as p75NTR) and Ngfrap1 (also known as NADE or 
Bex3) are able to induce neurotrophin-mediated apoptosis of neuronal cells even 
during normal development in mice (Mukai et al. 2002). However, it has been 
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suggested that Ngfr may have a more diverse role depending on the interactions 
with other neurotrophin receptors (reviewed in Chen et al. 2009). Atrogin-1 gene 
transcript (also known as Fbxo31) has been a well-established gene associated 
with muscle atrophy (Botine et al. 2001; Gomes et al. 2001; reviewed in Yang et 
al. 2015) and upregulation of this gene has been reported in the cartilage and 
chondrocytes of osteoarthritic mice (Kim et al. 2017). Transcription of Atrogin-1 
is closely dependent on activation of FoxO activation (Botine et al. 2001; Gomes 
et al. 2001). In contrary, Sirt-1 is capable of blocking FoxO activity leading to 
inhibition of muscle atrophy (Lee and Goldberg, 2013).  
Network analysis for miR-133 predicted target genes revealed strongest 
interactions between the following genes: Clta, Ap2m1, Vamp2, Syt1, Cplx2, 
Rims1 and Unc13a. Clta gene transcript encodes protein clathrin and along with 
AP2 (adaptor protein 2, encoded by Ap2m1) it forms a protein complex coating 
the outer surface of the vesicles during clathrin-mediated endocytosis (reviewed 
in Owen et al. 2004).  Syt1 gene transcript, predicted target of both miR-128 and 
miR133, encodes synaptotagmin 1 (SYT-1) protein, involved in calcium-
dependent neurotransmitter release and synaptic vesicle endocytosis (Poskanzer 
et al. 2003; Yao et al. 2011). Interestingly, Syt-1 is highly expressed in the brain 
during development and mutations in Syt-1 gene have been associated with 
neurodevelopmental disorders in humans (Baker et al. 2018). Another 
component of Ca2+-dependent exocytosis, complexin 2 protein (encoded by Cplx-
2 gene) is essential for normal neurological function. Mice lacking of complexin 2 
develop cognitive abnormalities and motor deficits (Glynn et al. 2003). Vamp-2 
gene (also known as Syb2) is a component of the protein complex SNARE, 
required for efficient neurotransmission via synaptic vesicles (Liu et al. 2015). 
Studies in mice have shown that even moderate alteration on Vamp2 expression 
could impair neurotransmission (Koo et al. 2015). Moreover, Vamp2 homozygous 
knock-out mice did not survive following birth and they exhibited profound 
changes in their body shape but no developmental abnormalities (Schoch et al. 
2001). Release of neurotransmitters through exocytosis also requires the 
proteins Rims1 and Unc13a (Kaeser et al. 2012). Knock-out mice for Rim1α 
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isoform manifested dysregulated presynaptic plasticity while depletion of both 
Rim1α and Rim1β isoform in mice resulted in increased lethality in early 
postnatal life (Kaesar et al. 2008). Similarly, deficiency of Unc13 in mice results in 
immediate paralysis and death at birth. Despite the severe phenotype the NMJ 
site of these mice display no apparent morphological alterations, however the 
number of the sites and the motoneurons they originate from are substantially 
altered (Varoqueaux et al. 2005).  
Evidence from previous studies suggest that a number of the predicted target 
genes of interest showing strong interactions may have an impact on metabolic 
mechanisms and neuromuscular communication. This was further investigated 
by exploring the metabolic processes those genes are involved at.  
 
4.4.3 Signalling pathway analysis of miR-128 and miR-133 predicted target 
genes using KEGG PATHAWAY Database 
In order to elucidate the impact of altered expression of miR-128 and miR-
133a, metabolic pathway analysis was performed using KEGG Pathway Database. 
Assessment of metabolic pathways was used for the prediction of potential 
dysregulation of key mechanisms due to imbalances on specific protein 
molecules, caused by altered levels of their gene transcript in a tissue.  
A number of predicted target genes of miR-128 and miR-133 showed strong 
interactions, as seen in Figures 4.3.3.1 and 4.3.3.2. When those predicted target 
genes were further investigated using KEGG Pathway database, most of them 
appeared to participate in the same metabolic pathway. Some of those genes 
were also seen in more than one metabolic pathway. Specifically, for miR-133, all 
the predicted target genes with strong interactions are involved in the synaptic 
vesicle cycle, shown in Figure 4.3.4 A. Furthermore, 2 more predicted target 
genes from miR-128 are also seen in the synaptic vesicle cycle, Snap25 and 
Cacna1a (also known as VGCC). It is noteworthy that Syt1 is a predicted target 
gene with preferential conserved binding sites for both miR-128 and miR-133a as 
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seen in TargetScanMouse database. These data suggest that downregulation of 
the predicted target genes, due to overexpression of miR-133, may impede 
endocytosis of the vesicles or inhibit the formation of the SNARE complex and 
therefore the fusion of the vesicles and release of neurotransmitters (reviewed in 
Jan and Fasshauer, 2012). Downregulation of the proteins in SNARE complex may 
lead to neurodegeneration similar to that seen during ALS while deletion of these 
proteins (Liu et al. 2015). In contrast, downregulation of miR133 could potentially 
result in overexpression of these proteins. One example from published data is 
the overexpression of Munc-18 protein, part of SNARE complex, which has been 
linked to schizophrenia-related behaviour in mice (Urigüen et al. 2013). Although 
several studies have demonstrated the adverse effects of SNARE proteins 
downregulation in mice, there is not much evidence for overexpression of those 
proteins. Therefore, the implications of a potential upregulation in the gene 
transcript in the case of downregulation of specific microRNAs can only be 
speculated.    
Contrary to miR-133, miR-128 predicted target genes with the strongest 
interactions in the network are seen in several different metabolic pathways. 
Previous studies have shown the association of predicted target genes of miR-
128 with pathways in cancer, MAPK pathway and neurotrophin pathway among 
others (Ching and Ahmad-Annuar, 2015). In line with these data, KEGG analysis 
shows that a number of the target genes of interest were involved in the 
neurotrophin signalling pathway (Figure 4.3.4 B). A study from Motohashi et al. 
has identified Irs1, Insr, and Pi3kr1 (subunit of PI3K) gene transcripts as direct 
targets of miR-128 (Motohashi et al. 2013). Among the predicted target genes 
seen in the neurotrophin pathway is also Pdpk1 gene encoding PDK, a master 
kinase responsible for the phosphorylation and therefore activation of AKT. 
Although complete lack of PDK in mice results in lethality at embryonic stages, 
lower protein levels have been linked to smaller body size during development 
(Lawlor et al. 2002). Of particular interests were the predicted target genes Ngfr 
(encoding p75NTR), Ngfrap1 (encoding NADE), Grb-2, Gab-1 and Sos-1. NGFR, 
predicted target of miR-128 and miR-133, is a lower affinity receptor for binding 
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of certain neurotrophins and pre-neurotrphins, including NGF and BDNF 
(reviewed in Chen et al. 2009). NGFR expression differs between organisms and 
increased expression levels have been noted during development or in 
pathological conditions associated with neural cell death (reviewed in Chao, 
2003). Increased levels of expression during development have been associated 
with regulation of neuronal innervation of target cells and subsequent 
elimination of neuronal cells that failed to innervate their target (reviewed in 
Majdan and Miller, 1999). The role of NGFR during development in conjunction 
with our data of miR-128 downregulation and NMJ morphology observed in 
Chapter 3 could agree with the hypothesis that NLL mice may exhibit a 
developmentally delayed NMJ phenotype. NGFR has been previously described 
to induce cell apoptosis via activation of NADE protein (encoded by Ngfrap1) 
following binding of NGF to the NGFR-NADE complex (Mukai et al. 2002). While 
Ngfr and Ngfrap1 encode proteins involved in cell death, the role of Grb-2, Gab-1 
and Sos-1 appear to be different. Gab-1 protein expression in both skeletal 
muscle and Schwann cells in peripheral nerves has been associated with 
postnatal NMJ maturation (Young Park et al. 2017). Moreover, Grb-2 and Sos-1, 
involved in Ras signalling, mediate cell survival, proliferation and differentiation 
(Mazzon et al. 2018). Specifically, recent studies show enrichment of Grb-2 at the 
post-synaptic site of the NMJ, and the importance of Grb-2 in the formation of 
AChR clusters (Gingras et al. 2016). Collectively, miR-128 predicted target genes 
within the neurotrophin signalling pathway are involved in cell apoptosis or cell 
survival. In the event of upregulation of those gene transcripts due to 
downregulation of miR-128, we speculate that the balance between 
neurotrophin-mediated cell survival/apoptosis could shift, but towards which 
direction requires further investigation.   
Predicted targets Grb-2, SOS-1, Insr, Irs-1, Pdpk1 and Pi3k isoforms (Pik3r1, 
Pik3ca) are also involved in FOXO signalling pathway, along with some miR-133 
target genes (Figure 4.3.4 C). Central protein molecules of FOXO signalling 
pathway, FOXO-1, FOXO-4 and Sirt-1 are also predicted target genes of miR-128. 
Interestingly, Sirt-1 gene transcript is targeted by both miR-128 and miR-133a, 
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and carries a conserved seed sequence for preferential binding of miR-133 (as 
seen in TargetScanMouse). A study from Lee and Goldberg (2013) shows that 
Sirt-1 levels fall dramatically following food deprivation only in Type II-rich 
skeletal muscles such as TA and EDL, contributing to increased muscle atrophy. 
Sirt-1 can promote deacetylation of FOXO proteins and therefore trigger muscle 
wasting, but overexpression of Sirt-1 has been reported to inhibit FOXO activity 
and protect the muscle from atrophy. This dual role of Sirt-1 makes it a crucial 
regulator of skeletal muscle atrophy (Lee and Goldberg, 2013). On the other 
hand, Atrogin-1 gene transcript itself is amongst the predicted target genes of 
miR-128. Gomez et al. have previously reported a dramatic upregulation of 
Atrogin-1 mRNA levels in GTN muscle following fasting, when compared to 
mRNA levels of other tissues such as brain and liver (Gomez et al. 2001). 
Although the selected miR-128 predicted targets appear to be most prevalent in 
FOXO signalling pathway, a few predicted target genes of miR-133 are also 
found. FoxG1 gene transcript, encoding FOXG1 protein, is one of the predicted 
target genes of miR-133, carrying a binding site for preferential binding of miR-
133 (as seen in TargetScanMouse). This protein appears to act independently of 
the rest of FOXO components, as seen in Figure 4.3.4 C. FoxG1 acts as a 
transcription factor crucial to the regional subdivision of the developing brain 
(Boggio et al. 2016). Although complete depletion of FoxG1 is lethal, mutations 
have been associated with neurodevelopmental disorders (Boggio et al. 2016), 
while overexpression of FOXG1 has been linked to autism (Mariani et al. 2015). 
Apart from its localization to the nucleus, FOXG1 can also translocate to the 
mitochondria, controlling energy biogenesis and other mitochondrial functions 
(Pancrazi et al. 2015).  
Gene transcripts Insr, Irs-1, Pi3k isoforms (Pik3r1, Pik3ca), FoxO-1, FoxO-4 and 
Sirt-1 appear also appear in Longevity regulation pathway. This is of no surprise 
considering that major metabolic pathways are involved in the regulation of 
longevity, including but not limited to insulin pathway, PI3K/AKT, FOXO, mTOR, 
AMPK and p53 signalling pathways (Figure 4.3.4 D). Gene transcripts not seen in 
the rest of the pathways are Ulk1, Rps6kb (encoding S6K) and Ppargc1a 
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(encoding PGC-1a). PGC-1a is a transcription factor which may act either 
antagonistically or in cooperation with FOXO molecules, depending on the tissue 
and the function it is involved (Lee and Goldberg, 2013). PGC-1a expression 
appears to be partly regulated by Sirt-1, acting as an inhibitor of muscle atrophy 
by inhibition of FOXO activity (Sandri et al. 2006). Studies have reported 
involvement of PGC-1a in mitochondria biogenesis and function (reviewed in 
Fernandez-Marcos and Auwerx, 2011), fatty acid oxidation (Vega et al. 2000) and 
the formation of type-I (or slow-twitch) muscle fibres in skeletal muscle (Lin et al. 
2002).  Thus, PGC-1a has been reported as anti-ageing factor, promoting 
longevity (Reviewed in Satoh and Imai, 2004). ULK1 protein in its phosphorylated 
form is involved in the regulation of autophagy in response to starvation (Lee and 
Tournier, 2011). ULK1 is regulated either by mTOR or by AMPK, depending on the 
nutrient availability (Kim et al. 2011). ULK1 interacts directly with mTOR during in 
conditions of high-nutrient availability (Hosokawa et al. 2009). However, during 
starvation, Ulk1 is activated via phosphorylation by AMPK, activating autophagy 
process (Kim et al. 2011). Activation of autophagy via AMPK-mediated 
phosphorylation and activation of ULK1 is necessary for stem-cell renewal and 
pluripotency and any disruption to this process may compromise the role of ES 
cells (Gong et al. 2018). Disruption of ULK1 phosphorylation via AMPK during 
starvation conditions may also impair mitochondrial biogenesis and cell survival, 
thus affecting energy biogenesis (Egan et al. 2011). Due to its nutrient-dependent 
activation, autophagy may be a potential target mechanism in our study, being 
differentially regulated in mice on a protein-deficient diet at different stages of 
development. S6K, which is involved in the regulation of protein synthesis, is a 
kinase also dependent on phosphorylation for its activation, mainly via mTOR 
(Zhang et al. 2014). Studies have shown the role of S6K in the regulation of 
protein synthesis and force generation in skeletal muscles, without causing an 
increase in skeletal muscle mass (Marabita et al. 2016). Interestingly, mice 
lacking of S6K have lower body weight and smaller size (Shima et al. 2016). 
Moreover, whole body S6K1-/- mice demonstrated increased lifespan, with 
female mice also showing an increase in the maximum lifespan greater than the 
male mice (Selman et al. 2009).   
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Overexpression of several proteins involved in the longevity pathway appears 
to have a beneficial effect on mouse lifespan and act as anti-ageing mechanisms. 
An example of such proteins is IRS-1, which was elevated in the skeletal muscle 
of mice following a low-protein diet postnatally, implying improved insulin 
sensitivity in those mice (Chen et al. 2009). Evidence gathered from previously 
published studies highlighting some protein molecules (e.g. S6K, ULK-1) which 
could potentially explain the phenotype observed in NLL mice and LNN mice. 
However, due to sample processing prior to use in experimental analysis it was 
not possible to investigate the levels of certain molecules any further. Whether 
alterations in the levels of these proteins and their gene transcripts may occur 
due to protein-deficient diet and/or dysregulation of miR-128 and miR-133 











Gain- and loss-of-function of miR-







MicroRNAs often show tissue-specific or tissue-enriched expression. In 
skeletal muscle tissue, two examples of such microRNAs are miR-128 and miR-
133a.  
In a study from Lee et al. microRNA-128 shows highest expression levels in 
skeletal muscle tissue (Lee et al. 2008). MicroRNA-128 has been described as a 
regulator of skeletal muscle development via targeting of myostatin in C2C12 
cells (Shi et al. 2015). Direct target genes of miR-128 also regulate myogenesis 
through insulin signalling/AKT pathway (Motohashi et al. 2013). Furthermore, 
miR-128 has been associated with the maintenance of quiescent state of muscle 
side population (SP) cells, a distinct type of muscle stem cells, as well as with the 
regulation of the differentiation of those cells in multiple cell types (Motohashi et 
al. 2012). Although some studies provide strong evidence of miR-128 
involvement in skeletal muscle development, the exact role of miR-128 in 
differentiated skeletal muscle cells has not been described.  
MicroRNA-133, also known as one of the “myomiRs” is specifically expressed 
in skeletal and cardiac muscle (Chen et al. 2006). Previous studies have 
demonstrated the regulation of skeletal muscle cell proliferation and 
differentiation by miR-133 either regulation of its expression levels from 
myogenic factors such as MyoD (Chen et al. 2006; Rao et al. 2006) or via 
regulation of Erk1/2 signalling pathway (Feng et al. 2013). In vivo studies have 
shown increased expression levels of miR-133 in the skeletal muscle of mdx 
mice; However, suppression of miR-133 function had no effect on skeletal 
muscle development and function (Deng et al. 2011). A study from Chen et al. 
2009 demonstrated the regulation of myogenic fate via direct targeting of UCP2 
by miR-133a, a member of the uncoupling proteins family involved in the 
inhibition of muscle differentiation and promotion of myoblast proliferation 
(Chen et al. 2009).  
Although many studies have investigated the role of miR-128 and miR-133a in 
skeletal muscle development, the implication of those two microRNAs in 
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terminal differentiation and maintenance of skeletal muscle cells has not been 
fully explored. Furthermore, investigation of the role of these two microRNAs in 
C2C12 myoblast and myotube cell behaviour could provide further 
understanding on the mechanisms involved in loss of myofibres and reduced 
muscle force in 12-week old mice on a low-protein diet pre- or postnatally. The 
aim of this chapter was to investigate the effect of gain- and loss-of-function of 
miR-128 and miR-133a in C2C12 cell proliferation, viability, mitotoxicity and 
differentiation. Results of these studies will provide an insight on the impact of 
imbalances in the expression levels of miR-128 and miR-133a in adult skeletal 




5.2.1 Culture and differentiation of C2C12 cells 
C2C12 cells were retrieved from LN2 and thawed in a 37oC water bath until 
there was no ice present in the vial. Cell suspension from the cryovial was mixed 
with 3 mL of pre-warmed growth media (Chapter 2, Section 2.16) and 
centrifuged immediately at 1,500 rpm for 5 min to discard freezing media 
containing DMSO. The supernatant was discarded and the cell pellet was 
resuspended in 10 mL of growth media (GMC2C12) and plated into a T75 flask 
(Corning). The cells were then incubated in a humidified incubator at 37oC with 
5% CO2 until they became confluent. When 70-80% confluency was reached, the 
cells were passaged 1:10 into fresh T75 flasks as described in Chapter 2, Section 
2.17.  
For C2C12 cell differentiation, cells were seeded into a 12-well plate at a 
confluency of 50,000 cells/well (13,158 cells/cm2), to be used for cell imaging 
following transfections (Chapter 2, Section 2.19).  The remaining cells were 
seeded into three 6-well plates, to be used for RNA and protein isolation 
following transfections with scrambled sequence, miR-128 mimic, AM-128, miR-
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133a mimic and AM-133a. Plates were incubated in GMC2C12 until fusion of 
myoblasts was evident and first signs of myotube formation were observed. Cells 
from all plates were then transfected according to the protocol in Chapter 2, 
Section 2.21. Following 48 h of transfections, C2C12 cells were harvested for RNA 
and protein isolation, as described in Chapter 2, Section 2.20. C2C12 myotubes at 
Day 7-11 of differentiation were stained for imaging and determination of their 
phenotype as described in Chapter 2, Section 2.22.  
 
5.2.2 Image analysis of C2C12 myotubes following transfections with miR-128 
and miR-133a 
Differentiated C2C12 cells were immunostained with MF20 antibody (myosin 
heavy chain II) and DAPI following transfections with either miR-128 or miR-133a 
as described in Chapter 2, Section 2.22. Cells were imaged using a Nikon Ti Live 
cell imaging microscope under x20 magnification. Myotube diameter, myotube 
area, nuclei per myotube and fusion index were analysed using ImageJ software 
(Chapter 2, Section 2.23).  
 
5.2.3 Assays for cell proliferation, viability and mitochondrial toxicity 
following transfections with miR-128 or miR-133a 
C2C12 cells were seeded on 96-well plates for use in proliferation, viability 
and mitotoxicity assays. For proliferation and viability, C2C12 cells were plated as 
described in Chapter 2, Section 2.27 (for proliferation assay) and Section 2.28 
(for cytotoxicity assay). Cells were allowed to incubate for 24h following plating 
before they were transfected with scrambled sequence, miR-128 mimic, AM-128 
or scrambled sequence (cholesterol conjugated), miR-133a mimic, AM-133a. 
Both proliferation and cytotoxicity assay were performed 48h following 
transfections. Experimental protocol and analysis of the data obtained from both 
assays were performed according to manufacturer’s instructions. Mitotoxicity 
assay was performed as described in Chapter 2, Section 2.19, following 
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transfection of C2C12 with scrambled, miR-128 mimic and AM-128. 
Interpretation of data was performed following the manufacturer’s instructions. 
Values recorded following measurement of fluorescence absorbance indicated 
the potential cytotoxic effect of miR-128 in C2C12 myoblasts, fluorescence 
measurement was followed by measurement of luminescence, which indicated 
the potential mitotoxic effect of miR-128 in C2C12 myoblasts. To determine 
whether miR-128 is a mitotoxic compound, fold-changes in mitotoxicity were 
assessed in comparison with the cytotoxicity values recorded. 
 
5.2.4 Statistical Analysis 
Statistical analysis was performed using Graphpad 5 (Graphpad Software, San 
Diego, USA). Analysis of the data was performed using One-Way ANOVA, with 
Dunnett’s post-hoc analysis, using scrambled-treated cells as the control group 
Distribution data were analysed using Chi-square (χ2) test. Data collected from 
mitotoxicity assay were analysed using Two-Way ANOVA, with Bonferroni post-
hoc analysis. Data from the cytotoxicity and mitotoxicity assays were presented 
as fold-changes compared to the control (scrambled-treated cells) group. Data 





5.3.1 The effect of miR-128 gain- and loss-of-function on C2C12 myotube 
phenotype 
C2C12 myotubes transfected with scrambled sequence (control), miR-128 
mimic (miR-128) and miR-128 inhibitor (AM-128) and stained with MF20 and 
DAPI are shown in Figure 5.3.1.1 A. C2C12 myotubes transfected with miR-128 
mimic (miR-128 overexpression) showed formation of a network of long and 
uniform myotubes, with nuclei fused within the myotubes seen spread across 
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the length of the cells. C2C12 myotubes transfected with AM-128 (miR-128 
inhibitor) appeared to be fewer in number and they displayed a circular-like 
morphology rather than an elongated morphology similar to that seen in miR-
128 transfected cells. Several occurrences of C2C12 with spherical appearance 
(arrows) rather than a long tube-like morphology were observed, which also 
appeared to have more nuclei/myotube. Analysis of C2C12 myotube diameter 
revealed no changes in myotube width following miR-128 overexpression or 
inhibition (Figure 5.3.1.1 B). Assessment of myotube area revealed a slight 
increase in the number of MF20-positive myotubes within each field of view, 
following overexpression of miR-128 (P=0.058; Figure 5.3.1.1 C).  Furthermore, 
C2C12 fusion index is higher following overexpression and inhibition of miR-128, 
when compared to the control (Scr) group (Figure 5.3.1.1 D). 
Distribution analyses of C2C12 myotube diameter and number of nuclei 
present per myotube are shown in Figure 5.3.1.2. Myotube diameter analysis 
indicated that the number of C2C12 myotubes transfected with miR-128 was 
higher in the diameter range of 20-40 μm, but no significant shift in the size 
distribution was recorded (Figure 5.3.1.2 A). Distribution analysis of the number 
of nuclei on myotubes of different diameter range revealed a proportional 
increase in the number of nuclei per myotubes with increase in of their diameter 







Figure 5.3.1.1 Gain- and loss-of-function of miR-128 in C2C12 myotubes. A) 
C2C12 myotubes transfected with Scr, miR-128 or AM-128 as indicated; myotube 
formation was established with myosin heavy chain and nuclei immunostaining 
(MF20=Green; DAPI=Blue). B) Myotube diameter of transfected C2C12 myotubes 
with ≥2 nuclei. C) Quantification of total C2C12 myotube area expressed as a 
















































































expressed as a % of nuclei in within the myotubes to total nuclei counted in each 
field of view. *represent significant differences compared with the Scr (control) 
group, *P≤0.05, *** P≤0.001 (mean ± SEM; n=3-4; One-Way ANOVA with 
Dunnett’s post-hoc analysis). Representative images shown.  
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Myotube nuclei distribution (C2C12, miR-128)



































Figure 5.3.1.2 Distribution analysis of A) myotube diameter and B) number of 
nuclei in C2C12 myotubes transfected with Scr, miR-128 and AM-128. *represent 
significant differences compared with the Scr (control) group (mean ± SEM; n=3; 
Chi-square test). 
 
5.3.2 The effect of miR-133a gain- and loss-of-function on C2C12 myotube 
phenotype 
C2C12 myotubes transfected with miR-133a mimic (miR-133a) and miR-133a 
inhibitor (AM-133a) are shown in Figure 5.3.2.1 A. Myotubes transfected with 
miR-133a mimic (miR-133a) appeared to be thinner in diameter compared to 
those transfected with miR-133a inhibitor (AM-133a). Myotube analysis showed 
a significant increase in the diameter of myotubes (Figure 5.3.2.1 B) and a larger 
area occupied by myotubes per field of view following transfection with AM-
133a, in comparison to the control group (Scr) (Figure 5.3.2.1 C). Fusion index of 
C2C12 myotubes transfected with miR-133a or AM-133a revealed no significant 
difference compared to the control group (Scr) (Figure 5.3.2.1 D).  
Examination of myotube diameter distribution revealed the prevalence of 
myotubes with diameter ≤30 μm in miR-133a transfected cells compared to the 
rest of the groups, but no significant shift was observed in diameter distribution 
between the groups (Figure 5.3.2.2 A). Similarly, myotube nuclei distribution 
showed no differences between the groups, indicating a proportional 
relationship between number of myotube nuclei number and myotube diameter 





Figure 5.3.2.1 Gain- and loss-of-function of miR-133a in C2C12 myotubes. A) 
C2C12 myotubes transfected with miR-133a or AM-133a as indicated; myotube 
formation was established with myosin heavy chain and nuclei immunostaining 
(MF20=Green; DAPI=Blue). B) Myotube diameter of transfected C2C12 myotubes 
with ≥2 nuclei. C) Quantification of total C2C12 myotube area expressed as a 















































































percentage of total area per field of view. D) Fusion index of C2C12 cells, 
expressed as a % of nuclei in within the myotubes to total nuclei counted in each 
field of view. *represent significant differences compared with the Scr (control) 
group, *P≤0.05, ***P≤0.001 (mean ± SEM; n=3; One-Way ANOVA with 
Dunnett’s post-hoc analysis). Representative images shown.  
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Figure 5.3.2.2 Distribution analysis of A) Myotube diameter and B) Number of 
nuclei in C2C12 myotubes transfected with miR-133a and AM-133a. Scr served as 
control for statistical comparison (mean ± SEM; n=3; Chi-square test). 
 
5.3.3 The effect of gain-of-function and loss-of-function of miR-128 and miR-
133a on C2C12 myoblast proliferation 
CCK-8 proliferation assay analyses from C2C12 myoblasts following miR-128 
and miR-133a transfections are shown in Figure 5.3.3. Proliferation rate of C2C12 
myoblasts following miR-128 overexpression and inhibition was significantly 
reduced compared to the control (Scr) group (Figure 5.3.3 A). Similarly, both 
miR-133a and AM-133a transfections appeared to have a positive effect in the 
proliferation of C2C12 myoblasts, with the number of cells being significantly 
increased after overexpression and inhibition of miR-133a (Figure 5.3.3 B). 















































Figure 5.3.3 CCK-8 proliferation assay of C2C12 myoblasts following transfection 
with miR-128 or miR-133a. A) C2C12 myoblast number following transfection 
with Scr, miR-128 or AM-128. B) C2C12 myoblast number following transfection 
with Scr, miR-133a or AM-133a. *represents significant differences compared 
with the Scr (control) group, **P≤0.01, ***P≤0.001 (mean ± SEM; n=6; One-
Way ANOVA with Dunnett’s post-hoc analysis). 
 
5.3.4 The effect of gain-of-function and loss-of-function of miR-128 and miR-
133a in C2C12 myoblast viability 
Analyses of CytoTox 96 assay on C2C12 myoblast following transfection with 
miR-128 or miR-133a is shown in Figure 5.3.4. C2C12 viability was determined 
based on cell death (expressed as % cytotoxicity) following transfections with 
either miR-128 or miR-133a. C2C12 myoblast cell death was significantly higher 
following both overexpression and inhibition of miR-128 (miR-128, AM-128) 
compared to the Scr transfected cells (Figure 5.3.4 A, C). Cell death in C2C12 
myoblasts transfected with miR-133a mimic was significantly lower compared to 














Figure 5.3.4 CytoTox96 cytotoxicity assay of C2C12 myoblasts following 
transfection with miR-128 or miR-133a. A) C2C12 cell death expressed as fold-
change in cytotoxicity following transfection with Scr, miR-128 or AM-128, using 
Scr as the control group. B) C2C12 cell death expressed as fold-change in 
cytotoxicity following transfection with Scr, miR-133a or AM-133a, using Scr as 
the control group. *represents significant differences compared with the Scr 
(control) group, *P≤0.05, **P≤0.01, ***P≤0.001 (mean ± SEM; n=6; One-Way 
ANOVA with Dunnett’s post-hoc analysis). 
 
































































5.3.5 The effect of miR-128 gain-of-function and loss-of-function on C2C12 
myoblast mitochondrial toxicity 
Data obtained from mitochondrial ToxGlo mitotoxicity assay following 
transfections of C2C12 cells with miR-128 is shown in Figure 5.3.5. Comparison 
of the fold-change observed in the cytotoxicity of the C2C12 cells showed 
significant increase following transfection of cells with miR-128 and AM-128. On 
the contrary, the fold-change of the ATP levels of the C2C12 following 
transfection with miR-128 and AM-128 was significantly decreased, indicating 
decreased production of ATP and therefore an increase in mitochondrial toxicity. 
These data indicate that miR-128 and AM-128 act as mitototoxicant compounds 
inducing necrosis of C2C12 myoblast. 
 
Figure 5.3.5 Mitochondrial ToxGlo two-stage mitotoxicity assay of C2C12 
myoblasts following transfections with miR-128. The first step measures 
dying/dead cells, whilst the second step measures ATP produced. C2C12 cell 
death expressed as cytotoxicity indicated as fold-change following transfection 
with Scr, miR-128 or AM-128, using Scr as the control group. C2C12 


























expressed as fold-change, using Scr as the control group. Scr served as the 
control for statistical comparison, *statistical comparison with Scr values in 
cytotoxicity, #statistical comparison with Scr values in mitotoxicity *,#P≤0.05, 
**,##P≤0.01, ***,###P≤0.001 (mean ± SEM; n=6; Two-Way ANOVA with 




This chapter focused on the effect of gain- and loss-of-function of miR-128 
and miR-133a in C2C12 cells. Findings from these experiments could serve as a 
useful tool to understand the mechanism affected during overexpression or 
inhibition of these two miRs in vitro and in vivo. Data collected from image 
analyses following transfection of C2C12 with either miR-128 or miR-133a 
appeared to have a different effect on the cell behaviour, suggesting a different 
mechanism involved during myogenesis and differentiation. The main findings 
can be summarised in the table below: 
 
Table 5.4 Summary of the main findings following miR-128 and miR-133a 
overexpression and inhibition in C2C12 myoblasts and myotubes. ↑ indicates 
increase in the specific phenotype/function, ↓ indicates reduction in the specific 
phenotype/function, − indicates no change in the specific phenotype/function.  
 miR-128 AM-128 miR-133a AM-133a 
Proliferation ↓ ↓ ↑ ↑ 
Cell death ↑ ↑ ↓ − 
Mitochondrial toxicity ↑ ↑ N/A N/A 
Myotube diameter − − − ↑ 
Myotube area − − − ↑ 
Cell fusion ↑ ↑ − − 
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5.4.1 Overexpression and inhibition of miR-128 in differentiated C2C12 
myotubes  
Image analysis of C2C12 myotubes transfected with Scr, miR-128 mimic or 
AM-128 showed no significant difference in myotube diameter, myotube area or 
number of nuclei per myotube between the groups. However, differences were 
observed in the fusion index of the C2C12 myotubes at Day 7 of differentiation. 
Specifically, cell fusion was increased in C2C12 myotubes transfected with miR-
128 and AM-128, compared to the scrambled-treated myotubes (Figure 5.3.1 D).  
Furthermore, it was evident that myotubes overexpressing miR-128 showed a 
“healthier” phenotype, with their nuclei spread across the length of the myotube 
as opposed to round cell phenotype with multiple fused nuclei. Unlike miR-128, 
myotubes transfected with AM-128 as well as those transfected with Scr 
sequence appeared to have a round shape, with their nuclei concentrated at the 
ends of the tube or in the centre. The formation of those round-shaped 
myotubes could be attributed to myotube detachment from the plate’s surface 
due to cell death or due to disruption in their attachment factors. A study from 
Schoneich et al. (2015) shows that Bcl-2 is likely to control myotube apoptosis at 
early stages but not at late stage of differentiation (Day6). Another explanation 
would be that inhibition of miR-128 could impact negatively terminal 
differentiation.  Although there is no evidence in current literature of such an 
effect of miR-128 on terminal differentiation of C2C12, there are studies showing 
that inhibition of certain microRNAs after the onset of differentiation may affect 
myogenesis (Goljanek-Whysall et al. 2012). A study from Dai et al. shows 
overexpression of miR-128 inhibiting skeletal muscle cell differentiation via 
direct targeting of SP1 gene while the opposite was observed with inhibition of 
miR-128 (Dai et al. 2016). Specifically, in their study Dai et al. show the formation 
of myotubes following overexpression of miR-128 but at a later time-point 
following transfection (Dai et al. 2016). Taken these data into consideration, it is 
possible that miR-128 overexpression may actually stall or delay the formation of 
myotubes rather than completely abolishing it. Therefore, the myotubes 
observed in miR-128 overexpression in Figure 5.3.1.1 A could have a “healthier” 
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phenotype due to their formation later during transfections. In contrary, 
inhibition of miR-128 could have resulted in formation of myotubes earlier 
during transfections, resulting in faster utilisation of the growth factors in the 
media due to increased metabolic rate and therefore myotube apoptosis at an 
earlier time point. Considering the fusion index data and the time of 
transfections (Day 3 post-differentiation), it is also possible that miR-128 
overexpression may prevent the fusion of more nuclei, while inhibition of miR-
128 may promote hyperfusion, resulting in these circular shapes in the 
myotubes. Similar morphology in C2C12 myotubes as the one observed in AM-
128 treated cells has been previously reported following treatment of myotubes 
with rotenone. Specifically, treatment of myoblasts with rotenone (inhibitor of 
mitochondrial complex I) did not cause detachment or cell death at Day 3 of 
differentiation, but a round-shaped morphology of those cells was observed 
(Grefte et al. 2015). Interestingly, increased expression of miR-128 in C2C12 
myotubes was detected at Day 4 of differentiation and was positively correlated 
with increased levels of ATP (Siengdee et al. 2015).  
Despite the lack of significant differences in the myotube diameter of miR-128 
transfected C2C12 myotubes, distribution analysis of myotube diameter was 
performed. Myotubes were separated in different diameter ranges allowing the 
estimation of the number of myotubes falling within each diameter range. 
Although no significant difference was observed in the distribution between the 
different groups, it was evident that myotubes overexpressing miR-128 were 
mostly within the 20-30 μm (Figure 5.3.1.2 A). Interestingly, miR-128 inhibition 
caused a slight shift of the distribution, with those myotubes being more 
abundant in number in the 30-40 μm diameter range. These data collectively 
suggest that inhibition of miR-128 could cause some hypertrophy in a portion of 
transfected myotubes, which may not be obvious when the average diameter is 
taken into consideration. In this case, these data are in agreement with that 
been previously shown (Motohashi et al. 2013).  
In order to examine whether these differences in the diameter distribution 
could be due to hypertrophy of the myotubes independently of the myoblast 
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fusion, distribution nuclei per myotube size for each myotube counted was 
plotted (Figure 5.3.1.2 A). Analysis revealed a linear relationship between the 
number of nuclei and the increase in the size range, suggesting that the number 
of cells fused to form myotubes was proportional to the diameter of the 
myotubes.  
 
5.4.2 Overexpression and inhibition of miR-133a in differentiated C2C12 
myotubes  
Analysis of C2C12 myotube images revealed a significant increase in myotube 
diameter following inhibition of miR-133a (AM-133a), although the opposite was 
not observed in cells overexpressing miR-133a (Figure 5.3.2.1 A, B). Significant 
increase following inhibition of miR-133a was also observed in total myotube 
area but no differences were observed in the fusion index of those cells (Figure 
5.3.2.1 C, D). These observations suggest that inhibition of miR-133a may cause 
myotube hypertrophy, however overexpression of miR-133a does not cause 
atrophy but instead inhibits hypertrophy.  
Distribution analysis of myotube diameter showed the highest number of 
myotubes in miR-133a with a diameter under 30 μm, in comparison with the 
AM-133a, where the number of myotubes is higher from diameter sizes >60 μm 
(Figure 5.3.2.1 A). Despite those differences in peak numbers, Chi-square test 
showed no significant differences in the diameter distribution between the 
groups. Distribution analysis of the number of nuclei per myotube showed a 
parallel relationship across all groups (Figure 5.3.2.1 B). These data reveal that 
the number of fused cells resulting in mature myotubes was the same across the 
different diameter ranges in all the groups. Therefore, miR-133a may have a role 
in hypertrophy of myofibres rather than myogenesis through extra fusion of cell. 
Moreover, these data on myotube hypertrophy and fusion index indicates that 
hypertrophy of myotubes may be independent of cell fusion. This is in line with a 
study from McCarthy et al. (2011) showing that satellite cells are not required for 
muscle fibre hypertrophy in mice. However, the number of myotubes in each 
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diameter distribution appears to shift slightly, with larger myotubes being 
present in AM-133a wells in comparison with the rest of the groups. Previous 
studies have shown that miR-133a expression is downregulated in skeletal 
muscle showing hypertrophy (Ge and Chen, 2011). Furthermore, a study from 
Huang et al. indicated that miR-133a overexpression can supress IGF-1R post-
transcriptionally in C2C12 cells (Huang et al. 2011). Suppression of IGF-1R may 
result in inhibition of IGF-1/Akt pathway, resulting in skeletal muscle atrophy 
(reviewed in Hitachi and Tochida, 2014). Despite these findings, Boettger et al. 
argue that manipulation of microRNAs in miR-133 family may have a distinctive 
phenotype in skeletal muscle. They support the notion that lack of miR-133b in a 
knockout mouse model may be rescued by other microRNAs of miR-133 family 
such as miR-133a (Boettger et al. 2014). In order to support this as the case in 
our study, further investigation is required including sequencing experiments or 
qPCR analysis to establish the levels of expression of other miRs of the miR-133 
family during inhibition of miR-133a. Although, many studies have described the 
role of miR-133a in skeletal muscle proliferation and differentiation in vitro and 
in vivo, there is not much evidence on the effect of miR-133a inhibition in 
terminal differentiation of C2C12 myotubes.  
 
5.4.3 The effect of miR-128 overexpression and inhibition on C2C12 cell 
proliferation, cell death and mitochondrial toxicity 
Overexpression and inhibition of miR-128 in C2C12 myoblasts caused 
significant reduction in the cell number as seen from the proliferation assay, 
indicating that proliferation rate of C2C12 is impaired (Figure 5.3.3 A). Reduction 
in the cell number seen in the proliferation assay is accompanied by significantly 
increased rate of cell death, as observed by the increased levels of C2C12 
cytotoxicity, compared to the control group (Scr) (Figure 5.3.4 A). In order to 
evaluate whether this increase in the cell death is the results of underlying 
mitochondrial dysfunction, a mitotoxicity assay was performed in C2C12 
myoblasts following transfections with miR-128. Analysis of the mitotoxicity data 
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showed a significant increase in the cytotoxicity following overexpression and 
inhibition of miR-128 and a parallel decrease in ATP levels of those two groups 
compared to the control (Figure 5.3.5). Increase in cytotoxicity with parallel 
decrease in ATP levels indicated that overexpression and inhibition of miR-128 
had a mitotoxic effect. Therefore, cell death occurring following transfections of 
myoblasts with miR-128 or AM-128 might be due to mitophagy. 
Overexpression of miR-128 in C2C12 myoblasts has been previously 
associated with inhibition of cell proliferation rate (Motohashi et al. 2013). 
Overexpression of miR-128 has been associated with reduction in proliferation 
rate of other cell types including muscle side population (SP) cells and 
cardiomyocytes (Motohashi et al. 2012; Huang et al. 2018). There seems to be no 
study indicating the role of miR-128 in the regulation of cell death. However, the 
data from the cytotoxicity assay indicate that overexpression of miR-128 is 
associated with increased cell death. This could be due to impaired cell 
metabolism, which would also explain the reduction in cell proliferation. 
Impairment of mitochondrial metabolism could result in mitochondrial 
dysfunction, leading to cell death via necrosis (Lemasters et al. 1991).  In order to 
assess whether the increase in the cell death was due to mitochondrial 
dysfunction, a mitotoxicity assay was performed. Results indicated that miR-128 
acts as a mitotoxin, therefore the increased cell death could be due to 
mitophagy. The same results were recorded following C2C12 myoblast 
transfections with AM-128, indicating that both overexpression and inhibition of 
miR-128 could result in mitophagy but possibly via different pathways. Similar 
role of miR-128 in proliferation of satellite cells was recorded in a previous study 
where both overexpression and inhibition of miR-128 resulted in stalling of cell 
proliferation, but via the regulation of different proteins (Dai et al. 2016). 
Therefore, miR-128 expression could be regulated by a feedback mechanism 
maintaining its levels for normal cell behaviour. This would be in line with recent 
findings from Gabisonia et al. (2019) showing that miR-199 expression can 
stimulate cardiac repair in pigs following myocardial infraction, but the levels of 
miR-199 need to be to be tightly regulated. This study also demonstrates that 
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uncontrolled levels of miR-199 can result in cardiac arrhythmia and sudden death 
(Gabisonia et al. 2019).  
 
5.4.4 The effect of miR-133a overexpression and inhibition on C2C12 cell 
proliferation and cell death  
Proliferation rate of C2C12 myoblasts following transfections with miR-133a 
showed a significant increase in the cell number following both overexpression 
and inhibition for miR-133a (Figure 5.3.3 B). C2C12 cell death rate appeared to 
be significantly reduced only after overexpression of miR-133a, which is in line 
with the increased proliferation rate (Figure 5.3.4 B). Furthermore, inhibition of 
miR-133a causes no difference in the rate of cell death in C2C12 myoblasts. This 
could be possible if inhibition of miR-133a could have triggered the endogenous 
cell overexpression of other miR-133 family members, providing protection 
against cell death. This could also explain the increase in the cell number 
observed following treatment of C2C12 myoblasts with AM-133a, which could be 
the result of activation of different cellular mechanisms by other members of the 
miR-133 family.  
Previous studies on the involvement of miR-133a in myoblast proliferation 
have been controversial. A study from Chen et al. shows the positive regulation 
of myoblast proliferation by miR-133, and inhibition of proliferation with miR-
133 inhibition (Chen et al. 2006). More studies support these findings, showing 
promotion of myoblast proliferation by miR-133 (Kim et al. 2006). However, miR-
133 has been shown to inhibit myoblast proliferation via ERK1/2 pathway (Feng 
et al. 2013). A study from Zhang et al. supports the negative role of miR-133 in 
myoblast proliferation, by inducing G1 phase arrest (Zhang et al. 2012).  Despite 
the extensive studies on miR-133 and muscle cell fate, there has been limited 
evidence on the specific effect of miR-133a in myoblast behaviour, in comparison 
with other members of the miR-133 family (e.g. miR-133b, miR-133c). A study 
from Liu et al. (2011) shows that deletion of miR-133a in vivo does not cause 
changes in the skeletal muscle of mice until after 4 weeks of age (Liu et al. 2011). 
189 
 
However, Liu et al. state that the absence of a phenotype with deletion of miR-
133a in skeletal muscle might be due to expression of miR-133b, which is not 
detected in the heart muscle of those mice; hence the phenotype in cardiac 
muscle is more severe (Liu et al. 2011).  
Phenotypic analysis of C2C12 myotubes following manipulation of miR-128 
and miR-133a expression revealed differences in the effect of miR-128 and miR-
133a in C2C12 differentiation, proliferation, survival and mitochondrial function. 
Therefore, miR-128 and miR-133a have an impact on C2C12 behaviour and 
differentiation via the control of separate mechanisms. Future approaches will 
involve the assessment of proliferation and viability of C2C12 cells with more 
sensitive techniques, such as Ki67 or BrdU and acridine orange/ethidium 















Gain- and loss-of-function of miR-











Multiple microRNAs have been shown to be involved in neuronal 
development and regulation of the central nervous system and have been 
carefully investigated in several neuronal cell types. One such cell type, the α-
motoneurons located in the spinal cord and lower brain stem, are often cultured 
in vitro using spinal cord explants (Nurcombe et al. 1984; Arnold et al. 2012). 
Such a technique can often be costly and time-consuming. An alternative in vitro 
model of motoneuron-like cells, known as NSC-34 cells, is a hybrid cell line which 
has been widely used for neuronal cell-based assays (Cashmann et al. 1992; 
Eggett et al. 2000; Matusica et al. 2008).   
MicroRNA-128 is abundantly expressed in the central nervous system and 
specifically the brain (Lee et al. 2008). During development, miR-128 expression 
levels control neuronal morphology and excitability (Franzoni et al. 2015). 
Despite being a key regulator of neuronal development, miR-128 levels appear to 
show the highest expression levels during adulthood (Tan et al. 2013). A study 
from Tan et al. has identified miR-128 as a suppressor of ion channel expression 
as well as signalling molecules involved in the ERK pathway (Tan et al. 2013). 
MicroRNA-128 has also been discussed in studies focusing on cognitive function 
and neuropsychiatric disorders (reviewed in Ching and Ahmed-Annuar 2015). 
Specifically, predicted target genes of miR-128 have been shown to be involved 
in neurotrophin signalling, MAPK and insulin signalling pathway (reviewed in 
Ching and Ahmed-Annuar, 2015).  
Unlike miR-128, miR-133 has not been studied as extensively in neuron cells. 
Known as a “myomiR”, miR-133 has been investigated in relation to 
neuromuscular interactions in vivo (Valdez et al. 2014), however there is limited 
evidence for its involvement in neuronal cell behaviour and function. Hoye et al. 
have identified increased levels of miR-133a in mouse motoneurons, similar to 
those of known motomiRs such as miR-218 (Hoye et al. 2017). Interestingly, in 
their study Hoye et al. support the possibility that miR-133a may have a 
functional rather than a morphological role in regulating motoneuron fate 
postnatally (Hoye et al. 2017).  
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The aim of the work was to assess the effect of gain- and loss-of-function of 
miR-128 and miR-133a on motoneuron cell function and morphology using NSC-
34 cell line. Furthermore, the potency of the two microRNAs in controlling cell 
proliferation, viability and mitochondrial toxicity specifically in motoneurons was 
investigated. Results from this study could provide a novel explanation for the 





6.2.1 Cell culture and differentiation of NSC-34 cells 
NSC-34 cells were recovered from LN2 and thawed either at RT or in a 37oC 
water bath until there was no ice visible. Cell suspension was collected from the 
cryovial, mixed with 3 mL of pre-warmed growth media (GMNSC-34; Chapter 2, 
Section 2.16) and centrifuged immediately at 1,500 rpm for 5 min to discard 
freezing media containing DMSO. The cell pellet was then resuspended in 10 mL 
of growth media (GMNSC-34) and plated into a T75 flask (Corning). Cells were then 
incubated in a humidified incubator at 37oC with 5% CO2, and media was 
replaced every two days until cells reach 70-80% confluency. When 70-80% 
confluency was reached, cells were passaged 1:4 into fresh T75 flasks in a total 
volume of 10 mL cell suspension, as described previously in Chapter 2, section 
2.17.  
For immunostaining and characterisation of the phenotype, NSC-34 cells were 
seeded into a 12-well plate pre-coated with 5 μg/mL laminin (Chapter 2, Section 
2.18), at a confluency of 50,000 cells/well (13,158 cells/cm2). Cells were left to 
differentiate for 7-11 days following transfections, in order to develop axonal 
projections. The remaining cells were plated into three 6-well plates, for use in 
RNA and protein isolation following transfections. All plates were incubated in 
GMNSC-34 for 24 h to allow appropriate attachment on the cell surface and were 
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then used for transfections with miR-128 or miR-133a according to the protocols 
in Chapter 2, Section 2.21). Following 48 h of transfections, NSC-34 cells from the 
6-well plates were harvested for RNA and protein isolation, according to the 
protocol described in Chapter 2, Section 2.20. NSC-34 cells plated in 12-well 
plates were left to differentiate in DMNSC-34 until Day 11-12 post-transfections 
before being stained for imaging and assessment of phenotypic changes (Chapter 
2, Section 2.22).  
 
6.2.2 Image analysis of NSC-34 differentiated cells (NSC-34D) following 
transfections with miR-128 and miR-133a 
NSC-34 cells were immunostained with Anti-Beta-III Tubulin antibody and 
DAPI following successful differentiation, as described in Chapter 2, Section 2.22. 
Images of cells were acquired using a Nikon Ti Live cell imaging microscope under 
x20 magnification and the axonal length of differentiated NSC-34 cells was 
analysed using ImageJ software (Chapter 2, Section 2.23).  
 
6.2.3 Plate assay for NSC-34 cell proliferation, viability and mitochondrial 
toxicity following transfections with miR-128 or miR-133a 
NSC-34 cells were plated on 96-well plates (Costar) pre-coated with 5 μg/mL 
laminin and used for proliferation, viability and mitotoxicity assays. For 
proliferation and viability, NSC-34 cells were seeded according to the instruction 
in Chapter 2, Sections 2.27 (for proliferation assay) and Chapter 2, Section 2.28 
(for cytotoxicity assay). Cells were left to incubate in GMNSC-34 for 24 h following 
plating and were subsequently transfected with scrambled sequence, miR-128 
mimic, AM-128, miR-133a mimic and AM-133a, as previously described (Chapter 
2, Section 2.21). Both proliferation and cytotoxicity assay were performed 48 h 
following transfections according to manufacturer’s instructions. Data analysis 
was performed as indicated in the manufacturer’s protocol. Mitotoxicity assay 
was conducted as described in Chapter 2, Section 2.19, following transfection of 
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NSC-34 cells with scrambled sequence, miR-128 mimic, AM-128. Data 
interpretation was performed according to manufacturer’s instructions. The 
cytototoxic effect of miR-128 was assessed using the values recorded from the 
fluorescence absorbance. The mitotoxic effect of miR-128 was assessed using the 
values of LDH and ATP release recorded from luminescence measurement of 
NSC-34 cells. To determine whether miR-128 is a mitotoxic compound, fold-
changes in mitotoxicity were assessed in comparison with the cytotoxicity values 
recorded.  
 
6.2.4 Statistical Analysis 
Statistical analysis was performed using Graphpad 5 (Graphpad Software, San 
Diego, USA). Data analyses of axonal length, proliferation and cytotoxicity assay 
were performed using a One-Way ANOVA, with Dunnet’s post-hoc analysis, using 
Scr as the control group. Data from the mitotoxicity assay were analysed using a 
Two-Way ANOVA, with Bonferroni post-hoc analysis. Data from cytotoxicity and 
mitotoxicity assays were presented as fold-changes compared to the control 
(Scr) group. Data were represented as mean ± SEM. N Number represents wells 




6.3.1 Phenotype changes in NSC-34 cells following gain-of-function and loss-
of-function of miR-128  
NSC-34 cells transfected with miR-128 mimic (miR-128) and miR-128 inhibitor 
(AM-128) are shown in Figure 6.3.1 A. NSC-34 cells transfected with miR-128 
mimic and imaged after 11 days of differentiation demonstrated distinct 
differences in the axonal length and confluency compared to the rest of the 
groups (Figure 6.3.1 A). Indeed, analysis revealed a significant decrease in the 
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axonal length of the NSC-34D cells transfected with miR-128 mimic in comparison 
with the control group (Scr) (Figure 6.3.1 C). The transfection process did not 
appear to have an impact on the axonal length of the cells, as seen from 
comparison between untreated cells (Control) and transfection control (Scr) 
(Appendix, Figure A.14). 
 
Figure 6.3.1 MicroRNA-128 gain- and loss-of-function in NSC-34D phenotype. A) 
Differentiated NSC-34 cells (NSC-34D) transfected with Scr, miR-128 or AM-128 as 
indicated; NSC-34D cells were stained with Alexa Fluor 488 B-III Tubulin (Green) 
and DAPI (Blue) for the visualisation of the nuclei. B) Axonal length of NSC-34D 
after 11 days of differentiation. *represent significant differences compared with 
the Scr (control) group. *P≤0.05 (mean ± SEM; n=3; One-Way ANOVA with 
Dunnett’s post-hoc analysis). Representative images show.  
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6.3.2 Phenotype changes in NSC-34 cells following gain-of-function and loss-
of-function of miR-133a  
NSC-34 cells transfected with miR-133a mimic (miR-133a) and miR-133a 
inhibitor (AM-133a) and differentiated for 11 days are shown in Figure 6.3.2 A. 
Overexpression or inhibition of miR-133a did not seem to have an apparent 
effect on the axonal length or number of NSC-34D cells following 11 days of 
differentiation (Figure 6.3.2 A). Analysis of the axonal projections revealed a 
significant increase in the length of the axons of the NSC-34D transfected with 
AM-133a compared to the control group (Scr) (Figure 6.3.2 C). Interestingly, 
axonal length of NSC-34D treated with Scr showed a significant reduction when 
compared to non-transfected (Control) cells (Appendix, Figure A.15). 
 
Figure 6.3.2 MicroRNA-133a gain- and loss-of-function in NSC-34D phenotype. A) 
Differentiated NSC-34 (NSC-34D) cells transfected with Scr, miR-133a or AM-133a 
miR-133a 
AM-133a 




























as indicated; NSC-34D cells were stained with Alexa Fluor 488 B-III Tubulin 
(Green) for and DAPI (Blue) for the visualisation of the nuclei. B) Axonal length of 
NSC-34D after 11 days of differentiation. *represent significant differences 
compared with the Scr (control) group. *P≤0.05 (mean ± SEM; n=3; One-Way 
ANOVA with Dunnett’s post-hoc analysis). Representative images shown.  
 
6.3.3 Proliferation rate of NSC-34 cells following gain-of-function and loss-of-
function of miR-128 and miR-133a 
Analysis of the CCK-8 proliferation assay on NSC-34 cells following 
manipulation of miR-128 or miR-133a expression are shown in Figure 6.3.3. 
Transfection of miR-128 and AM-128 had no effect on the proliferation of NSC-34 
cells compared to the Scr-treated cells (Figure 6.3.3 A). Similar results were 
obtained from analysis of the proliferation rate of NSC-34 cells following miR-
133a and AM-133a transfection, when compared to Scr-treated cells (Figure 
6.3.3 B). 
 
Figure 6.3.3 CCK-8 proliferation assay of NSC-34 cells following manipulation of 
miR-128 or miR-133a expression. A) NSC-34 number following transfection with 
miR-128 or AM-128. B) NSC-34 number following transfection with miR-133a or 
AM-133a. Scr served as control group for statistical comparison, (mean ± SEM; 
n=6; One-way ANOVA with Dunnett’s post-hoc analysis). 















































6.3.4 The effect of miR-128 and miR-133a gain-of-function and loss-of-
function on NSC-34 viability 
The viability of NSC-34 cells was determined by a CytoTox96 cytotoxicity assay 
following manipulation of miR-128 and miR-133a expression as shown in Figure 
6.3.4. NSC-34 cell viability was assessed based on the rate of cell death 
(expressed as fold-change in cytotoxicity). Transfection did not seem to affect 
the viability of NSC-34 cells, as no differences were observed in the cytotoxicity 
between Scr-treated cells and non-transfected (Control) cells (Appendix, Figure 
A.16).  Overexpression of miR-128 led to a significant increase in cytotoxicity, 
compared to the control group (Scr) (Figure 6.3.4 A). However, miR-133a and 
AM-133a transfection had no impact on NSC-34 cell viability (Figure 6.3.4 B). 
 
Figure 6.3.4 CytoTox96 cytotoxicity assay of miR-128 and miR-133a on NSC-34 
cell for the determination of NSC-34 cell death. A) NSC-34 cell cytotoxicity 
following transfection with miR-128 or AM-128. B) NSC-34 cell cytotoxicity 
following transfection with miR-133a or AM-133a. *represent significant 
differences compared with the Scr (control) group. *P≤0.05. (mean ± SEM; n=6; 
One-way ANOVA with Dunnett’s post-hoc analysis). 
 
 




























































6.3.5 Mitochondrial toxicity following miR-128 and miR-133a gain-of-function 
and loss-of-function in NSC-34 cells 
Results obtained from mitochondrial ToxGlo mitotoxicity assay analysis 
following transfections of NSC-34 cells with miR-128 are shown in Figure 6.3.5. 
Changes in cytotoxicity following overexpression or inhibition of miR-128 were 
not significantly higher compared to the control group. Similarly, fold-changes 
recorded in ATP release following overexpression or inhibition of miR-128 did not 
reveal a significant reduction compared to control group (Scr). These findings 
indicate that miR-128 does not act as a mitochondrial toxin. 
 
Figure 6.3.5 Mitochondrial ToxGlo two-stage mitotoxicity assay of NSC-34 
neuronal cells following manipulation of miR-128 expression. The first step 
measures dying/dead cells, whilst the second step measures ATP produced. NSC-
34 cell death (cytotoxicity) indicated as fold-change following transfection with 
Scr, miR-128 or AM-128. NSC-34 mitochondrial ATP release following 






















as the control group for statistical comparison (mean ± SEM; n=6; Two-Way 




In this chapter, gain- and loss-of-function of miR-128 and miR-133a were 
investigated in NSC-34 cells. The aim was to understand the mechanism affecting 
motoneuron cell behaviour following the dysregulation of miR-128 and miR-133a 
expression in vivo and in vitro. The main findings from this chapter are 
summarised in the table bellow: 
 
Table 6.4 Summary of the main findings following miR-128 and miR-133a 
overexpression and inhibition in NSC-34 cells. ↑ indicates increase in the specific 
phenotype/function, ↓ indicates reduction in the specific phenotype/function, − 
indicates no change in the specific phenotype/function.   
 
 
6.4.1 MicroRNA-128 gain- and loss-of-function effects on the phenotype of 
differentiated NSC-34 (NSC-34D) cells   
Image analysis of NSC-34 cells following 11 days of differentiation showed 
significant reduction in axonal length of NSC-34D following overexpression of 
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miR-128 (miR-128) (Figure 6.3.1 C). Overexpression of miR-128 appeared to have 
an impact on the overall cell number present per field of view suggesting a 
possible impact on either cell viability or proliferation. Unlike the rest of the 
groups, miR-128 transfected cells showed very little to no signs of “networking” 
with the neighbouring cells and lack of formation of “mesh-like” structure usually 
seen in untransfected differentiated cells (control) or scrambled-transfected 
cells.  
MicroRNA-128 is known as a brain-enriched microRNA due to its high levels of 
expression in the brain and during development in mice (Franzoni et al. 2015). 
Previous studies have shown that a dysregulation of miR-128 can play a 
significant role in the development of neurological disorders (reviewed in Ching 
and Ahmad-Annuar, 2016). Specifically, inhibition of miR-128 expression has 
been associated with increased neuronal excitability and seizures in mice 
(McSweeney et al. 2016; Tan et al. 2013). Overexpression of miR-128 results in 
inhibition of neuronal responsiveness and suppression of motor activities in mice 
(Tan et al. 2013). This is in line with the phenotype recorded in our study 
following overexpression or inhibition of miR-128 in NSC-34 cells. The special and 
temporal versatility of miR-128 expression has been previously investigated in 
vivo (Franzoni et al. 2015). Both increased and decreased levels of miR-128 in 
vivo have been linked to the rise of diseases such as cancer and psychiatric 
disorders (reviewed in Ching and Ahmad-Annuar, 2016). Moreover, previously 
published data in vitro highlight the effect of inhibition and overexpression of 
miR-128 in regulating cell proliferation via two different mechanisms (Dai et al. 
2016). Collectively, these data demonstrate the need for a tight regulation in the 
levels of miR-128 expression, as both up- and down-regulation of its expression 
levels may have a negative effect in vivo and in vitro.  Furthermore, in order to 
assess whether the function of the NSC-34 cells is impaired during gain- or loss-of 




6.4.2 MicroRNA-133a gain- and loss-of-function effects on the phenotype of 
differentiated NSC-34 (NSC-34D) cells   
Analysis of differentiated NSC-34 images following transfections with AM-
133a revealed a significant increase in the axonal length of NSC-34 cells following 
11 days of differentiation (Figure 6.3.2 C). Interestingly, miR-133a overexpression 
did not seem to have an impact in the axonal length of NSC-34 cells, compared to 
the control group (Scr). Unlike miR-128, miR-133a did not seem to cause such 
severe phenotype changes, since NSC-34 cells sprouted axons during 
overexpression and inhibition of miR-133a.  
MiR-133a is a “myomiR”, highly expressed in skeletal and cardiac muscle. Its 
involvement in neuronal behaviour and morphology has not been extensively 
studied. Previous studies have shown changes in miR-133a expression levels 
following spinal cord injury (reviewed in Li et al. 2016). Most importantly, miR-
133a along with miR-218, a well-known “motomiR”, has been associated with 
motoneuron fate determination postnatally. A study from Hoye et al. showed 
several target genes of miR-133a being downregulated specifically in 
motoneuron cells suggested a more distinctive functional role of miR-133a in 
motoneurons (Hoye et al. 2017). MicroRNA-133a has also been found to be 
elevated in human in vitro models during neuronal differentiation (Pallocca et al. 
2014). Furthermore, overexpression of miR-133a in vitro has been shown to 
decrease the expression of neuronal marker genes during neuronal 
differentiation (Izarra et al. 2017). All things considered, miR-133a has been 
associated with neuronal cell function and behaviour, specifically motoneuron 
cells. However, there is limited evidence on the effect of miR-133a in 
motoneuron function and differentiation in vitro and in vivo. It is possible that 
miR-133a, may have a more significant role in cell function rather than the 
phenotype determination of the motoneurons, hence the effects we saw in the 




6.4.3 The effect of miR-128 overexpression and inhibition on NSC-34 
proliferation rate, cell viability and mitochondrial function 
Data analysis from proliferation assay of NSC-34 cells following transfections 
with miR-128 showed no significant differences in the cell number between the 
three groups (Figure 6.3.3 A). Although some studies are in support of the 
protective effect of miR-128 in neuronal cell proliferation (Zhou et al. 2018), 
other studies provide evidence of inhibition or reduction in the rate of cell 
proliferation with miR-128 overexpression (Zhang et al. 2016). Taken into 
consideration our data showing no difference in cell proliferation, it is possible 
that miR-128 could target different mechanisms in different neuronal cell types 
or act in a dose-dependent manner. Results obtained from the cytotoxicity assay 
measuring rate of cell death revealed a significant increase in NSC-34 cell death 
rate following overexpression of miR-128 (Figure 6.3.4 A), which could explain 
the lower number of cells seen during imaging. A study from Guidi et al. 
identified the downregulation of the TMSB10 gene, acting as an anti-apoptotic 
factor in chicken embryonic motoneurons, when miR-128 is overexpressed in 
neuronal cells (Guidi et al. 2010). In order to examine whether this increase in 
the cytotoxicity is due to an underlying mitochondrial dysfunction, a mitotoxicity 
assay was performed following manipulation of miR-128 expression in NSC-34 
cells. This assay records cell death (cytotoxicity) and ATP release from cells, and a 
comparison of those two variables determine whether the microRNA under 
investigation acts as a mitochondrial toxin on the cells. Unlike in C2C12, neither 
the cytotoxicity nor the mitotoxicity data obtained from the assay revealed any 
significant differences in miR-128 transfected NSC-34 cells. It is noteworthy 
though that both cytotoxicity and mitotoxicity fold-changes show the same 
pattern as that seen in C2C12 (Chapter 5, Section 5.3.5). The lack of significant 
difference changes in cell death and ATP release as seen in this assay indicates 
that miR-128 does not act as a mitotoxin in NSC-34 cells. In order to identify the 
exact molecular mechanism resulting in increased cell death following 
overexpression of miR-128 in NSC-34 cells, further experiments need to be 
conducted specifically in motoneuron cells. Such experiments may include, but 
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not limited to, proteomics analysis in order to identify whether proteins involved 
in cell death may be overexpressed following transfections with miR-128 or AM-
128.  
 
6.4.4 The effect of miR-133a overexpression and inhibition on NSC-34 
proliferation rate and cell viability  
Analysis of data obtained from the proliferation assay showed no effects of 
miR-133a overexpression or inhibition on NSC-34 cell number (Figure 6.3.3). 
Similar results were also obtained from the cytotoxicity assay performed 
following overexpression or inhibition of miR-133a (Figure 6.3.4). Taken into 
consideration that miR-133a is predominantly a skeletal muscle microRNA and 
the levels of its expression are very low in neuronal cells, it is not surprising that 
the change of its expression has no impact on proliferation or viability of NSC-34 
cells. Association of miR-133a with motoneuron cells has only been described by 
Hoye et al. supporting the role of miR-133a as functional in determining 
motoneuron cell fate (Hoye et al. 2017). Few other studies have associated miR-
133a in neuronal cell differentiation. Members of the miR-133 family have been 
shown to play a role in NMJ formation and function (Valdez et al. 2014). 
However there is very limited evidence to support the exact role and mechanism 
of miR-133a in motoneuron cell phenotype and behaviour. 
Analysis of the phenotype of NSC-34 cells following manipulation of miR-128 
and miR-133a expression showed differences in the effect of the two microRNAs 
in NSC-34 cells. Therefore, the two microRNAs are likely affecting motoneuron 
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Analysis of predicted target genes 
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MicroRNAs control gene expression via inhibition of translation and/or 
degradation of the mRNA transcript resulting in reduced protein expression 
(reviewed in Fazi and Nervi, 2008). Certain microRNAs have been proposed to 
induce upregulation of their mRNA targets and proteins under certain conditions 
(Orang et al. 2014). Some microRNAs may also control expression levels of their 
target genes indirectly via repression of mRNA degradation mechanisms. One 
such example is microRNA-128 which has been associated with repression of 
nonsense-mediated decay in neural cells, resulting in upregulation of certain 
mRNA transcripts (Bruno et al. 2011). MicroRNA-128, a brain-enriched 
microRNA, is highly expressed in CNS and skeletal muscle tissue (Lee et al. 2008). 
Previously published data and the bioinformatics analysis presented in Chapter 4 
indicate that miR-128 may control the expression of several genes involved in 
key biochemical pathways in muscle and motoneurons. Specifically, predicted 
target genes of miR-128 are involved in neurotrophin signalling, MAPK and 
insulin signalling pathway (reviewed in Ching and Ahmed-Annuar, 2015). 
A number of genes has been predicted to interact with miR-128 in muscle and 
nerve cells and tissues. Cytochrome c oxidase subunit I and IV genes (COX-I and 
COX-IV respectively) are major components of the mitochondrial electron 
transport chain and play a key role in energy production (reviewed in Gnaiger, 
2009). NRF-1 is a transcription factor that has been associated with the 
regulation of the gene expression of all cytochrome c oxidase subunits, including 
COX-I and COX-IV (Dhar et al. 2008). Parkin-2 (Park-2) gene is linked to the 
removal of dysfunctioning mitochondria and regulation of mitochondrial activity 
(Narendra et al. 2008; Leduc‐Gaudet et al. 2019). TOM-20 is localised in 
mitochondrial membrane and is a marker of mitochondrial content (Billing et al. 
2010). PDGFRα has been associated with hypertrophy of skeletal muscle fibres 
via interaction with PI3K/AKT pathway (Sugg et al. 2017). PDGFRα expression is 
also necessary during embryonic stages and neuronal myelination (Oumesmar et 
al. 1997). GRB-2 and Gab-1 are essential for NMJ morphology and axonal 
myelination in peripheral nerve (Park et al. 2017; Gingras et al. 2016). SOS-1 
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forms a complex via binding with GRB-2 activation the RAS/ERK pathway 
following binding of growth factors to the upstream receptors (Findlay et al. 
2013). SIRT-1 is capable of promoting de-acetylation of FoxO proteins, inhibiting 
the expression of atrophy-related genes (Lee and Goldberg, 2013). 
The aim of this chapter was to assess the effects of miR-128 gain- and loss-of-
function on the expression levels of predicted target genes associated with 
mitochondrial quality and quantity, skeletal muscle hypertrophy and 
neurotrophin signalling in C2C12 and NSC-34 cells. Furthermore, the levels of 
predicted target genes most likely directly regulated by miR-128, were assessed 
in vivo, in TA muscle and SN of 12-week old mice subjected to a low-protein diet 




7.2.1 First-strand cDNA synthesis and real-time qPCR analysis of miR-128 
predicted target genes in cell and tissue lysates  
For cell lysates: 
C2C12 and NSC-34 cells were harvested as described in Chapter 2, Section 
2.20 and stored in -20oC until RNA isolation. Prior to RNA isolation, cell samples 
were retrieved from -20oC and left at RT for 5 min. RNA isolation was performed 
as described in Chapter 2, Section 2.12. Following RNA isolation and 
determination of RNA concentration and integrity using the NanoDrop2000 
(Thermofisher Scientific), RNA samples were used for first strand cDNA synthesis 
using SuperScript™ II Reverse Transcriptase (Chapter 2, Section 2.13). Following 
completion of cDNA synthesis, cDNA reaction volume was diluted 1:10 to a final 





For tissue lysates: 
TA muscle and SN isolated from 12-week old mice were ground in a mortar 
using LN2 and prepared for RNA isolation as described in Chapter 2, Section 2.12.  
RNA concentration and purity were recorded using NanoDrop2000 
(Thermofisher Scientific). First Strand cDNA synthesis was performed using 
SuperScript™ IV VILO™ Master Mix, according to manufacturer’s protocol (Cat# 
11756050, Invitrogen, Paisley, UK). Following cDNA synthesis, each sample was 
diluted 1:10 to a final volume of 200 μL and stored at -20oC until used for qPCR.  
 
For real-time qPCR: 
Real-time qPCR in cell and tissue samples was performed according to the 
protocol in Chapter 2, Section 2.15. Analysis of the data collected following 
completion of qPCR runs was performed according to the delta-delta Ct method 
(ddCt). For qPCR runs in cell samples, b2 microglobulin was used as the 
housekeeping gene and 18S was used as housekeeping gene for qPCR runs in 
tissue samples. Primer sequences were designed according to the instructions 
outlined in Chapter 2, Section 2.14 and shown in Table 7.2.1 bellow:   
Table 7.2.1 Primer sequences of miR-128 predicted target genes of interest. 
Gene name Primer sequences (5’ – 3’) 
 Forward Reverse 
Gab-1 (1) CAGAGTCCCAGCGGAGC TCTTCCACGCATAACGCTTC 
Gab-1 (2) GCGCACTGAAAGAAGGTCG CTTCCACGCATAACGCTTCA 
Pdgfrα-2 GGAACCTCAGAGAGAATCGGC CATAGCTCCTGAGACCCGCTG 
Cox-I CACTAATAATCGGAGCCCCA TTCATCCTGTTCCTGCTCCT 
Cox-IV TTCTTCCGGTCGCGAGCAC GCTCTGGAAGCCAACATTCTGC 
Grb-2 CGGAAGCTAGGTTGCTCTGT ACACAATGCCACCCGTGA 
Nrf-1 TTACTCTGCTGTGGCTGATGG CCTCTGATGCTTGCGTCGTCT 
Park-2 CAAGGACACGTCGGTAGCTT ACAGGGCTCCTGACATCTG 
Sirt-1 GATGACAGAACGTCACACGC ACAAAAGTATATGGACCTATCCGC 
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Sos-1 CCGTGTGTGCCTTTCTTTGG AGAACCTCTTGATGTCCGGC 
Tomm-20 AGTCGAGCGAAGATGGTGG GCCTTTTGCGGTCGAAGTAG 
β2 microglobulin TAAGCATGCCAGTATGGCCG TGTCTCGATCCCAGTAGACG 
18S CGGCTACCACATCCAAGGAAGG CCCGCTCCCAAGATCCAACTA 
 
 
7.2.2 Quantification of the protein levels of miR-128 predicted target genes 
following manipulation of miR-128 levels in C2C12 and NSC-34 cells 
Cell lysates from C2C12 and NSC-34 cells were used for protein extraction and 
determination of protein concentration using BCA assay (Chapter 2, Section 2.24 
and Section 2.25). Protein expression was quantified using western blotting 
technique, as described in Chapter 2, Section 2.26. Data analysis for 
quantification of proteins of interest was performed according to instructions in 
Chapter 2, Section 2.26.5.  
 
7.2.3 Statistical Analysis 
Statistical analysis was performed using Graphpad 5 (Graphpad Software, San 
Diego, USA). Data analysis relative gene expression analysis and protein 
quantification analysis was performed using One-Way ANOVA with Dunnett’s 
post-hoc analysis, using NNN as the control group for statistical comparisons. 
Data are represented as mean ± SEM. N number represents animals used per 
group for molecular analysis in tissue samples. N number represents wells used 








7.3.1 Changes in the expression profile of miR-128 predicted target genes 
following transfections of miR-128 in C2C12 cells 
Relative gene expression of miR-128 predicted target genes of interest 
following transfections with miR-128 in C2C12 cells are shown in Figure 7.3.1.1 
and Figure 7.3.1.2. Expression of Gab-1, isoforms 1 and 2, was not affected 
following overexpression or inhibition of miR-128 (Figure 7.3.1.1 A, B). 
Additionally, no differences in the expression levels were recorded for Tomm-20 
(Figure 7.3.1.1 E), Sirt-1 (Figure 7.3.1.2 B) and Grb-2 (Figure 7.3.1.2 C) genes. 
Significant upregulation in the gene expression level was recorded in Cox-IV and 
Park-2 genes following overexpression of miR-128, when compared to Scr (Figure 
7.3.1.1 C, Figure 7.3.1.2 F). Gene expression levels were significantly 
downregulated for Pdgfrα-2 following miR-128 overexpression (Figure 7.3.1.1 D) 
and Sos-1 and Nrf-1 only after inhibition of miR-128 (Figure 7.3.1.2 A, F). 
Interestingly, Cox-I expression levels were significantly downregulated following 
both overexpression and inhibition of miR-128 (Figure 7.3.1.2 E), consistent with 














Figure 7.3.1.1 Relative expression of miR-128 predicted target genes following 
transfections with miR-128 in C2C12 cells. A) Gab-1, isoform 1, B) Gab-1, isoform 
2, C) Park-2, D) Pdgfrα-2, E) Tomm-20 expression levels.  *represent significant 
differences compared with the Scr (control) group. *P≤0.05, **P≤0.01, *** 

















































































































































Figure 7.3.1.2 Relative expression of miR-128 predicted target genes following 
transfections with miR-128 in C2C12 cells. A) Sos-1, B) Sirt-1, C) Grb-2, D) Nrf-1, 











































































































































































compared with the Scr (control) group, *P≤0.05, **P≤0.01 (mean ± SEM; n=6; 
One-Way ANOVA with Dunnett’s post-hoc analysis). 
 
7.3.2 Changes in the expression levels of miR-128 predicted target genes 
following manipulation of miR-128 levels in NSC-34 cells  
Analysis of the expression level of miR-128 predicted target genes of interest, 
following transfection of NSC-34 cells with miR-128, are shown in Figure 7.3.2.1 
and 7.3.2.2 Expression levels of Cox-I gene was significantly decreased in NSC-34 
cells following overexpression of miR-128 (Figure 7.3.2.2 A). Moreover, 
expression levels of Nrf-1, Grb-2 and Pdgfrα-2 were significantly increased 
following inhibition of miR-128, when compared to control group (Scr) (Figure 
7.3.2.2 C-E). Interestingly, Cox-IV expression levels were significantly increased 
following both overexpression and inhibition of miR-128 in NSC-34 cells (Figure 
7.3.2.2 B). Sirt-1 and Tomm-20 expression levels were unaffected by miR-128 
transfections (Figure 7.3.2.1 A, B).  
 
Figure 7.3.2.1 Relative expression of miR-128 predicted target genes following 
overexpression or inhibition of miR-128 in NSC-34 cells. A) Sirt-1 and B) Tomm-20 
expression levels. Scr served as the control group for statistical comparison. 



























































Figure 7.3.2.2 Relative expression of miR-128 predicted target genes following 
overexpression or inhibition of miR-128 in NSC-34 cells. A) Cox-I, B) Cox-IV, C) 



















































































































































differences compared with the Scr (control) group. *P≤0.05, **P≤0.01 (mean ± 
SEM; n=6; One-Way ANOVA with Dunnett’s post-hoc analysis). 
 
7.3.3 Protein expression levels in C2C12 and NSC-34 cells following 
overexpression or inhibition of miR-128 
Data collected from analysis of protein expression in C2C12 cells following 
overexpression or inhibition of miR-128 are shown in Figure 7.3.3.1 – 7.3.3.4. 
Protein levels of LC-3 I and LC-3 II (recruited during autophagy/mitophagy 
process) were quantified using Ponceau S stain as an internal control (Figure 
7.3.3.1 A). The ratio of LC-3 II/I protein expression revealed no significant 
differences following miR-128 transfections (Figure 7.3.3.1 B). Same results were 
obtained from analysis of LC-3 II/I ratio in NSC-34 cells following miR-128 
transfections (Figure 7.3.3.2). Protein levels of NRF-1 were also unaffected by 
miR-128 transfections both in C2C12 and NSC-34 cells (Figure 7.3.3.3, Figure 
7.3.3.4 B). Similar results were observed for protein expression levels of COX-IV 
in NSC-34 cells, which remained unaltered following overexpression and in 




Figure 7.3.3.1 Quantification of protein levels of LC-3 following overexpression or 
inhibition of miR-128 in C2C12 cells. A) Blots LC-3 (I) and LC-3 (II), normalised to 
Ponceau S stain used as internal control for total protein concentration B) Ratio 
of LC-3 II/I, in order to determine the presence of autophagy/mitophagy in 
transfected cells. Scr served as the transfection control for statistical comparison. 
(mean ± SEM; n=3; One-Way ANOVA with Dunnett’s post-hoc analysis). 
 
 









































Figure 7.3.3.2 Quantification of protein levels of LC-3 following overexpression or 
inhibition of miR-128 in NSC-34 cells. A) Blots of LC-3 (I) and LC-3 (II) isoforms, 
normalised to Ponceau S stain used as internal control for total protein levels B) 
Ratio of LC-3 II/I, in order to determine the presence of autophagy/mitophagy in 
transfected cells. Scr served as the control group for statistical comparison. 
(mean ± SEM; n=3; One-Way ANOVA with Dunnett’s post-hoc analysis). 
 
 











































Figure 7.3.3.3 Quantification of protein levels of NRF-1 following inhibition or 
overexpression of miR-128 in C2C12 cells. A) NRF-1 protein blot, normalised to 
Ponceau S stain used as internal control for total protein concentration B) 
Protein levels of NRF-1. Scr served as the transfection control for statistical 




















































Figure 7.3.3.4 Quantification of protein levels of NRF-1 and COV-IV following 
overexpression or inhibition of miR-128 in NSC-34 cells. A) NRF-1 protein blot, 
normalised to Ponceau S stain used as internal control for total protein 
concentration B) Protein levels of NRF-1. Scr served as the control group for 























































7.3.4 Expression levels of miR-128 predicted target genes in TA muscle and 
sciatic nerve of 12-week old mice 
Relative gene expression analysis of miR-128 predicted target genes in TA 
muscle and SN of 12-week old mice are shown in Figure 7.3.4. Expression levels 
of NRF-1 and COX-IV in TA muscle showed no significant differences between the 
three groups (Figure 7.3.4 A, B). Expression of COX-IV in SN was also similar 
between the three groups, without significant changes being observed (Figure 
7.3.4 D). However, relative expression levels of NRF-1 and GRB-2 were 
significantly increased in SN of NLL mice compared to the control group (NNN) 


















Figure 7.3.4 Relative expression levels of miR-128 predicted target genes in TA 
and SN of 12-week old mice. A) NRF-1 in TA, B) COX-IV in TA, C) NRF-1 in SN, D) 
COX-IV in SN, E) GRB-2 in SN. 18S was used as a housekeeping gene for 
normalisation of expression levels of the genes of interest. *represent significant 






























































































































This chapter focused on the expression patterns of miR-128 predicted target 
genes in vitro and in vivo. Analysis of the data obtained provided an insight into 
the molecular mechanisms affected by the deregulation of miR-128 expression 
on a post-transcriptional and post-translational level. Several predicted target 
genes showed differences in the expression patterns in vitro and in vivo in 
muscle and neurons, but no differences at a protein level were detected. Data 
suggested that changes in mitochondrial dynamics occurs, consistent with 
previous data on ATP production (Chapters 5 and 6), but the mechanisms causing 
these changes is not entirely clear.  
 
7.4.1 The effects of miR-128 gain- and loss-of-function on the expression of 
predicted target genes in C2C12 and NSC-34 cells 
Following the analyses of miR-128 gain- and loss-of-function in C2C12 and 
NSC-34 cells, we investigated whether changes in genes relevant for muscle and 
nerve function or development are affected by changes in miR-128 expression. It 
is important to note the unusual effects of miR-128 inhibition and 
overexpression on muscle cell phenotype with both overexpression and 
inhibition of miR having similar effects on proliferation, viability and myotube 
size of C2C12 cells. Quantitative PCR analysis of miR-128 predicted target gene 
expression in C2C12 cells showed significant downregulation of Pdgfrα-2 gene 
following overexpression of miR-128 (Figure 7.3.1.1 D). This observation may 
indicate that Pdgfrα-2 transcript might be a direct target of miR-128 in C2C12 
cells. PGDFRα has been identified as a mediator of proliferation and survival of 
skeletal muscle during development (Fantauzzo and Soriano, 2018). 
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Downregulation of the Pdgfrα-2 gene could explain the reduction in cell 
proliferation and increase in cell death of C2C12 cells in Chapter 5, following 
overexpression of miR-128. PDGFR also plays an important role in regulating 
skeletal muscle hypertrophy via AKT/p70S6K pathway (Sugg et al. 2017). 
Interestingly, Pdgfrα-2 expression levels were significantly increased following 
inhibition of miR-128, while the opposite was not observed with overexpression 
of miR-128 in NSC-34 cells (Figure 7.3.2.2 E). PDGFRα is expressed in mouse 
motoneurons during embryonic stages and persists until adulthood (Oumesmar 
et al. 1997). PDGFRα knockout mice die at birth and exhibit defective 
myelination and tremor (reviewed in Funa and Sasahara, 2013). Therefore, 
upregulation of Pgdfrα-2 gene may have a neuroprotective role towards the NSC-
34 cells, however the link between the expression of this gene with miR-128 
remains to be established. 
Overexpression of miR-128 in C2C12 cells was accompanied by upregulation 
of Cox-IV and Park-2 gene transcripts (Figure 7.3.1.2 F, Figure 7.3.1.1 D). Park-2, 
encoding parkin (PARK-2) protein, has been associated with removal of the 
dysfunctional mitochondria (Narendra et al. 2008). Overexpression of the Park-2 
gene in skeletal muscle has been associated with muscle hypertrophy and 
improvement of mitochondrial enzyme activity (Leduc‐Gaudet et al. 2019). COX-
IV plays a central role in oxidative phosphorylation (OXPHOS) and mitochondria 
biogenesis (reviewed in Gnaiger, 2009). Specifically, COX-IV, like COX-I, is a 
subunit of cytochrome c oxidase, known as Complex IV, which is the terminal 
enzyme in the electron transport chain (Wong-Riley, 2013). Cox-IV is encoded by 
the nuclear DNA (Zeviani et al. 1987), unlike Cox-I which is encoded by the 
mitochondrial DNA (Anderson et al. 1981). Reduction of COX-IV has been 
associated with the dysfunction of cytochrome c oxidase activity and therefore 
mitochondrial dysregulation in various cell types (reviewed in Arnold, 2012).  
Increased expression of Cox-IV gene transcript could be an indicator of increased 
mitochondrial activity during overexpression of miR-128. However, in NSC-34 
cells, Cox-IV expression was upregulated following both overexpression and 
inhibition of miR-128 (Figure 7.3.2.2 B). This could either be due to expression of 
224 
 
different gene transcripts following overexpression or inhibition of miR-128 
(reviewed in Arnold, 2012), or due to indirect regulation of Cox-IV transcripts. 
Upregulation of Park-2 and Cox-IV in C2C12 cells imply that their expression is 
unlikely to be directly mediated by miR-128 overexpression; it is possible that the 
expression levels of these two gene transcripts are controlled indirectly by miR-
128. Another explanation is that miR-128 may regulate a different pool of target 
genes depending on its expression levels. A study from Shu et al. (2012) shows 
that miR-17-92 regulates a different subset of target genes in a dose-dependent 
manner, with implications for cell viability.   
Interestingly, overexpression and inhibition of miR-128 resulted in 
downregulation of Cox-I gene expression in C2C12 cells (Figure 7.3.1.2 E), but 
Cox-I gene was downregulated following miR-128 overexpression in NSC-34 cells 
(Figure 7.3.2.2 A). COX-I, like COX-IV, plays a crucial role in OXPHOS and electron 
transport chain in the mitochondria (reviewed in Gnaiger, 2009). Cox-I gene is 
encoded by mitochondrial DNA (Anderson et al. 1981; reviewed in Taylor and 
Turnbull, 2005); therefore, alteration in the gene expression levels might be a 
marker of changes occurring in the mitochondria. Similar to Cox-IV, 
downregulation for Cox-I mRNA could be associated with deregulated oxidative 
phosphorylation and altered mitochondrial activity. Downregulation of Cox-I 
gene expression in NSC-34 cells following miR-128 overexpression make it a 
promising candidate target for direct binding by miR-128. Reduction in Cox-I 
expression levels following inhibition of miR-128 in C2C12 cells, might signify the 
regulation of Cox-I gene expression by multiple mechanisms. The 
downregulation of Cox-I mRNA following overexpression and inhibition of miR-
128 in C2C12 is consistent with the reduction of ATP release seen in mitotoxicity 
assay in Chapter 5, Section 5.3.5. Therefore, it is possible that manipulation of 
miR-128 levels have a direct impact on the mitochondrial function, through 
control of genes encoding key enzymes of the mitochondrial electron transport 
chain. Increase in the levels of Cox-IV mRNA could also act as a compensation 
mechanism for the downregulation of Cox-I mRNA, as an attempt to restore or 
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maintain Complex IV integrity, during overexpression of miR-128 in C2C12 and 
NSC-34 cells. 
In addition to these findings, miR-128 inhibition but not overexpression 
significantly reduced the expression levels of Nrf-1 and Sos-1 transcripts in C2C12 
cells (Figure 7.3.1.2 D, A). The opposite was observed in NSC-34 cells, with Nrf-1 
expression levels being increased following inhibition of miR-128 (Figure 7.3.2.2 
C). Studies have shown that NRF-1 regulates the expression of all cytochrome c 
oxidase (Complex IV) subunits, including COX-I and COX-IV (Dhar et al. 2008). 
Although Cox-IV expression levels were not affected following inhibition of miR-
128 in C2C12 cells, it is possible that the reduction in Nrf-1 expression is 
responsible for the reduction of Cox-I gene expression levels following miR-128 
inhibition. Nrf-1 may have played a role in the increased expression of Cox-IV 
gene in NSC-34 cells, as both transcripts were upregulated following inhibition of 
miR-128. These data indicate the variable effect of miR-128 inhibition in C2C12 
and NSC-34 cells. Both cell types have a high demand for mitochondrial 
respiration and OXPHOS activity in order to ensure proper mitochondrial 
function and metabolic activity. However, skeletal muscle and neuronal cells 
have shown distinct differences in mitochondrial bioenergetics during ageing. A 
study from Li et al. (2013) showed that skeletal muscle mitochondria were more 
susceptible to the presence for mitotoxins (e.g. FCCP). Mitochondrial respiration 
in skeletal muscle cells following treatment with FCCP declined earlier and the 
decline was more severe compared to the neuronal cells (Li et al. 2013). 
However, when ATP content was measured, the decline in total ATP produced 
was more severe in neuronal cells. Overall, mitochondrial deterioration occurred 
earlier and was more severe in skeletal muscle cells, compared to neuronal cells, 
which could be associated with the earlier decline in skeletal muscle mass and 
function during ageing, in comparison with the cognitive decline (Li et al. 2013).  
 SOS-1 forms a complex with GRB-2, activating RAS/ERK pathway following 
FGF or EGF signalling (Findlay et al. 2013). Downregulation of Sos-1 mRNA could 
have an impact on RAS/ERK signalling resulting in changes to downstream 
processes. Aside from forming a complex with SOS-1, GRB-2 is an essential 
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component of AChR cluster formation (Gingras et al. 2016). Although miR-128 
overexpression had no impact on Grb-2 expression, inhibition of miR-128 
resulted in increased expression of this transcript in NSC-34 cells (Figure 7.3.2 E). 
Upregulation of Grb-2 gene could promote upregulation of GRB-2 protein levels 
resulting in increased activation of downstream pathways such as PI3K and RAS 
signalling pathways (reviewed in Reichardt, 2006).  
 
7.4.2 Changes in protein expression levels following miR-128 gain- and loss-
of-function in C2C12 and NSC-34 cells   
Protein levels of LC-3 and NRF-1 in C2C12 and NSC-34 cells showed no 
significant changes following overexpression or inhibition of miR-128 (Figure 
7.3.3.1-4). Despite the significant changes seen in the levels NRF-1 transcripts in 
both C2C12 and NSC-34 transfected cells, there was no observed effect of miR-
128 on NRF-1 protein levels. There are many parameters that could result in this 
difference between mRNA and protein expression. Protein levels depend on the 
rate of translation; therefore, abundance or inadequacy of mRNA transcript 
cannot automatically result in similar changes on a protein level. As a result, it is 
necessary to take into consideration any delays between transcription and 
translation process when comparing protein level changes with their respective 
mRNA transcript (reviewed in Liu et al. 2016). Another possibility is that despite 
the increase in the expression levels of Nrf-1 mRNA, there is no demand for new 
protein synthesis therefore the translation rate is not affected. Whether cell 
requirement for these protein increases, cells could undergo a “translation on 
demand” utilising the higher number of mRNA transcripts for increase of protein 
synthesis (reviewed in Liu et al. 2016). Absence of differences on a protein levels 
for NRF-1 and COX-IV could also be due to subtle changes seen on an mRNA 
detected via qPCR, which is a more sensitive method compared to protein 
quantification via Western Blot.  
Protein expression levels also depend on the protein turnover rate, which is 
regulated by autophagy mechanism. LC3 proteins (LC3 I and LC3 II) play a crucial 
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role in autophagy and mitophagy process, as they are necessary for expansion 
and closure of autophagosomes (reviewed in Chen et al. 2018).  During activation 
of autophagy, LC3 I is converted to LC3 II which is then recruited to 
autophagosome membrane (Tanida et al. 2008). LC3 proteins are also recruited 
during mitophagy, with dysfunctioning mitochondrial being discarded via 
phagocytosis (reviewed in Yoo and Jung, 2018). In order to measure activation of 
autophagy/mitophagy process, the ratio of LC3 II to LC3 I (LC3 II/I) was calculated 
following western blot analysis (Tanida et al. 2008). Western blot analysis of LC3 
II/I ratio showed no significant changes following overexpression or inhibition of 
miR-128 in C2C12 and NSC-34 cells (Figure 7.3.3.1-2). Therefore, protein 
degradation rate via autophagy does not seem to be affected by alterations in 
miR-128 expression levels. As such, protein turnover rate could be either 
regulated via a different mechanism or remain stable in miR-128 transfected 
cells. Taken into consideration the cell viability and mitotoxicity data from 
Chapters 5 and 6 in C2C12 and NSC-34 cells, absence of differences in LC 3 ratio 
could indicate cell death in the presence of dysfunctioning mitochondria, but 
without the recruitment of autophagosomes (reviewed in Palikaras and 
Tavernarakis, 2014).  
Despite the findings form the Western blot analysis, the low n number and 
the insufficient intensity of the band (potentially due to issues with the specific 
antibody binding or issues with sufficient protein loading) do not allow for solid 
conclusions to be drawn. Optimisation of antibody binding and protein loading or 
use of more sensitive techniques such as mass spectrometry or ELISA could 
provide more information about the levels of these proteins in C2C12 and NSC-
34 cells following manipulation of miR-128 expression. 
 
7.4.3 Expression of Nrf-1, Cox-IV and Grb-2 in TA muscle and SN tissue of 12-
week old mice 
Expression levels of Nrf-1 and Cox-IV mRNA levels showed no differences in 
the TA muscles of the three mouse groups (NNN, NLL, LNN) but Nrf-1 expression 
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was upregulated in SN of NLL mice (Figure 7.3.4 C). Significant upregulation of 
Grb-2 expression levels in SN of NLL mice was also recorded (Figure 7.3.4 E). 
MicroRNA-128 expression levels were significantly lower in NLL and LNN in TA 
muscle but no such differences were recorded in SN of those mice (Chapter 4, 
Figure 4.3.2 A, C). Together, these data indicate that Nrf-1 and Grb-2 are most 
likely not direct targets of miR-128, although this requires further investigation 
via 3’UTR reporter constructs. A possible scenario would be that Grb-2 and Nrf-1 
expression might be regulated independently of miR-128 as a response to the 
low-protein diet postnatally.  Considering the role of GRB-2 in the formation of 
AChR clusters at NMJs, it is possible that upregulation of its expression levels in 
NLL mice is a mechanism for repair of the defects at NMJ site or maturation of 
NMJ formation on a pre-synaptic level (discussed in detail in Chapter 3, Section 
3.3.5). Increase in Nrf-1 expression could be associated with increased 
mitochondrial activity in SN of NLL mice. Mitochondria located in Schwann cells 
of myelinated axons are essential for their development and maintenance 
(reviewed in Ino and Lino, 2017). Therefore, increase in mitochondria biogenesis 
may signify the presence of an injury or damage caused by insufficient protein 
intake. In the case of delayed neuronal development due to low protein intake, 
increase in mitochondria activity could be necessary for the development and 
sufficient myelination of the axons. In order to answer these questions, further 
analysis of the morphology of the SN and quantification of mitochondrial content 
is required.  
It is evident that miR-128 may control the expression of a number of 
transcripts differently in muscle and nerve in vitro and in vivo. Furthermore, miR-
128 may also control a different pool of target genes in a dose-dependent 
manner, with implications for cell viability. However, further investigation is 
required, in order to identify the transcripts directly targeted by miR-128 and 
what would be the implications in metabolic processes in vitro and in vivo. A 
method commonly used in order to assess direct mRNA target/miR-128 


























The present study examined the effect of low-protein diet at pre- and 
postnatal stages on the neuromuscular development and function in 12-week old 
mice. Furthermore, this study aimed to examine whether dietary protein 
restriction may alter the expression profile of microRNA molecules and therefore 
result in altered signalling of key metabolic pathways in skeletal muscle and 
motoneurons, using in vivo and in vitro approaches.  
The main findings of this study are:  
1. Pre- or postnatal protein restriction results in reduced muscle fibre 
number and increase of Atrogin-1 gene expression levels in 12-week old 
mice. Protein restriction only in postnatal stages resulted in reduced body 
weight and size, reduced weight of slow muscles or mixed muscles (but 
not in fast muscles), reduced maximum muscle forces without changes in 
specific force, and increase in morphological abnormalities of NMJs. 
Postnatal protein restriction was also accompanied by an increase in 
MyHC IIa expression levels in TA muscle.  
2. Expression levels of miR-128 were downregulated in 12-week old mice on 
a low-protein diet pre- or postnatally, but expression levels of miR-133a 
were supressed only in 12-week old mice on a protein-deficient diet 
postnatally. In silico analysis of predicted target genes for miR-128 and 
miR-133a revealed a number of genes involved in key metabolic 
pathways including neurotrophin signalling pathway, FoxO signalling 
pathway, synaptic vesicle cycle and longevity regulating pathway. A 
number of predicted target genes were associated with mitochondrial 
function. 
3. Gain- and loss-of-function of miR-128 in C2C12 cells resulted in increased 
fusion index, increased cell death, reduced myoblast proliferation and 
increased mitochondrial toxicity. miR-128 did not affect the diameter of 
terminally differentiated C2C12 myotubes following gain- and loss-of-
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function experiments. Gain-of-function of miR-128 in NSC-34 cells 
resulted in reduction of axonal length and increase in cell death, but had 
no effect in cell proliferation.  
4. Gain- and loss-of-function of miR-133a in C2C12 cells increased myoblast 
proliferation but had no impact on cell fusion. Overexpression of miR-
133a reduced cell death, while inhibition of miR-133a increased myotube 
diameter and myotube area. Overexpression of miR-133a does not induce 
atrophy but possibly inhibits hypertrophy of C2C12 myotubes. miR-133a 
plays a role in regulation of myotube hypertrophy but not myogenesis. 
Inhibition of miR-133a in NSC-34 cells increased axonal length but had no 
impact in cell death and proliferation.  
5. Gain-of-function of miR-128 resulted in increased expression of Park-2 
and Cox-IV transcripts and reduced expression of Cox-I and Pdgfrα 
transcripts. Loss-of-function of miR-128 lead to reduction in Cox-I, Nrf-1 
and Sos-1 transcripts in C2C12 myoblasts. Gain- and loss-of-function of 
miR-128 had no impact on NRF-1 and LC-3 protein content in C2C12 
myoblasts. Findings suggest divergent mechanisms of miR-128 leading to 
cell death when miR-128 levels dysregulated (too high or low).  
6. Gain- and loss-of-function of miR-128 resulted in increased expression of 
Cox-IV transcript in NSC-34 cells. Loss-of-function of miR-128 resulted in 
increased expression levels of Nrf-1, Grb-2 and Pdgfrα transcripts, while 
gain-of-function of miR-128 reduced the expression levels of Cox-I 
transcript in NSC-34 cells. Gain- and loss-of-function of miR-128 had no 
impact on NRF-1 and LC-3 protein content in NSC-34 cells. Nrf-1 and Grb-
2 expression levels were upregulated in the SN of 12-week mice from the 
NLL group only.   
 
In summary, dietary protein restriction postnatally has a negative impact in 
normal development, as seen in 12-week old mice, in line with previously 
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published data (Chen et al. 2009). Although 12-week old mice on a protein 
restricted diet pre-or postnatally seem to have similar muscle phenotype, muscle 
function and NMJ integrity is affected only by postnatal protein restriction. 
Furthermore, protein restriction appeared to have an impact on muscle weight 
of slow-twitch (SOL) or mixed-fibre-type (Quad, GTN) muscles, but no reduction 
in muscle weight was recorded in fast-twitch muscles (EDL, TA). Histological 
examination of the EDL muscle showed no apparent differences in the fibre 
crossectional area but a reduction if fibre number in both NLL and LNN groups of 
mice, indicating the role of dietary protein intake in muscle fibre number 
determination during development. Although the reduction in fibre number 
without accompanying differences in fibre sizes would be expected to have an 
impact on the muscle weight, such difference was not observed in the EDL 
muscle. One possible explanation for this phenomenon is that the protein-
deficient diet at pre- or postnatal stages of development may have resulted in 
water retention in fast-twitch muscles, such as the EDL and TA muscle, which 
could explain the absence of significant differences in the muscle weight 
between the three groups of mice. Previous studies have highlighted the effect 
of a protein-deficient diet early in life on the water retention and abnormal 
water and electrolyte distribution, resulting in growth abnormalities (Fiorotto et 
al. 1987). However, water retention has been reported to affect differently the 
fast-twitch and the slow-twitch muscles due to their different osmolality 
sensitivity (Farhat et al. 2018). However, due to the lack of evidence supporting 
water imbalances in our study, the role of water in the muscle weight and fibre 
number differences in fast-twitch muscles (EDL, TA) in comparison with the slow-
twitch or mixed fibre-type muscles (SOL, GTN, Quad) can only be speculated. In 
order to exclude the possibility that the reduction in fibre number in NLL and 
LNN groups is due to unintended selection of muscles belonging to a specific 
subgroup (muscles with lower weight), analysis of the body weight and muscle 
weight of the mice selected for histological examination were compared to the 
rest of the mice in each group (Appendix Section A7, Figure A19). Body weight 
and EDL muscle weight analysis confirm that the samples chosen for histological 
analysis did not present significant differences with the rest of the population in 
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each group. Therefore, we are confident that findings on body and muscle 
weight as well as muscle fibre number and size are real and not an unintended 
consequence of subgroup analyses. Furthermore, the differences recorded in the 
muscle force of the EDL muscle do not seem to be consistent with the 
differences in EDL fibre number analysis, which could indicate that reduction in 
muscle fibre number alone may not be sufficient to induce changes in the muscle 
strength. The reduction in the EDL muscle force may also be attributed to 
significant morphological changes seen at the NMJ site. Whether these 
morphological changes could also be due to or result in functional changes of the 
NMJ, remains currently unknown and requires further investigation with 
electrophysiology techniques. All things considered, the physiological differences 
observed between the NLL and LNN groups of mice highlight the possibility that 
protein restriction may modulate development via different mechanisms 
depending on the developmental stage it is introduced. Protein restriction seems 
to regulate the expression level of two microRNAs expressed in muscle, miR-128 
and miR-133a. These findings are supported by a recent study from Sharma et al. 
showing regulation of small RNA fragments following parental dietary protein 
restriction and their influence in embryonic development of the offspring 
(Sharma et al. 2015). In vitro analysis focusing on the manipulation of miR-128 
expression in skeletal muscle (C2C12) and motoneuron (NSC-34) cells indicates 
potential involvement of miR-128 in mitochondrial homeostasis and function, 
which may subsequently modulate cell survival and/or proliferation.  
Previously published data on miR-128 directly targeting transcripts of 
components of IGF-1 signalling pathway, Sirt-1 and Pdgfrα, along with the data 
from gene expression analysis on Grb-2, Nrf-1, Cox-I and Cox-IV, we propose the 
following: 
i) Regulation of skeletal muscle function occurs indirectly of miR-128 
expression via genes involved in NMJ formation (Grb-2) and 
potentially mitochondrial function (Nrf-1, Cox-I, Cox-IV) in 12-week 
old mice.  
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ii) miR-133a may have a role in regulation of genes involved in 
neurotransmission and axonal sprouting in neuronal cells while 
inhibition of miR-133a may induce hypertrophy in myotubes in vitro. 
The role of miR-133a in neuromuscular transmission in vivo needs 
further exploration.  
Downregulation of miR-128 expression levels in mice from both NLL and LNN 
groups are in line with upregulation of Atrogin-1 expression levels and reduction 
in EDL muscle fibre number of 12-week old mice. Despite the fibre loss, 
downregulation of miR-128 in 12-week old mice should increase the levels of its 
direct targets, Igf1, Igf1r, Sirt-1 and Pdgfrα, which would cause hypertrophy of 
the remaining EDL muscle fibres in NLL and LNN mice. Despite the potential 
effect of miR-128 following a low-protein diet pre- or postnatally, skeletal muscle 
function could be regulated indirectly of miR-128 via a different mechanism. 
Immature NMJ morphology (small area of synaptic site, limited branching and 
fragmentation) might be the result of slow growth of mice in the NLL group. This 
would be in line with the data from Chen et al. (2009) showing that mice on a 
normal diet pre-natally, but subjected to a protein-restricted diet postnatally 
displayed slow growth but increased lifespan. It is possible that slow growth may 
be attributed to decrease in ATP production from the mitochondria affecting 
both muscle function and neurotransmission, although this would need further 
investigation. Furthermore, the differences seen in the phenotype of mice of the 
NLL and LNN groups along with the reduction in miR-128 expression levels 
support the possibility that miR-128 may be regulated by a feedback mechanism 
involving different subset of genes controlling different aspects of cell behaviour 
and survival. Collectively, despite the significant reduction seen in miR-128 and 
miR-133a expression levels in skeletal muscle in vivo and taking into 
consideration the phenotype and gene expression changes seen in muscle and 
motoneuron cells in vitro, it remains unclear whether the difference in miR-128 
and miR-133a expression in the skeletal muscle of mice is a direct consequence 
of the protein-deficient diet. Furthermore, the reduction in miR-128 and miR-
133a levels may be the result of deregulation of molecular mechanisms directly 
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affected by the protein-deficient diet, which may differ depending on the 
developmental stage in which this diet was introduced. Therefore, the 
mechanisms affecting miR-128 and/or miR133a expression or the mechanisms 
affected by the downregulation of miR-128 and/or miR-133a expression might 
be different between the NLL and LNN groups of mice.  
 
8.2 Limitation 
Muscle and SN tissue samples from 12-week old mice used for molecular work 
in this study had been previously fixed with 10% NBF for 24 h. Fixation of this 
samples was a significant limitation towards investigating components of 
signalling pathways, such as FoxO, whose activity depends on post-translational 
modifications (acetylation, phosphorylation). Therefore, the exact effect of 
protein-restricted diet on these signalling pathways remains unknown. Tissue 
fixation was a limitation for detection of miR-128 and miR-133a in α-
motoneurons on the spinal cord via in situ hybridisation. Tissue fixation was an 
important factor for the absence of MyHC isoform assessment, as the staining 
for the different MyHC isoforms requires unfixed tissue samples. Despite the 
absence of experimental analysis of the protein expression levels, the gene 
expression levels of many these proteins was performed via qPCR, which is a 
more sensitive technique for the detection of even subtle changes in their 
expression level.   
Due to time restrictions, it was not possible to access the morphology of the 
SN and determine the degree of myelination and the number and size of axons. 
Although the morphology of the SN does not reflect the morphology and 
function of the motoneuron, it would provide important data on the efficiency of 
neurotransmission and/or motor unit number following dietary protein 
restriction.  
Analysis of miR-133a following gain- and loss-of function experiments was 
limited, due to challenges achieving sufficient inhibition of miR-133a in C2C12 
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and NSC-34 cells. Additionally, design of primers for miR-133a predicted target 
genes of interest proved challenging. Therefore, investigation of predicted target 
genes was mainly focused on miR-128. Optimisation of in vitro miR-133a 
inhibition and primer design for predicted target genes of interest is of future 
interest.  
Fixation of tissues in combination with limited financial support and time did 
not allow the investigation of the expression levels of specific proteins and their 
gene transcripts in vivo and in vitro. Transcriptomics and sequence analysis in 
vivo (in muscle and nerve) and in vitro (in C2C12 and NSC-34 cells following 
transfection experiments with miR-128 and miR-133a) could aid our 
understanding of the potential role of miR-128 and miR-133a following a low-
protein diet pre- or postnatally. Specifically, identification of potentially common 
genes showing similar expression patterns in vivo and in vitro could refine 
potential molecular mechanisms most likely being affected by a protein-deficient 
diet and whether they are directly associated with or controlled by miR-128 
and/or miR-133a. Additionally, proteomic analysis could reveal potential changes 
in the protein expression levels in vivo and in vitro, and whether these changes 
are in line the bioinformatics data, confirming the involvement of miR-128 and 
miR-133a in certain signalling pathways both in vivo and in vitro. Furthermore, 
protein expression changes in muscle and nerve both in vivo and in vitro would 
provide further explanation of the signalling pathways implicated in the 
physiological and functional changes seen in mice subjected to a low-protein diet 
pre- or postnatally.   
 
8.3 Future directions 
This study has provided some novel data on the effect of low-protein diet at 
pre- or postnatal stages of development on the neuromuscular physiology and 
function of adult mice and the potential molecular mechanisms involved.  
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In order to access whether reduction in skeletal muscle function is also 
attributed to fibre type distribution, immunofluorescent staining and analysis for 
different MyHC isoforms (type I, IIa, IIb, IIx/d) is necessary in both fast muscles 
(EDL, TA) and slow muscles (SOL).  
To understand the exact mechanism of neuromuscular regulation by miR-128, 
assessment of direct binding of the predicted target genes by miR-128 should be 
conducted using 3’UTR luciferase assay in C2C12 and NSC-34 cells, following by 
western blotting to access protein content changes following manipulation of 
miR-128 expression levels. Similar protocol should be followed for miR-133a as 
well, in both in vitro models. Whether a successful muscle:nerve co-culture 
model is available, gain- and loss-of-function of miR-128 and miR-133a should be 
tested, to examine the effect of the two microRNAs at the early stages of 
synaptic formation. This experiment would determine whether delayed 
development indeed occurs following protein-restriction prenatally. Motoneuron 
function could also be assessed using electrophysiology techniques, in order to 
determine whether manipulation of miR-128 and miR-133a expression has any 
effect on neurotransmission. These data could provide an additional explanation 
on the mechanism causing reduced muscle function in mice of the NLL group. 
Assessment of miR-128 and miR-133a levels in skeletal muscle and α-
motoneurons and their impact on signalling pathways in mice on a low-protein 
diet could also be investigated using high-throughput methods, including 
proteomics and RNA sequencing.  
In vivo assessment of α-motoneuron and SN integrity should be assessed 
following appropriate histochemistry techniques. As mentioned in Section 8.2, 
histological examination of the SN would provide valuable data on the 
myelination, axonal size and axon number. These data would indicate whether 
reduced muscle function in mice of the NLL group might also be attributed to 
defective neurotransmission due to disruption ion myelination and/or reduced 
motor unit number. Transverse section of the lumbar region of the spinal cord 
would allow the direct assessment of the size and number of motoneurons, as 
well as assessment of miR-128 and miR-133a levels via in situ hybridisation. 
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Expression of neurotrophic factors and mitochondrial markers could also be 
assessed by immunofluorescent techniques.  
In order to determine the quality and number of mitochondria, assessment of 
mitochondria respiration using muscle or neuronal tissue could be evaluated. 
Mitochondrial respiration can be measured using a Seahorse platform or an 
Oroboros O2k Oxygraph, using both cell and tissue samples. This instrument 
would allow the determination of mitochondrial respiration from both in vivo 
and in vitro models following miR-128 and miR-133a manipulation or tissues 
from mice on a protein restricted diet. This technique would allow the 
determination the determination of mitochondrial function and direct 
correlation of these data with data from mitochondrial marker assessment.  
Importantly, to investigate the impact of miR-128 and/or miR-133a in 
neuromuscular maintenance of 12-week old mice on a low-protein diet pre- or 
postnatally, in vivo gain- and loss-of-function experiments would be crucial. 
These experiments would determine whether miR-128 and/or miR-133a could be 
used as therapeutic targets for any defects occurring in muscle and nerve, 
following dietary protein restriction.   
In order to determine whether dietary protein restriction can contribute to 
premature ageing phenotype in muscle and nerve, maintenance of mice on a 
low-protein protocol until 22-24 months of age and assessment of their 
phenotype and neuromuscular function would be essential. Gain- and loss-of-
function of miR-128 and/or miR-133a in ageing mice would provide evidence on 
whether this approach could rescue neuromuscular phenotype only early in life 
or whether it could be used as a therapeutic tool for improvement of 
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A.1 Amplification curves and melt peaks of qPCR on TA muscle and SN in 12-
week old mice 
  
Figure A.1 Melt peaks of 18S and MyHC isoforms (I, IIa, IIb, and IId/x) qPCR in TA 
muscle of 12-week old mice. A) Amplification peak and B) melt peak of 18S gene, 





















Figure A.2 Melt peaks of Atrogin-1, MuSK and FoxO-3 qPCR in TA muscle of 12-





















Figure A.3 Melt peaks of 18S and Grb-2, Nrf-1 and Cox-IV qPCR in SN of 12-week 
old mice. A) Amplification peak and B) melt peak of 18S gene, C) Grb-2, D) Nrf-1 




















Figure A.4 Amplification curve and melt peaks of SNORD-61, miR-128 and miR-
133a qPCR in TA muscle of 12-week old mice. A) Amplification curve of SNORD-




















Figure A.5 Amplification curve and melt peaks of SNORD-61, miR-128 and miR-
133a qPCR in SN of 12-week old mice. A) Amplification curve of SNORD-61 and 
melt peaks of B) SNORD-61, C) miR-128 and D) miR-133a.  
 
A.2 Predicted target genes of miR-128 and miR-133a with seed regions for 
binding of alternative miRs 
A.2.1 Predicted target genes of miR-128 with seed regions for miR-133a binding 
 
Table A.1 List of the selected miR-128 predicted target with seed regions 
targeted by miR-133a, recorded using TargetScanMouse 7.1. Ensembl ID and 








A.2.2 Predicted target genes of miR-133a with seed regions for miR-128 binding 
Table A.2 List of the selected miR-133a predicted target with seed regions 
targeted by miR-128, recorded using TargetScanMouse 7.1. Ensembl ID and seed 
region in 3’UTR are shown.  
 
 
 miR-128 predicted target genes (TargetScan)  
    miR-133a seed region (in the 3'-UTR) 
Gene Ensembl ID Conserved Poorly conserved  
Ngfr ENSMUST00000000122.6 N/A 925-932, 1404-1410 
Insr ENSMUST00000091291.4 1063-1069 N/A 
Fbxo32 ENSMUST00000022986.6 N/A 1195-1201, 3735-3741 
Foxo1 ENSMUST00000053764.5 N/A 1788-1794, 1812-1818 
Sirt1 ENSMUST00000120239.2 344-350 N/A 
Syt1 ENSMUST00000105276.2 1606-1612, 2246-2252 N/A 
Nrf1 ENSMUST00000115212.2 N/A 457-463 
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  miR-133a predicted target genes (TargetScan) 
    miR-128 seed region (in the 3'-UTR) 
Gene Ensembl ID Conserved Poorly conserved  
Syt1 ENSMUST00000105276.2 1460-1467, 1692-
1698 N/A 
Rims1 ENSMUST00000115273.3 N/A 1844-1850 
Cplx2 ENSMUST00000026985.8 N/A 5493-5500, 5584-5590 
Braf ENSMUST00000002487.9 N/A 4044-4051 
Insr ENSMUST00000091291.4 207-213 3851-3858 
Fgf1 ENSMUST00000117566.2 N/A 1016-1022, 1121-1127, 1593-1599, 1749-1755, 3116-3122 
Pax7 ENSMUST00000030508.8 N/A 755-761 
Myo9b ENSMUST00000168839.2 N/A 870-876, 2893-2900 
Myh1 ENSMUST00000124516.2 N/A 763-769 
Nrf1 ENSMUST00000115212.2 N/A 1232-1239, 1603-1609 
 
 
A.3 Assessment of transfection efficiency of C2C12 and NSC-34 cells following 
manipulation of miR-128 or miR-133a expression 
 
Figure A.6 Amplification curve and melt peak of SNORD-61 in C2C12 and NSC-34 

















curve and B) melt peak of SNORD-61 in C2C12 cells. C) Amplification curve and D) 
melt peak of SNORD-61 in NSC-34 cells. 
 
Figure A.7 Amplification curve and melt peak of miR-128 qPCR in C2C12 and NSC-
34 cells following transfections with either Scr, miR-128 or AM-128. A) 
Amplification curve and B) melt peak of miR-128 in C2C12 cells. C) Amplification 
























Figure A.8 Transfection efficiency of miR-128 and AM-128 in C2C12 and NSC-34 
cells. Scr serves as the control for statistical comparison, **P≤0.01, ***P≤0.001 










































Figure A.9 Amplification curve and melt peak of SNORD-61 and miR-133a in 
C2C12 (red) and NSC-34 (blue) cells following transfections with either Scr, miR-
133a or AM-133a. A) Amplification curve and B) melt peak of SNORD-61. C) 









NSC-34 (Scr, miR-133a, AM-133a) 
 












Figure A.10 Transfection efficiency of miR-133a and AM-133a in C2C12 and NSC-
34 cells. Scr serves as the control for statistical comparison, *P≤0.05, *** 
P≤0.001 (mean ± SEM; n=3; One-Way ANOVA with Dunnett’s post-hoc analysis). 
 
 

































A.4 Phenotypic analysis and comparison of C2C12 and NSC-34 untransfected 
cells in comparison with scrambled-treated cells, following manipulation of 
miR-128 and miR-133a expression experiments 
A.4.1 Analysis of C2C12 untransfected and scr-treated cells 
 
Figure A.11 Phenotype analysis of untransfected (control) and scrambled-
transfected (Scr) C2C12 myotubes, following manipulation of miR-128 expression 
experiments. A) Untransfected (control) and Scr C2C12 myotubes; myotube 
formation was established with myosin heavy chain and nuclei immunostaining 
(MF20=Green; DAPI=Blue). B) Myotube diameter of untransfected and Scr C2C12 
myotubes with ≥2 nuclei. C) Quantification of total C2C12 myotube area 
expressed as a percentage of total area per field of view, of untransfected 
(control) and Scr C2C12 myotubes. (mean ± SEM; n=3-4; Unpaired two-tailed t-
test with Welsh correction). Representative images shown. 
Scr Control A. 





















































Figure A.12 Phenotype analysis of untransfected (control) and scrambled-
transfected (Scr) C2C12 myotubes, following manipulation of miR-133a 
expression experiments. A) Untransfected (control) and Scr C2C12 myotubes; 
myotube formation was established with myosin heavy chain and nuclei 
immunostaining (MF20=Green; DAPI=Blue). B) Myotube diameter of 
untransfected and Scr C2C12 myotubes with ≥2 nuclei. C) Quantification of total 
C2C12 myotube area expressed as a percentage of total area per field of view, of 
untransfected (control) and Scr C2C12 myotubes. (mean ± SEM; n=3-4; Unpaired 





Scr Control A. 



































































Figure A.13 CCK-8 proliferation and CytoTox96 cytotoxicity assay of 
untransfected (control) C2C12 myoblasts and C2C12 myoblasts transfected with 
scrambled negative control (Scr). C2C12 myoblast number in control group and 
scrambled-transfected group for A) miR-128 and B) miR-133a. C2C12 cell death 
expressed as fold-change in cytotoxicity in control group and scrambled-
transfected group for C) miR-128 and D) miR-133a. **P≤0.01 (mean ± SEM; n=6; 












































































































A.4.2 Analysis of NSC-34 untransfected and scr-treated cells 
 
Figure A.14 Phenotype analysis of untransfected (control) and scrambled-
transfected (Scr) differentiated NSC-34 (NSC-34D) cells, following manipulation of 
miR-128 expression experiments. A) Untransfected (control) and Scr NSC-34D 
cells stained with Alexa Fluor 488 B-III Tubulin (green) for and DAPI (blue) and B) 
Axonal length of untransfected (control) and Scr NSC-34D after 11 days of 
differentiation. (mean ± SEM; n=3; Unpaired two-tailed t-test with Welsh 
correction). Representative images shown.  
 
 
Scr Control A. 






























Figure A.15 Phenotype analysis of untransfected (control) and scrambled-
transfected (Scr) differentiated NSC-34 (NSC-34D) cells, following manipulation of 
miR-133a expression experiments. A) Untransfected (control) and Scr NSC-34D 
cells stained with Alexa Fluor 488 B-III Tubulin (green) for and DAPI (blue) and B) 
Axonal length of untransfected (control) and Scr NSC-34D after 11 days of 
differentiation. (mean ± SEM; n=3; Unpaired two-tailed t-test with Welsh 




Scr Control A. 





























Figure A.16 CCK-8 proliferation and CytoTox96 cytotoxicity assay of 
untransfected (control) C2C12 myoblasts and NSC-34 cells transfected with 
scrambled negative control. NSC-34 cell number in control group and scrambled-
transfected group for A) miR-128 and B) miR-133a. NSC-34 cell death expressed 
as fold-change in cytotoxicity in control group and scrambled-transfected group 
for C) miR-128 and D) miR-133a. (mean ± SEM; n=6; Unpaired two-tailed t-test 









































































































A.5 Amplification curves and melt peaks of qPCR of predicted target genes 
following manipulation of miR-128 expression experiments in vitro 
 
Figure A.17 Melt peaks from qPCR analysis following manipulation of miR-128 
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Figure A.18 Melt peaks from qPCR analysis following manipulation of miR-128 






















A.6 Dietary information of normal and protein-restricted diet used for in vivo 
experiments 



































































Figure A.19 Total body weight and EDL muscle of 12-week old mice used for 
histological analysis in comparison with those not selected for experimental 
analysis. A) Total body weight (g) and B) EDL muscle weight (mg) used in 
histological analysis compared to those that were not selected for experimental 
analysis. (mean ± SEM; n=3-9; Two-Way ANOVA with Bonferroni post-hoc 
analysis). 
 
 
